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Thesis Portfolio Abstract 
Evidence shows that non-motor symptoms of Parkinson’s Disease are 
associated with reduced quality of life (QOL). Anxiety is one such symptom and it is 
highly prevalent among people with Parkinson’s (PwP). A systematic review, 
incorporating a meta-analysis, was undertaken to review the relationship between 
anxiety and QOL in PwP. By pooling data from 17 studies, the meta-analysis 
established that the relationship was strong (r = 0.53). Additionally, a review of 
regression data from 20 studies highlighted that anxiety predicted significant 
variance in participant QOL in all but two studies. Given the significance of anxiety 
highlighted in the review, it is important that the experience of anxiety among PwP 
is well understood. Research was therefore undertaken using a modified Nominal 
Group Technique to better characterise the ways in which anxiety is experienced by 
PwP. The range of anxiety experiences was broad, with some experiences 
representing generic anxiety experiences that are not unique to the Parkinson’s 
population. However, the majority of experiences related specifically to the 
symptoms of Parkinson’s or had the potential to be aggravated by them. Additional 
findings are reported relating to the existing approaches taken by our participants to 
manage their anxiety. Theoretical and clinical implications for all findings are 
discussed. 
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Chapter One: Introduction to Thesis Portfolio 
Mental and physical health are closely interrelated and impact one another in 
a multitude of ways (Naylor et al., 2016; Prince et al., 2007). It is now recognised 
that people with chronic physical health conditions are two to three times more likely 
to experience mental health difficulties compared to the general population (Naylor 
et al., 2012). This comorbidity of physical and mental health conditions is associated 
with increased use of physical health services (Das-Munshi et al., 2007), poorer 
health outcomes (Felker et al., 2010) and reduced quality of life (QOL; Moussavi et 
al., 2007). In recognition of this, mental health services have been given greater 
responsibility to support the psychological needs of people with chronic physical 
health conditions (National Collaborating Centre for Mental Health, 2018; NHS 
Confederation, 2012). Related research stemming from these initiatives has 
repeatedly demonstrated the value of tailoring psychological interventions to 
acknowledge the complexity and heterogeneity of the comorbidity (Evers, 
Kraaimaat, van Riel, & de Jong, 2002; Greer et al., 2012; Johansson et al., 2019; 
Thieme, Flor, & Turk, 2006).  
It is notable that there are no nationwide initiatives that specifically address 
the mental health needs of people with Parkinson’s (PwP). Parkinson’s Disease is a 
neurodegenerative disorder of unknown aetiology that is estimated to affect 0.3% of 
the entire population, a figure rising to 1.8% of people over the age of 65 (Mayeux, 
2003). What is more, prevalence is anticipated to double by 2065 owing to an aging 
population (Parkinson’s UK, 2017). Parkinson’s is largely considered a disorder of 
the extrapyramidal system (a neural network that regulates and modulates motion) 
and is associated with impaired dopaminergic function (Chen & Swope, 2014). 
Consequently, there are a range of movement related symptoms that can be 
experienced in Parkinson’s (Jankovic, 2008) (see Appendix A for full breakdown). It 
is typically defined by the presence of at least two of the following motor symptoms: 
shaking (tremor), slowness of movement (bradykinesia), muscle stiffness (rigidity) 
and difficulties with maintaining balance (postural instability) (Jankovic, 2008). 
There are known to be two distinct motor phenotypes in Parkinson’s disease, namely 
tremor-dominant and postural instability gait difficulty (PIGD) dominant (Jankovic 
et al., 1990). Unlike tremor-dominance, which is experienced in the limbs, the 
PIGD-dominance presents in symptoms of the central body. These symptoms are 
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considered to be more disabling (van Rooden, Visser, Verbaan, Marinus, & van 
Hilten, 2009) and more greatly associated with non-motor symptoms (Ba, Obaid, 
Wieler, Camicioli, & Martin, 2016).  
There are a range of non-motor symptoms of Parkinson’s. These can be 
categorised as cognitive, neuropsychiatric, gastrointestinal, sleep-related and 
autonomic (Chaudhuri, Yates and Martinez-Martin, 2005) (see Appendix A for full 
breakdown). Neurotransmitters of the dopaminergic, glutamatergic, cholinergic, 
serotonergic, and adrenergic systems are implicated in the presence of these 
symptoms (Lim, Fox, & Lang, 2009; Willis, Moore, & Armstrong, 2012). Non-
motor symptoms are common (Chaudhuri, Healy, & Schapira, 2006; Poewe, 2008) 
and impact patient QOL (Barone et al., 2009), but are typically less well recognised 
and addressed by health professionals (Chaudhuri & Schapira, 2009; Shulman, 
Taback, Rabinstein, & Weiner, 2002). This was well exemplified when researchers 
generated a ranked list of research priorities as identified by people with direct and 
personal experience of Parkinson’s. One non-motor symptom in particular came to 
the fore as the study population named ‘effective stress and anxiety management’ as 
the second greatest of all research priorities (Deane et al., 2014).  
The existing evidence base for the use of psychological therapy for anxiety in 
PwP is in its infancy. It has been argued that theoretical models and interventions of 
anxiety in this population should be augmented to address issues specific to 
Parkinson’s (Egan, Laidlaw and Starkstein, 2015). In line with this, Egan et al. 
(2015) developed an augmented Cognitive Behavioural model of anxiety and 
depression in Parkinson’s. This augmented CBT model sits alongside augmented 
CBT models in other areas of clinical neuropsychology and older adult psychology 
(Broomfield et al., 2011; Gracey, Longworth, & Psaila, 2016; Kishita & Laidlaw, 
2017). It incorporates well-established CBT predisposing and maintaining factors of 
anxiety and depression including core beliefs (Beck, 2011), rumination (Ehring, 
2008), hypervigilance relating to physical symptoms (Clark, 1986), 
counterproductive behaviours (Salkovskis, Clark, Hackmann, Wells & Gelder, 1999) 
and avoidance (Barlow et al., 2017), but adapts them to incorporate Parkinson’s 
specific components. This adaptation includes the incorporation of specific 
categories of Parkinson’s related cognitions, illness beliefs and cohort beliefs about 
disability. 
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Currently, anxiety in Parkinson’s is poorly defined, researched, diagnosed 
and treated (Chen & Marsh, 2014; Egan et al., 2015; Pontone et al., 2009; Todorova, 
Jenner, & Chaudhuri, 2014), arguably providing insufficient evidence with which to 
evaluate the augmented CBT model of Egan and colleagues (2015). In particular, it 
has been argued that for anxiety in PWP to be better addressed, research should 
strive to better understand and characterise the anxiety (Pontone et al., 2019).  
There are a number of factors that make it challenging to characterise the 
anxiety experienced by PwP. Firstly, chronic disease in general can contribute to 
anxiety through the reduction in sense of self, uncertainty about the future, 
challenges in relationships and social isolation (DeJean, Giacomini, Vanstone, & 
Brundisini, 2013). Yet, for those with Parkinson’s, the anxiety experience is also 
known to relate in part to disrupted dopaminergic, noradrenergic, cholinergic and 
serotonergic pathways associated with the disease (Barone, 2010; Chaudhuri & 
Schapira, 2009). A further challenge to the characterisation of the anxiety in 
Parkinson’s is that the anxiety can be intermittent, associated with variations in 
motor symptoms and antiparkinsonian medications (Siemers, Shekhar, Quaid, & 
Dickson, 1993; Witjas et al., 2002). It is also reported that an interaction occurs 
between the symptoms of Parkinson’s and those of anxiety, whereby one can 
activate the other (Pontone, 2013). The symptoms of the two disorders can also be 
difficult to distinguish from one another, owing to the overlap in many of the 
symptoms (Higginson, Fields, Koller, & Tröster, 2001). 
This thesis portfolio seeks to investigate the impact of anxiety on QOL for 
PwP and to better characterise their experience of anxiety. Chapter Two presents a 
Systematic Review which examines the relationship between anxiety and QOL for 
PwP. The Systematic Review has been written for publication in Movement 
Disorders. The review includes 22 studies, 17 of which were pooled in a correlation 
meta-analysis and 20 reviewed for their regression data. Chapter Three provides a 
link between the Systematic Review and Empirical Research Project. It also 
introduces the rationale for incorporating Patient and Public Involvement (PPI) into 
the project and for our choice of research methodology. Chapter Four presents the 
Empirical Research Project, which has also been written for publication in Movement 
Disorders. The project investigates the anxiety experienced by PwP to develop a 
detailed characterisation of the anxiety. Chapter Five describes the methodology 
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used in the Empirical Research Project in a level of detail not afforded by the 
Movement Disorders article word limit. Chapter Five specifically expands on the 
standardised clinical psychometric measures used and ethical considerations. Owing 
to word count restrictions of the empirical paper, additional results are presented in 
Chapter Six. Chapter Seven, the final chapter of this portfolio, integrates the findings 
from the Systematic Review and the Empirical Research Project, considering them in 
the context of wider psychological theory and literature in this area. It also provides 
a critical appraisal of the work, addresses clinical implications and makes 
suggestions for future research. Appendices spanning each of the chapters are 
provided at the end of the portfolio.  
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Chapter Two: Systematic Review 
 
The Relationship Between Anxiety and Quality of Life Among People with 
Parkinson’s. 
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Abstract 
Anxiety management remains an area of unmet need for people with 
Parkinson’s Disease (PwP) despite anxiety’s high prevalence in this population. This 
systematic review explored the relationship between anxiety and quality of life 
(QOL) among PwP. Searches of CINAHL, MEDLINE and PsycINFO yielded 22 
eligible studies. Included studies examined the correlation and/or regression of 
anxiety and QOL using validated measures in adults with idiopathic Parkinson’s 
disease. The studies examined 3834 PwP. Participants were 63% male, mean ages 
ranged from 58 to 72 years, disease duration ranged from 2.1 to 9.93 years and 
average Hoehn and Yahr disease severity scores fell between 1.4 and 4. Quality was 
assessed using a modified National Institutes of Health (NIH) Quality Assessment 
Tool. Most items were well conducted but 21/22 studies failed to justify their sample 
size. However, 25% of those reporting regression statistics did meet established 
criteria for adequate sample size. Meta-analysis of correlation data of 17 studies 
showed a pooled effect size (r = 0.53, (95% CI 0.44-0.61), Z = 9.96, p < 0.0001) 
indicating a strong relationship between anxiety and poorer QOL. There was 
significant heterogeneity in this finding (I2 = 86.1%), likely due to the diverse range 
of participants and measures. Exploration of regression analyses identified that 18 
out of 20 studies found that anxiety predicted significant variance in participant 
QOL. This review identified a strong correlation between anxiety and QOL, with 
regression identifying anxiety as a significant predictor of poor QOL. Therefore, 
more research is needed in anxiety management in PwP to address its negative 
impact.   
 
Prospero Registration: CRD42019152793 
Keywords: Parkinson’s; anxiety, quality of life, correlation, regression 
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Introduction 
Anxiety is a common non-motor symptom (NMS) in Parkinson’s Disease,1 
with a prevalence of 31%.2 This significantly exceeds the prevalence of anxiety 
disorders in the general population of older adults which is estimated to fall between 
3.2% and 14.2%.3,4 Unfortunately, anxiety in Parkinson’s is also an important area of 
unmet need.5 
Parkinson’s research has established that quality of life (QOL) is 
significantly worse for those with NMS than for those without.6 Anxiety is one such 
NMS that has been regularly implicated as a correlate or predictor of QOL. Studies 
exploring the relationship between anxiety and QOL in people with Parkinson’s 
(PwP) typically study anxiety as one of multiple NMS investigated in relation to 
QOL, an approach which supports the development of a holistic understanding. 
However, no review has yet systematically brought the anxiety-QOL findings of 
each of these studies together for collective consideration. Given that people with 
personal and professional experience of Parkinson’s have identified effective stress 
and anxiety management as their second greatest of all future research priorities in 
Parkinson’s,7 it is important that such a review is conducted. 
Current Systematic Review  
The aim of this study was to provide a systematic review of the relationship 
between anxiety and QOL in PwP. This includes a meta-analysis to provide an 
estimate of weighted pooled correlation coefficient effect sizes and an additional 
review of regression analyses. 
Method 
The review was registered with Prospero (CRD42019152793). 
Inclusion Criteria 
The review was restricted to papers written in English and published in full, 
in peer reviewed journals. Articles were included if their adult participants had a 
diagnosis of idiopathic Parkinson’s Disease and if they directly explored the 
relationship between anxiety and QOL using standardised measures validated in this 
population. No date restrictions were applied. 
Search Methods 
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A scoping search was conducted on 8th February 2019 through the Google 
Scholar Database using the search: ‘Parkinson’s Anxiety Quality of Life’. The 
results of the scoping search informed the MESH terms and keywords used in a 
systematic computerised search using CINAHL (EBSCO), MEDLINE (Ovid) and 
PsycINFO (EBSCO) databases. They were searched from inception of the databases 
to 9th March 2019. The search terms were Parkinson Disease AND Quality of Life 
AND Stress OR Anxiety. Full search strings used in each database are provided in 
Appendix C. 
Study Selection 
Duplicate articles were removed. Study titles and abstracts were examined to 
exclude obviously irrelevant studies, and then the remaining full texts assessed 
against the inclusion criteria by DC. Where there was any uncertainty about 
inclusion KD was consulted and inclusion agreed by discussion. 
Data Extraction 
Relevant data were extracted from the included articles by DC. 
Quality Assessment 
The quality of the included articles was assessed against five of the 14 
criteria from the National Institutes of Health (NIH) National Heart, Lung and Blood 
Institutes Quality Assessment Tool for Observational, Cohort and Cross-Sectional 
Studies8 (Appendix D). The quality criteria were selected to be relevant to the design 
and focus of this review. The wording of four items were taken verbatim from the 
NIH tool. An additional question regarding outcome measures was used that merged 
items nine and 11 from the NIH tool to create an item that did not make a distinction 
between independent and dependent variables. For the first item: ‘population clearly 
defined’, emphasis was placed on how representative the participants were of the 
whole Parkinson’s population, i.e. the study’s exclusion criteria and recruitment 
methods. We allowed studies to exclude comorbidities, non-idiopathic Parkinson’s, 
Dementia, and significant sensory impairment. The quality of studies was assessed 
for each study by DC and for 50 percent of the studies by CIC (Appendix E).  
Data Analysis 
Meta-Analysis 
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Studies reporting a correlation coefficient (r) of the relationship between 
anxiety and QOL were meta-analysed using a random effects model. Positive 
correlation coefficients indicate that symptoms of anxiety are associated with 
impairment to quality of life. Higher values of r represent a stronger positive 
association between anxiety symptoms and impaired quality of life. Effect sizes were 
considered as small, medium and large using .1, .3 and .5 respectively.9 
Some studies did not report the correlation coefficient (r) but instead reported 
the standardised beta coefficient (β) from regression analyses. A formula is 
recommended by which a relatively accurate estimate of r can be derived from β.10 
This formula was adopted in the current meta-analysis to convert β to r values such 
that they could be included in the meta-analysis.    
The meta-analysis was calculated using the MAVIS package version 1.1.3.11 
The correlation coefficients were extracted from each study and pooled to provide a 
weighted estimate of the size of the correlation between anxiety and QOL. These 
were reported alongside their 95% confidence interval values. Forest plots as well as 
Cochran’s Q test12 and the I-squared statistic13 were used to assess heterogeneity. 
The Cochran’s Q test reports the significance level of the heterogeneity within the 
studies. The I-squared provides a percentage of variation across studies attributed to 
heterogeneity as opposed to chance.   
Sensitivity Analysis 
Sensitivity analysis was undertaken to examine whether results were skewed 
by studies which required the conversion from beta coefficient (β) to correlation 
coefficient (r). 
Review of Regressions 
A number of studies completed regression analyses. As the types of 
regression differed substantially between studies, a quantitative synthesis of the 
findings was not feasible. Therefore, the results were extracted and reported together 
in a table. Each study was considered against established rules of thumb for 
adequacy of sample size (N ≥ 50+8m for testing the multiple correlations or N ≥ 
104+m for testing individual predictors - where m is the number of independent 
variables).14 As multicollinearity can contribute to the accuracy and precision of 
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regression coefficients,15 the studies’ acknowledgment and management of 
collinearity was also considered. 
Results 
This systematic search found 458 articles. An additional 24 articles were 
selected from the initial scoping search. This total of 482 articles was reduced to 317 
following the removal of duplicates, and a further 213 articles were removed as it 
was evident from their titles and abstracts that they did not meet the inclusion 
criteria. The remaining 104 articles were obtained in full and 82 removed (Appendix 
F) as they did not meet the inclusion criteria. A total of 22 articles were included in 
this review, see Figure 1 for a PRISMA diagram of this process. 
 
Figure 1. PRISMA diagram outlining the searching and exclusion process. 
 
Anxiety in Parkinson’s Disease 
19 
 
Characteristics of Studies 
Characteristics of the 22 studies included in this review 16-37 can be found in 
Table 1. Every study employed a cross-sectional design, whereby participants 
completed standardised questionnaires at a single time point to determine the 
relationship between a range of non-motor symptoms (including anxiety) and QOL. 
Eleven reported both correlation and regression analyses. 16,18,21,22,23,26,31,32,33,34,35 
Two reported correlational analyses only,17,36 whilst nine reported regression 
analysis only. 19,20,24,25,27,28,29,30,37  
Participants 
Participant characteristics are summarised in Table 1. Of the 22 studies, 19 
reported the setting from which participants were recruited. Sixteen of these had 
recruited through specialist clinics related to neurology, movement disorders, or 
Parkinson’s. Three of these studies additionally recruited from the community; 
namely a Parkinson’s Disease Society group,20 care for the elderly centre,24 and 
Parkinson’s support group.26 Of the remaining three studies, two recruited from 
hospitals22,25 and one from a Parkinson’s Research Centre.29 
Seventeen of the 22 studies reported their population’s stage of disease 
through an average Hoehn and Yahr Score. Of these, 16 averaged a score between 
one and three on the rating scale, representing the early to mid-stages of the disease. 
Only one study20 reported a mode of stage four and no studies reported stage five as 
an average score. This indicates that the more severe stage of the disease was not 
well represented by the studies included in this review.  
Twenty of the 22 studies reported the gender of participants. Seventeen of 
these reported a higher number of male than female participants. A total of 63% of 
participants were male, which is slightly greater than the estimated percentage of 
males living with Parkinson’s in the UK.38 Twenty studies reported the mean age of 
participants, which ranged between 58 and 72 years.  
Sixteen studies used the Parkinson’s Disease Questionnaire 39 (PDQ-39)39 as 
a measure of Quality of Life, whilst two studies used the shorter Parkinson’s Disease 
Questionnaire 8 (PDQ-8).40 The remaining studies used the Short Form Health 
Survey 36 (SF-36)41, Short Form Health Survey 12 (SF-12)42 and EuroQol five-
dimensional descriptive system (EQ5D)43. All of the QOL measures were self-rated. 
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To measure anxiety, fourteen studies used the Hospital Anxiety and Depression 
Scale – Anxiety (HADS-A)44. The Beck Anxiety Inventory (BAI)45 was used by 
three studies. The remaining studies used the Kouhout Anxiety Scale (KAS)46, Leeds 
Anxiety and Depression Scale-Anxiety (LAD-A)47, State Trait Anxiety Inventory-
Trait (STAI-T)48, Hamilton Anxiety Scale (HAS)49, and Parkinson's Anxiety Scale 
(PAS)50. Just two of these scales (HAS and PAS) were observer rather than self-
rated. 
Quality Assessment 
Individual quality assessment scoring for each study can be found in 
Appendix E, and an overview of these found in Figure 2. The decision was taken not 
to calculate overall quality scores, as not all items will have the same impact.51 
Twelve studies had met the quality criterion for their recruitment as their 
participants reasonably represented the whole Parkinson’s population. For six 
studies, it was unclear whether they met the criterion because they either did not 
provide sufficient detail on recruitment strategy16,19,22,26,34 or did not adequately 
describe the clinical criteria used to identify participants.20 Four studies did not meet 
the criterion as they excluded participants below the age of 65 27 or selectively 
recruited those with a recent diagnosis.29,33,36 
Five studies16,20,23,29,37 met the quality criterion for participation rate as it was 
greater than 50%, whilst two19,25 did not as their participation rates were less than 
50%. For fifteen of the studies it was not possible to ascertain whether they met the 
criterion as they did not provide sufficient detail on the numbers invited to 
participate.  
Twenty studies met the quality criterion of uniform recruitment and 
application of inclusion/exclusion criteria. For the remaining two it was unclear 
whether they met the criterion they did not report where they recruited patients 
from19 or clearly specify inclusion/exclusion criteria.20 
As part of our selection criteria we only included studies that used measures 
of anxiety and QOL that have been validated in Parkinson’s populations. It was 
therefore unsurprising that all studies used clearly defined, valid and reliable 
measures. However, one study19 had missing data from 7 out of 49 participants, so 
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we found the measures were not implemented across all study participants, meaning 
it did not meet this criterion.  
In contrast, all but one study21 did not justify their sample size and therefore 
did not meet this quality criterion. This meant that we were unable to ascertain if 
they had sufficient numbers of participants to ensure the statistical robustness of their 
findings. 
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Table 1 
Summary of Studies Included in the Review 
 
Reference Country Setting Sample 
size 
Mean 
age 
Gender (%) Hoehn and 
Yahr  
Disease 
duration 
(years) 
Anxiety 
measure 
QOL 
measure 
Relevant analysis 
Chrischilles et al., 
200216 
USA Neurology clinic 193 68.2 M = 58.5, F = 
41.5 
2-2.5* NR KAS SF-36 Pearson’s correlation; 
Stepwise regression 
Carod-Artal et 
al., 200717 
Brazil Outpatient neurology 
department 
144 62 M = 53.5, F = 
46.5 
2** 6.6 HADS-A PDQ-39 Spearman’s correlation 
Carod-Artal et 
al., 200818 
Brazil Outpatient neurology 
department 
115 62.5 M = 56.5, F = 
43.5 
3** 8.7 HADS-A PDQ-39      Spearman’s 
correlation; Standard 
multiple regression 
McKinlay et al., 
200819 
New 
Zealand 
NR 49 66.5 M = 63.3, F = 
36.7 
2.5* 6 HADS-A PDQ -39 Hierarchical multiple 
regression 
Rahman et al., 
200820 
UK Hospital for neurology 
and neurosurgery; 
Parkinson’s Disease 
society 
130 67 M = 65, F = 35 4* 9.28 BAI PDQ-39 Stepwise multiple 
regression 
Quelhas & Costa, 
200921 
Portugal Movement disorder 
consultation at hospital 
33 72 M = 44, F = 56 2* NR HADS-A SF-36 Spearman’s correlation; 
Standard multiple 
regression 
Gallagher et al., 
201022 
UK Hospital 94 67.5 M = 65, F = 35 2* 7.8 HADS-A PDQ-39 Spearman’s correlation; 
Stepwise multiple 
regression 
Haviklova et al., 
201123      
Slovakia Outpatient neurology; 
hospitals 
93 68 M = 49.5, F = 
50.5 
2*** 6.1 HADS-A PDQ-39 Pearson’s correlation; 
Hierarchical multiple 
regression 
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Table 1           
Reference Country Setting Sample 
size 
Mean 
age 
Gender (%) Hoehn and 
Yahr  
Disease 
duration 
(years) 
Anxiety 
measure 
QOL 
measure 
Relevant analysis 
Hinnell et al., 
201224 
UK Neurology; Care for 
elderly centres 
462 67.5 M = 64.9, F = 
35.1 
2* 5 HADS-A PDQ-8 Hierarchical multiple 
regression 
Dubayova et al., 
201225 
Slovakia Hospital outpatient 142 67.6 M = 73, F = 27 NR 7.6 HADS-A SF-36 Stepwise multiple 
regression 
Hanna & Cronin 
Golomb, 201226 
USA Neurology clinic; 
Local PD support 
groups 
38 62.1 M = 52.6, F = 
47.4 
2* 8.4 HADS-A PDQ-39 Spearman’s correlation; 
Hierarchical multiple 
regression 
Skorvanek et al., 
201327 
Slovakia NR 106 NR NR NR NR HADS-A PDQ-39   Standard multiple 
regression 
Fereshtehnejad et 
al., 201428      
Iran Movement disorders 
clinic 
140 61.3 NR NR 
 
NR HADS-A PDQ-39 Standard multiple 
regression 
Baig et al., 
201529 
UK Parkinson’s Disease 
research centre 
796 64.8 M = 66.1, F = 
33.9 
2* 2.9 LAD-A  EQ-5D Logistic regression 
Fereshtehnejad et 
al., 2015
30
 
Iran Movement disorder 
outpatient department 
157 61.4 M = 68.8, F = 
31.2 
2** 6.8 HADS-A PDQ-39 Standard multiple 
regression 
Jones et al., 
201531 
USA Centre for movement 
disorders; 
Neurorestoration 
107 64 M = 69, F = 31 2* 9 STAI-T PDQ -39 Correlation (type NR); 
Stepwise multiple 
regression 
Walton et al., 
201532  
Australia Parkinson’s' Disease 
research clinic 
203 66.8 M = 68, F = 32 2* 5 HADS-A PDQ-39 Pearson’s correlation; 
Standard multiple 
regression 
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Note. NR = not reported; * = mode; ** = median; *** = mean. KAS = Kouhout Anxiety Scale; HADS-A = Hospital Anxiety and Depression Scale - Anxiety; LAD-A = Leeds Anxiety 
and Depression Scale - Anxiety; STAI-T = State Trait Anxiety Inventory-Trait; BAI = Beck Anxiety Inventory; HAS = Hamilton Anxiety Scale (observer rated); PAS = Parkinson’s 
Anxiety Scale (observer rated); PDQ-39 = Parkinson’s Disease Questionnaire 39; PDQ-8 = Parkinson’s Disease Questionnaire 8; SF-36 = Short Form Health Survey 36; SF-12 = 
Short Form Health Survey 12; EQ-5D = EuroQol five-dimensional descriptive system. 
Table 1  
 
Reference Country Setting Sample 
size 
Mean 
age 
Gender (%) Hoehn and 
Yahr  
Disease 
duration 
(years) 
Anxiety 
measure 
QOL 
measure 
Relevant analysis 
Wu et al., 201533     China Department of 
neurology 
301 58.4 M = 54.8, F = 
45.2 
1.9*** 2.1 HAS  PDQ-39 Correlation (type not 
specified); Stepwise 
multiple regression 
Fan et al., 201634 
 
Taiwan Movement disorder 
outpatient department 
134 65 M = 63.4, F = 
36.6 
1.4*** 7.9 BAI PDQ-39 Pearson’s correlation; 
Standard multiple 
regression 
D’Iorio et al., 
201735 
Italy NR 84 65.4 NR 1.75*** 9.3 PAS PDQ-8 Pearson’s correlation; 
Standard multiple 
regression 
Yoon et al., 
201736 
South 
Korea 
Movement disorder 
clinic 
89 NR M = 52.8, F = 
47.2 
NR NR BAI PDQ-39 Spearman’s correlation 
Prisnie et al., 
201837 
Canada Movement disorder 
clinic 
224 67.5 M = 63.4, F = 
36.6 
NR NR HADS-A SF-12 Standard multiple 
regression 
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Figure 2. Proportion of studies that met each of the quality assessment criteria.  
Meta-Analysis 
Five studies could not be included in the meta-analysis as they did not report 
their data in a manner that could be incorporated into the analysis16,25,28,29,37. A total 
of 17 studies were included in the meta-analysis, based on data from 2332 
participants. The correlation coefficients included were taken directly from 12 
studies, whilst for the remaining five studies an estimate of the correlation 
coefficient was calculated from the β value. The distribution of coefficients is 
presented in Figure 3. Anxiety was strongly correlated with QOL (r = 0.53, (95% CI 
0.44-0.61), Z = 9.96, p < 0.0001). The test of homogeneity of variance indicated 
significant heterogeneity across studies: [Q(16) = 115.45, p < 0.0001, I2 = 86.1%]. 
The potential sources of heterogeneity included the mean disease duration ranging 
from 2.1 to 9.3 years, mean age ranging from 58.4 to 72 years old, and the gender 
split ranging from 44% to 69% males. Additionally, five measures of anxiety: 
HADS, BAI, HAS, PAS, STAI-T and three measures of QOL: PDQ-39, SF-36, 
PDQ-8 were used. 
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Figure 3. Forest plot estimating pooled correlation effect size.  
Sensitivity Analysis 
Converting β to an estimate of r allowed the inclusion of studies into the 
meta-analysis that would otherwise have been omitted. The increased breadth of 
research designs and increased number of correlation coefficients that this approach 
affords is associated with respective reduction in the size of non-sampling and 
sampling errors. Sensitivity analysis was undertaken to examine whether results 
were skewed by studies which required the conversion from beta coefficient (β) to 
correlation coefficient (r). When those studies were removed from the correlation, 
the analysis identified that the range of r’s (0.44 to 0.75) was smaller. Anxiety 
remained strongly correlated with QOL [r = 0.58, (95% CI 0.52-0.63), Z = 15.73, p < 
0.0001]. The test of homogeneity again indicated significant heterogeneity across the 
studies: [Q(11) = 24.84, p < 0.05, I2 = 55.7%].  
Based on this sensitivity analysis, the decision was taken to include all 17 
studies in the meta-analysis. A number of factors influenced this decision. Firstly, 
when the beta-converted studies were added to the analysis, the correlation effect 
size remained strong. Secondly, given that there was a slight overall reduction in 
effect size when the studies were added, we have confidence that their incorporation 
did not inflate the effect size. With this in mind, the addition of these five studies and 
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their data for 897 participants was considered a valuable addition to the meta-
analysis. However, it is important to acknowledge that the inclusion of these 
additional data increased the heterogeneity of variance across the studies.  
Regression 
The twenty studies that completed regression analyses are summarised in 
Table 2. Four different types of multivariate regression were used: standard, 
18,21,27,28,30,34,35,37, stepwise, 16,20,22,25,31,32,33 hierarchical, 19,23,24,26 and logistic 29. 
Eighteen of the studies found that anxiety predicted QOL. Anxiety is consistently 
among the studies’ variables (motor and non-motor) that are most predictive of QOL 
and contribute significant unique variance in QOL. Five of those eighteen 
studies18,24,30,32,37 met the rule of thumb for appropriate sample size14 and reported 
consideration of multicollinearity between predictors and which invites increased 
confidence in the findings from these studies.  
Two studies22,33 did not find anxiety to be a significant predictor of QOL. 
Consideration should be made regarding the observer rated anxiety measure 
(Hamilton Anxiety scale) that was used by the latter study. It is possible that the 
observers did not sufficiently capture the anxiety as well as a self-report study. 
Further, for regression analyses, it divided the population in half according to disease 
phenotype, so this may have limited the power to find an effect. The former study22 
also had a concerningly small sample size (n=94) for the nine variables entered into 
the regression. 
 
 
 
 
 
 
 
 
Anxiety in Parkinson’s Disease 
28 
 
 Table 2 
Summary of Regressions where Reported 
 
 
 
Study 
Type of 
multivariate 
regression 
Adequate 
sample size 
Collinearity 
consideration 
reported 
Anxiety statistics All factors in model 
Chrischilles, 200216  Stepwise ✓ X Mental QOL (R2 = 0.303, p 
< 0.05); Physical QOL (NS 
– NR) 
As no summary score of QOL was included, we report no further 
details. 
Carod-Artal, 200818 Standard ✓ ✓ (B = 2.3, p < 0.0001) Disability (B = 1.1, p < 0.001); anxiety (β = 2.3, p < 0.0001). 
McKinlay, 200819 Hierarchical X X (β = 0.69, p < 0.001) 1. Motor symptoms (tremor), motor symptoms (non-tremor). 2. 
Anxiety (β = 0.69, p < 0.001); apathy (NS); fatigue (NS); depression 
(β = 0.51, p < 0.01); sleep (NS); hallucinations (β = 0.39, p < 0.01). 
Rahman, 200820 Stepwise X X (β = 0.478, p < 0.0005) 1. Age of PD onset; disease stage; disability; disease duration. 2. 
Depression (β = 0.409, p < 0.0005; UV = 40.8%). 3. Anxiety (β = 
0.478, p < 0.0005, UV = 17%). 
Quelhas & Costa, 
200921 
Standard X X (β = -0.36, p < 0.05) Disease stage (β = -0.28, p<0.05); depression (NS); anxiety (β = -
0.36 p < 0.05) 
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Table 2 
Summary of Regressions where Reported  
 
 
 
Study 
Type of 
multivariate 
regression 
Adequate 
sample size 
Collinearity 
consideration 
reported 
Anxiety statistics All factors in model 
Gallagher, 201022 Stepwise X ✓ Anxiety is not a significant 
predictor of QOL (value 
not reported) 
Autonomic symptoms (β = 0.49, p < 0.001); depression (β= 0.22, p < 
0.005), fatigue (β = 0.18, p < 0.01); sleep (β = 0.17, p < 0.05); 
psychosis (NS), pain (NS); sleep quality (NS); anxiety (NS), motor 
symptoms stage (NS). 
Havlikova, 201123 Hierarchical X X (β = 0.38, p = 0.001) 
 
 
1.Age; gender and disease duration. 2. Motor symptoms (β = 0.48, p 
< 0.001). 3. Anxiety (β = 0.38, p = 0.001, UV = 28%). 4. Depression 
(NS). 5. Sleep quality sleep quality (β = 0.31, p < 0.001). 6. Daytime 
somnolence (NS). 
Hinnell, 201224 Hierarchical ✓ ✓ (β = 0.196), p < .001) 
 
1.Age, comorbidities, independence, disease duration, dopaminergic 
medication. 2. Cognitive ability (NS);  motor symptoms (β = 0.148, p 
< 0.001, UV= 1.3%); anxiety (β = 0.196, P < .001, UV = 2.2%); 
other non-motors symptoms (β = 0.232, p < 0.001, UV = 3.7%; 
depression (β = 0.308; p < 0.001, UV = 5.6%). 
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Table 2 
Summary of Regressions where Reported 
 
 
 
 
Study 
Type of 
multivariate 
regression 
Adequate 
sample size 
Collinearity 
consideration 
reported 
Anxiety statistics All factors in model 
Dubayova, 201225 Stepwise ✓ X Mental QOL (β = -0.24, p < 
0.01); Physical QOL (β = -
0.19, p < 0.05) 
As no summary score of QOL was included, we report no further 
details. 
Hanna, 201226 Hierarchical X X (β = 0.34, P < .05) 1. Anxiety (β = 0.34, P < .05, UV = 29%). 2. Depression (β = 0.37, 
P < .05, UV = 10%). 3. Overall cognition (NS). 
Skorvanek, 201327 Standard X X (β = 0.36, P < .001) Anxiety (β = 0.36, P < .001); depression (β = .21, P < .05); education 
(β= 0.18, p < 0.05); disease duration (β =.18, p < 0.05); disease 
progression (motor) (β = 0.24, p < 0.01). NS = age, gender, apathy, 
dopaminergic medication. 
Fereshtehnejad, 201428 Standard X X (𝐵 = 0.6, 𝑃 = 0.003) Anxiety (𝐵 = 0.6, 𝑃 = 0.003); depression (B = 1.5, p < 0.001). NS = 
early onset, sex, education level, comorbidity, disease stage, 
nutritional status. 
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Table 2 
Summary of Regressions where Reported  
Study 
Type of 
multivariate 
regression 
Adequate 
sample size 
Collinearity 
consideration 
reported 
Anxiety statistics All factors in model 
Baig, 201529 Logistic X X (OR = 4.89 p < 0.001) 
 
Pain (OR = 13.7, p < 0.001) and depression (OR = 6.76, p < 0.001), 
anxiety (OR = 4.89, p < 0.001). Remaining 20 non-motor symptoms 
(see paper for full list), had lower OR than anxiety. 
Fereshtehnejad, 201530 Standard ✓ ✓ (β = 0.17, p < 0.01) Anxiety (β = 0.17, p < 0.01); depression (β = 0.32, p < 0.001); 
activities of daily living (β = 0.43, p < 0.001); UPDRS parts I, II, IV 
(NS); motor symptoms (NS), fatigue (NS), nutritional status (NS). 
(Added to baseline covariates of sex, level of education, comorbidity 
score and PD duration). 
Jones, 201531 Stepwise X ✓ (β = 0.472, p < 0.001) 1. Age, global cognitive ability, and disease severity. 2. Anxiety (β = 
0.472, p < 0.001); depression (NS - data not provided); apathy (NS - 
data not provided). 
Walton, 201532 Stepwise ✓ ✓ (B = 1.041, p < 0.001) 1. Dopaminergic medication use; time since diagnosis. 2. Freezing of 
Gait (B = 0.955, p < 0.001, UV = 9.4%); depression (0.527, p < 
0.001, UV = 4.4%); anxiety (B = 1.041, p < 0.001, UV = 4.2%); 
sleep I (B = 0.842, p < 0.001, 3.2%); sleep II (B = 0.283, p < 0.05, 
1%); stage of disease (NS).  
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Table 2 
Summary of Regressions where Reported  
 
Note. NS = non-significant at p < 0.05; UV = unique variance in QOL accounted for by variable; NR = not reported; OR = odds ratio; ADL = activities of daily living.
Study 
Type of 
multivariate 
regression 
Adequate 
sample size 
Collinearity 
consideration 
reported 
Anxiety statistics All factors in model 
Wu, 201533 
 
Stepwise ✓ X Anxiety is not a significant 
predictor of QOL (NR) 
1. Motor phenotype, age, gender, comorbidity, disease duration, 
treatment, UPDRS III score, disease stage. 2. Depression (β  = 0.646, 
p < 0.001). NS = anxiety, cognitive function, ‘other non-motor’.  
Fan, 201634 
 
Standard X ✓ (𝐵 = 0.95, 𝑝 = 0.001) Anxiety (𝐵 = 0.95, 𝑝 < 0.005); depression (B = 0.70, p < 0.001), 
ADL (B = 1.47, p < 0.001); mental state (B = -1.97, p < 0.019). NS = 
sex, disease duration, disease stage, dopaminergic medications, 
disease stage (UPDRS parts I, III, IV, V, VI,) sleep. 
D’Iorio, 201735 Standard X ✓ (𝐵 = 0.389, p < 0.001) Anxiety (𝐵 = 0.389, p < 0.001); apathy (executive) (B = 0.251, p < 
0.05); cognitive function (B = 0.283, p < 0.05); depression (NS); 
global functioning (NS); apathy (cognitive/behaviour initiation) (NS).  
Prisnie, 201837 
 
Standard ✓ ✓ Mental QOL (B = -1.09, p 
< 0.0001); Physical QOL 
(B = 0.25, p > 0.05) (NS) 
As no summary score of QOL was included, we report no further 
details. 
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Discussion 
This systematic review is the first to review the relationship between anxiety 
and QOL in PwP. Twenty-two studies were identified, with a combined total of 3834 
participants. Overall, the quality of the studies was deemed relatively high. However, 
just one study21 provided a power calculation. So individually the studies may have 
been at risk of identifying spurious relationships, but this may be mitigated by 
entering their results into a meta-analysis. Seventeen of these studies (n = 2332) 
informed a meta-analysis that indicated a strong positive relationship (r = .53) 
between anxiety symptoms and impacted QOL (i.e. higher anxiety is associated with 
lower QOL). Whilst the relationship is strong, causality cannot be inferred from this 
relationship. It is possible that relationship is bidirectional, or that the presence of 
artifacts inflates the result. To extend our review beyond bivariate correlational 
relationships, 20 studies (n = 3601) that completed regression analyses, were 
reviewed, with all but two studies finding anxiety to account for significant variance 
in participant QOL. The unique variance in QOL accounted for by anxiety, and its 
position among the consistently strong predictors, also brings its role to the fore. 
The findings of this review highlight the significance of the role of anxiety in 
Parkinson’s. The indicated impact of anxiety may explain why those with personal 
experience of Parkinson’s have prioritised the need for research on stress and anxiety 
management techniques in Parkinson’s.7 The findings are also consistent with the 
body of research outside of Parkinson’s, which indicates that anxiety disorders have 
a significant impact on QOL.52 
The extent of this relationship between anxiety and QOL appears comparable 
to that present among other long-term physical health conditions including 
respiratory53, cardiac54, diabetic55 and stroke56. However, patients with these 
conditions now have greater access to condition-specific anxiety and depression 
focused psychological interventions provided by primary care mental health 
services.57-59 This allocation of resource stemmed from the acknowledgement that 
untreated mental health in physical health patients can exacerbate symptoms and 
increase cost expenditure in the health care system.60 Yet, no such tailored support is 
provided for those with Parkinson’s. By highlighting the significant role of anxiety 
in QOL for PwP, it is hoped that the disparity in care is highlighted. 
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Limitations 
Whilst overall the quality of included studies was good, not every study 
clearly reported participation rate or clearly defined their participants. The omission 
of sample size justification was the biggest threat to study credibility, but this was 
managed through our retrospective sample size calculations and review of 
collinearity measures. It is also notable that some of multiple regression studies did 
not report standardised beta values. This meant that, for these studies, predictive 
ability of variables could not be compared. This restricted conclusions for these 
studies. 
 It is important that the findings are considered in the context of significant 
heterogeneity across these studies, likely reflecting the range of differences in 
samples and methodologies.13 The range in population demographics, such as mean 
disease duration (2-9 years) and age (58-72 years) are an example of the 
heterogeneity of the samples. In the meta-analysis the sensitivity analysis highlighted 
that heterogeneity increased following the addition of studies where standardised 
beta was converted to r. We also acknowledge that the introduction of these papers 
may also have impacted the accuracy of the correlation effect size estimate.  
A significant methodological consideration is that the studies are not 
specifically designed to explore the experience of an anxious population. Therefore, 
the anxiety experience within and between studies is broad and the conclusions about 
‘disorders’ of anxiety are limited. Further, six different measures of anxiety were 
used, including two that were observer rated. The validity and reliability of observer 
rated measures may be problematic given the known challenges in identifying and 
diagnosing anxiety in this population.5 Additionally, four different measures of QOL 
were used. The overall diversity of both the QOL and anxiety measures is such that 
they may have been assessing different facets of anxiety and QOL relationships.  
As can be seen from the PRISMA diagram (Figure 1), articles that were not 
written in English were excluded, and no ‘grey literature’ or additional literature was 
sought. We acknowledge that this increases the risk of publication bias in this 
review. Finally, the screening of full text papers according to eligibility for inclusion 
in this study was carried out by the principle author and not replicated by a second 
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author. A full independent replication of the screening process may have provided 
increased confidence in the review. 
Clinical and Research Recommendations 
As this study did not assess a clinical intervention, no specific 
recommendations can be made. However, the review does highlight a significant 
negative impact of anxiety on QOL. Placed within the wider context of anxiety in 
this population being highly prevalent yet poorly defined, diagnosed and 
treated,5,61,62 this finding emphasises the importance of further research being 
conducted. This research should target improved conceptualisation, diagnosis and 
treatment of anxiety among PwP. Based on the quality assessment of the papers 
included in this review, we would also encourage future research to consistently 
report participation rate, clearly define participants and justify sample size.  
Conclusion 
The current review identified a strong correlation between anxiety and QOL. 
It also identified that anxiety is a significant predictor of poor QOL. In the context of 
the unmet therapeutic needs of PwP with anxiety, the findings highlight the 
importance of more research in the area. 
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Chapter Three: Bridging Chapter 
Overview of Chapter 
This chapter provides a bridge between the Systematic Review in Chapter 
Two and the Empirical Research Project in Chapter Four. It also introduces the 
rationale for incorporating Patient and Public Involvement (PPI) input into the 
empirical project, as well as detailing how PPI enhanced the project. Finally, it 
includes information on the decision-making process that led to our choice of 
research methodology.  
Introduction 
The systematic review in Chapter Two established a strong relationship 
between anxiety and quality of life in participants with Parkinson’s. It also identified 
their anxiety to be a significant predictor of poor QOL. It follows that appropriate 
conceptualisation, diagnosis and intervention for anxiety among people with 
Parkinson’s (PwP) is important.  
As outlined in Chapter One, anxiety in Parkinson’s has a complex 
symptomology. Yet, research attempting to capture the experience of anxiety in 
Parkinson’s has typically used the Diagnostic and Statistical Manual, Fourth Edition 
(DSM-IV; American Psychiatric Association, 1994), a standard classification of 
mental disorders used by mental health professionals. Consequently, many PwP do 
not meet the diagnostic criteria for an anxiety disorder despite having clinically 
significant anxiety (Chen et al., 2010; Leentjens et al., 2011; Pontone et al., 2009). It 
is argued that if the anxiety symptoms could be characterised beyond the restrictions 
of such standardised anxiety criteria and measures, it would significantly improve 
the diagnosis and subsequent treatment of anxiety in this population (Dissanayaka et 
al., 2017).  
In recognition of this, our research team sought to design an empirical 
research project that could explore the potentially broad and nuanced content of 
anxiety experiences among PwP. We felt it important not to be led by, or indeed 
restrict participant experiences to, predetermined symptom criteria. Instead we 
wanted to generate a participant led understanding of their symptomology. The aim 
of the study was not only to capture the experiences of PwP, which it did using 
Nominal Group Technique (NGT), but also for PwP to support every step of the 
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research. Accordingly, the project incorporated Patient and Public Involvement 
(PPI).  
Patient and Public Involvement 
PPI refers to the process whereby research is conducted ‘with’ or ‘by’ 
patients, carers, service users, services or their representatives, rather than ‘to, 
‘about’ or ‘for’ them (Hayes, Buckland, & Tarpey, 2012). It is increasingly 
recognised as instrumental in improving the quality, relevance and impact of 
research projects (Ocloo & Matthews, 2016). Crucially, PPI can shift research 
attention to areas that most concern health service users (Brett et al., 2014; Crowe, 
Fenton, Hall, Cowan, & Chalmers, 2015). Further, PPI input to the creation of plain 
English participant facing documents has been found to widen the acceptability and 
accessibility of the documents (Brett et al., 2014). Similarly, more effective 
dissemination has been achieved through PPI involvement in presentation of 
findings (Baxter et al., 2016). It has also been reported that the exchange of expertise 
between researchers and PPI members promotes reciprocal learning (Staley & 
Barron, 2019).  The mutual benefit extends further, such that PPI volunteers can feel 
empowered through skill development and contribution to progress whilst 
researchers are reported to better understand patient experience and are increasingly 
motivated to develop the research (Hanson & Hanson, 2017; Wilson et al., 2015). 
Understandably then, incorporation of PPI into health research is increasingly 
promoted (Wilson et al., 2015) and it has been more recently argued that PPI should 
be extended to doctoral research (Tomlinson, Medlinskiene, Cheong, Khan, & Fylan, 
2019). 
It was decided that PPI volunteers would be recruited to join the empirical 
project steering group from the beginning of the research process. This was achieved 
through liaison with the Research Involvement Officer at Parkinson’s UK and 
subsequent completion of application documents. A total of two volunteers were 
recruited, both had Parkinson’s and experience of anxiety that affected their quality 
of life. We were fortunate to recruit one male and one female. One had tremor 
dominant Parkinson’s and one postural instability gait difficulty dominant (PIGD) 
Parkinson’s. This gave our team a range of expertise of the impact of the symptoms 
of Parkinson’s and anxiety. They were given an hour-long training session on the 
role of PPI volunteers in research processes and an outline of the research project by 
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KD. KD has previously developed PPI training materials for Parkinson’s UK and 
promotes its utility in all her research. They were also able to contact Parkinson’s 
UK for further support and training as they wished. 
Their role included attendance of quarterly steering group meetings. They 
reviewed and amended all participant-facing documents. This included the 
participant information sheets, consent forms, and two online surveys. They 
supported the qualitative analysis of the first survey responses and subsequent 
development of summary statements for second survey.  Finally, they helped with 
interpretation of results of the second survey. Due to their substantive input to the 
design and conduct of the research they will be authors on the peer reviewed journal 
articles to be published from the empirical findings. They will also aid the team in 
reporting study findings in lay reports to Parkinson’s UK and in press releases. 
We experienced the mutual benefit of incorporating PPI into the project. As 
the principal researcher, conversations with our volunteers about their experiences of 
both anxiety and of Parkinson’s reinforced the importance of beginning with open-
ended survey questions to capture the nuances of experiences. It also provided the 
entire steering group with a renewed sense of the importance of the research and 
made the process exciting. Their editing of patient facing documents and shift to 
plain English increased their acceptability and accessibility. Further, their piloting of 
questionnaires helped to maximise the content of the survey without it becoming a 
burden for participants. These benefits were highlighted to us by a participant from 
the first survey who contacted us to “congratulate the designers/programmers of the 
survey” as it did not have the “problems (ambiguity, etc)” associated with other 
surveys they had completed. Alongside the principle investigator, one of the PPI 
volunteers (BC) presented a piece at the UEA Health Sciences Festival 2019 about 
his experience of the benefits of PPI. He reported feeling a sense of achievement and 
reward not just from his involvement, but also from the success of the project and 
positive feedback. He found it interesting to compare survey responses with his own 
situation. Finally, he enjoyed the social aspect and found it fun to be part of the 
steering group. 
Choice of Method 
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The steering group met to discuss ideas for a research method that would best 
enable us to achieve the aims of the study (summarised in Table 1). Firstly, given the 
limited characterisation of anxiety among people with Parkinson’s, it was important 
that the chosen method gave participants the opportunity to present any and all 
aspects of their anxiety experiences. Crucially then, the method could not be 
restricted to the exploration of predetermined factors in the way that a purely 
quantitative style questionnaire would be (Pothas, De Wet, & De Wet, 2001). 
Choosing a methodology with a qualitative component was therefore key. It was also 
important that the method enabled the experiences of a large number of participants 
across the UK to be gathered to capture the breadth of the anxiety experience in 
PwP. Qualitative methods such as focus groups and interviews, which are typically 
time consuming, limited to a small number of participants and restricted by 
geographical location, were therefore not appropriate. Finally, beyond capturing just 
the breadth and detail of anxiety experiences, it was important that the method 
enabled us to generate some form of consensus about which experiences were most 
common. Interviews and purely qualitative questionnaires would not be able to 
achieve this. Accordingly, this led us to consider the more novel methodologies, 
namely the Nominal Group Technique (NGT), Concept Mapping and the Delphi 
method. These methodologies have distinct qualitative process, but can also be used 
on a large scale and allow researchers to summarise the data quantitatively. 
NGT provides a methodology to generate and subsequently rank ideas from a 
given population (Boddy, 2012). This approach has been described as ‘semi 
quantitative and qualitative’ (Perry & Linsley, 2006) and thus some authors class it 
as a mixed method design (Potter, Gordon, & Hamer, 2004). Typically, participants 
are presented with a question(s) and are invited to provide a written response 
containing their ideas. Each participant response is anonymous, and the contribution 
of each participant is given equal weighting (Harvey & Holmes, 2012). The 
responses of the individuals are then pooled into a list and shared among the group, 
with the goal that the group will prioritise each item on the list according to 
predetermined criteria (Boddy, 2012). Essentially, this process can be divided into 
two phases; brainstorming and prioritisation. The benefits of this approach to 
brainstorming are numerous. Firstly, the generation of ideas as individuals is more 
productive than as a group (Taylor, Berry, & Block, 1958). A number of reasons for 
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this have been cited, including: openness of response due to participant preference 
for anonymity (Boddy, 2012), absence of the wasted time and stunted creativity that 
can be associated with turn taking in groups (Nijstad & Stroebe, 2006), and space for 
reflection and creativity being greater without the presence of the noise of a group 
(Campbell, 1999). In sum, the quality and quantity of ideas generated have been 
found to be significantly greater using NGT than other forms of brainstorming 
groups (Mullen, Johnson, & Salas, 1991). With regards to ranking ideas using NGT, 
this is reported to generate more structured data than other methods, such as focus 
groups (Claxton, Ritchie, & Zaichkowsky, 1980).  
NGT has been previously used in Clinical Health Psychology research 
studies to identify service user priorities or needs (e.g. Sanderson, Hewlett, Richards, 
Morris, & Calnan, 2012) or to develop greater understanding of clinical difficulties 
(Elliot & Shewchuk, 2002). NGT has been modified recently, with face-to-face 
contact increasingly replaced with large scale online surveys (Deane et al., 2014). 
The steering group agreed that the modified NGT methodology met all of our 
desired criteria. Crucially, the qualitative stage means that participant answers are 
not restricted to the exploration of predetermined factors. It also enables a ranking 
process and results in data that are easy to quantify. Further, as participant input is 
only required at two phases, participant input would be relatively quick. Finally, if 
NGT was modified to use online surveys for the brainstorming and prioritisation 
phases would enable us to reach over 300 participants nationwide. This would 
represent a characterisation of anxiety in PwP on an unprecedented scale.  
Concept mapping is a multi-staged, mixed methods approach designed to 
develop understanding of complex issues (Kane & Trochim, 2007). The method 
involves a process of multiple stages which, through collection of participant 
generated ideas and application of multivariate analysis, generates an interpretable 
visual map of ideas (Flaherty, 2014). The map prioritises ideas, clusters them within 
a circle or box and identifies links between clusters through connecting lines (Davis, 
2011; Kinchin, Streatfield, & Hay, 2010). Aspects of this approach that were suitable 
for this project were that it was not restricted to the exploration of predetermined 
factors, data can be easy quantified and the information can be ranked. However, 
other aspects meant it was less suitable. Firstly, participant input is typically required 
for the majority of the six stages of this process (Burke et al., 2005), meaning that 
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participant burden well exceeded that of other comparable methods. This burden 
seemed unjustified, particularly as the linking of clusters was not required to answer 
our research questions. Concept mapping also stipulates that participants are asked 
just one question at the brainstorming phase of the process. This was at odds with 
our desire to ask multiple questions to best capture the detail of their experience. At 
the ranking phases of thesis process, concept mapping requires that the number of 
items within each cluster are approximately equal. It was felt that this was not well 
suited to the anxiety experience where some clusters may justifiably differ in size to 
others. Finally, the experience of concept mapping with people with Huntington’s 
disease (Smith et al., 2015) highlighted that the clustering and ranking stages of the 
process require significant cognitive capacity. Given that a significant percentage of 
our target population may have some level of mild cognitive impairment (Chaudhuri, 
Yates, & Martinez-Martin, 2005) we were concerned that this might impact on 
participant ability to complete these stages online.  
The Delphi technique is an approach which seeks to generate consensus 
among a group (Lynn, Layman, & Englebardt, 1998). This is an iterative process, 
typically spanning a number of rounds of data collection and analyses (Green, Jones, 
Hughes, & Williams, 1999). Round one typically requires the participants to 
provides answers to open ended questions, which are then processed presented to 
each participant through a questionnaire at the next round (Keeney, Hasson, & 
McKenna, 2001). The results are then prepared and then presented in another 
questionnaire and feedback round, a process that continues until a consensus is 
reached (Beretta, 1996). In many ways the Delphi was well suited to our project. It is 
not restricted to predetermined factors, data can be easy quantified, the information 
can be ranked, it is suited to large scale data collection and multiple questions can be 
asked at brainstorming the phase. However, we felt that the Delphi method placed 
too great an emphasis on consensus. Whilst we considered it useful to have the 
patient experiences ranked in some way, our principle objective was to identify the 
breadth of anxiety experiences in Parkinson’s, not to emphasise a consensus. The 
multiple rounds taken to achieve consensus is also criticism of this method as it is 
synonymous with participant drop out in the later stages (Keeney et al., 2001).   
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Table 1  
Comparison of Methodologies Against Project Requirements 
Methodology Suitable for 
large scale 
UK wide 
representation 
n > 300 
Data easily 
quantifiable 
Can identify 
new 
experiences 
as well as 
pre-
determined 
Ranking/ 
Prioritisation 
achieved 
Participant 
input < 1 
hour 
Participants 
can be 
asked 
multiple 
questions  
Modified 
NGT 
✓ ✓ ✓ ✓ ✓ ✓ 
Concept 
mapping 
✓ ✓ ✓ ✓ X X 
Delphi ✓ ✓ ✓ ✓ X ✓ 
Focus group X X ✓ ✓ ✓ ✓ 
Interviews X X ✓ X ✓ ✓ 
Qualitative 
questionnaire 
✓ X ✓ X ✓ ✓ 
Quantitative 
questionnaire 
✓ ✓ X ✓ ✓ ✓ 
 
Approach to Modified Nominal Group Technique 
The steering group established that the modified Nominal Group Technique 
using online surveys would best enable us to achieve the aims of the study. The 
qualitative brainstorming phase would be achieved through an online survey of 
open-ended survey questions created by the steering group. The questions would ask 
participants to describe their anxiety, its impact and the role of medication. Then a 
series of prompting questions to encourage participants to expand on their answers. 
These prompts, informed by the Five Areas CBT assessment model (Williams, 
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2001), would ask about triggers, thoughts, behaviours, physical sensations, emotions. 
This model has high acceptability in a variety of healthcare settings (Williams & 
Whitfield, 2001) and accesses patient problems across a range of domains such as to 
provide a clear conceptualisation of the difficulties (Wright, Williams, & Garland, 
2002). Our lay advisors also felt it would be a good way to capture experiences. 
Questions regarding the impact of anxiety and the role of Parkinson's medication 
would also be used. The analysis of all collected submissions would be influenced 
by the protocol established by the James Lind Alliance (2018b). The submissions 
would be reviewed, such that duplicate or similar responses are grouped to create 
representative summary statements. The PPI volunteers would give advice to the 
research team on the clarity, relevance, and uniqueness of each statement. They 
would ensure that all aspects raised by the brainstorming respondents are represented 
in the second rating survey. These statements would then be taken to the quantitative 
phase of the process: a second online survey, to be rated by participants according to 
the extent to which they are typical of their experience.  
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Chapter Four: Empirical Paper 
 
The Anxiety Experiences in Parkinson’s Disease: A Mixed Methods 
Investigation. 
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Abstract 
Objective: Anxiety is highly prevalent among people with Parkinson’s Disease 
(PwP), yet it is poorly characterised and treated. This project aimed to better 
characterise the anxiety by surveying the detailed insights of PwP with anxiety. 
Method: With the support of Patient and Public Involvement volunteers, modified 
Nominal Group Technique methodology facilitated data collection across two online 
surveys. Participant with a diagnosis of Idiopathic Parkinson’s Disease and 
experience of significant anxiety were recruited through the Parkinson’s UK 
Research Support Network, Parkinson’s UK Support Groups and on the Parkinson’s 
UK website.  
Results: The first brainstorming survey collected the anxiety experiences of 205 
PwP. These experiences were deduplicated and converted to 137 unique 
representative statements for a second survey. Here 341 participants Likert rated the 
extent to which each item is typical of their experience. The range of anxiety 
experiences identified is beyond anything previously captured by research in this 
population. Whilst some of the anxiety experiences are similar to those of anxiety 
disorders in the general population, the majority of items were related specifically to, 
or exacerbated by, Parkinson’s symptoms.   
Conclusions: This is the largest survey ever conducted characterising anxiety in 
Parkinson’s. It identifies the anxiety’s complexity and the significant impact of 
Parkinson’s on the expression of the symptoms. The strong relationship between 
Parkinsonian and anxiety symptoms likely requires therapists with Parkinson’s-
specific knowledge and the support of a multidisciplinary clinical team. 
 
Keywords: Parkinson’s; Anxiety, Characteristics, Nominal Group Technique, Patient 
and Public Involvement. 
 
 
 
 
 
 
Anxiety in Parkinson’s Disease 
52 
 
Introduction 
Anxiety is a common non-motor symptom of Parkinson’s Disease. With 31% 
of people with Parkinson’s (PwP) experiencing clinically significant anxiety,1 the 
prevalence is greater than that reported in the general population.2 Yet, anxiety in 
Parkinson’s remains poorly characterised, underdiagnosed and undertreated.3,4 
Anxiety disorders negatively impact both quality of life (QOL) 5,6 and self-perceived 
health status.7 Unsurprisingly, people affected by Parkinson’s identified stress and 
anxiety management as their second highest research priority.8   
There is a paucity of research into the treatment of anxiety for people with 
Parkinson's (PwP) whether pharmacological or psychological.9 For effective 
psychological therapy the character of Parkinsonian anxiety needs to be well 
understood.10 It has been identified that many different anxiety disorders such as 
social phobia, panic disorder and generalised anxiety disorder are common among 
PwP.11,12 However, a significant percentage of anxiety experienced by PwP is 
classified as ‘Anxiety Disorder Not Otherwise Specified (NOS)’ 4,13,14 i.e. anxiety 
that affects QOL, but does not meet criteria for a specific anxiety disorder. It is 
hypothesised that NOS anxiety among PwP stems from clinical anxiety features that 
are unique to Parkinson’s.13 Yet, there is a dearth of research investigating this 
‘Parkinson’s specific’ anxiety. This is unfortunate given that it has been identified as 
way to improve understanding, diagnosis and treatment of anxiety in Parkinson’s.9 
The aim of the present study is to enhance the existing characterisation 
seeking the detailed insights of PwP who have experience of such anxiety.  
Research Questions 
1. What are the characteristics of anxiety experienced by PwP? 
2. To what extent are each of these characteristics typically experienced? 
Method 
Design 
We used a modified Nominal Group Technique (NGT), which is a 
methodology that incorporates both qualitative and quantitative components. 14,15 
The modifications were influenced by the approach of the James Lind Alliance 
(JLA), a partner organisation of the National Institute for Health Research (NIHR). 
 
Anxiety in Parkinson’s Disease 
53 
 
They have used the approach to identify, prioritise and publish uncertainties in over 
100 areas of health and care that could be better understood and answered by future 
research. The JLA Priority Setting Partnership (PSP) guidebook16 provides a step by 
step framework for how to conduct and analyse modified online NGT in a PSP. This 
provided a useful blueprint for our methodology, albeit with some adaptations in 
instances where their emphasis on priority setting was not relevant to our research 
questions. Our emphasis on the qualitative steps facilitated the collection of rich, 
representative descriptions of anxiety on a large scale, whist the more condensed 
qualitative step established a sense of the extent to which each characteristic was 
experienced. Patient and Public Involvement (PPI) volunteers were involved in all 
steps of this research process. 
The first step involved setting up a steering group. Two fully trained PPI 
volunteers (BC and JM), with experience of significant anxiety since their 
Parkinson’s diagnosis, were recruited to the steering group from the Research 
Support Network at Parkinson’s UK. Their roles included attendance of quarterly 
steering group meetings, reviewing all participant-facing content, and supporting 
with the design and analysis of both surveys. Their expertise provided an important 
additional perspective to the steering group which also included perspectives of a 
Clinical Psychologist, a Cognitive Behavioural Therapist, and a Health researcher 
with over 20 years expertise in Parkinson’s and personal experience of a functional 
movement disorder. 
In line with the next step of the JLA approach, the steering group then 
developed an online survey to gather participant experiences. In this case, we used 
open-ended questions about the participants’ experience of anxiety since their 
Parkinson's diagnosis. This facilitated the qualitative ‘brainstorming’ element of this 
NGT methodology. The survey asked participants to describe their anxiety, its 
impact, and the role of Parkinsonian medications. In line with the Five Areas CBT 
assessment model,17 subsequent questions asked about triggers, thoughts, 
behaviours, physical sensations and emotions. The steering group, including PPI 
volunteers, agreed that these questions were an appropriate way to prompt 
participants to consider the anxiety experiences across a range of domains.  
Once participant responses had been submitted, a series of analysis steps 
from the JLA guidebook were followed (see analysis), with steering group input and 
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verification at each step. The analysis enabled the generation of ‘indicative’ 
statements that represented the major themes identified in the participant responses. 
The aim was that the statements would capture what the participants had meant, 
whilst being concise and easily understood.   
 Once the indicative statements had been generated, they were incorporated 
within a second online survey.  Participants were invited to rate the representative 
statements on five-point Likert scales according to the extent to which they typically 
experience each one (‘Never or almost never’, ‘Rarely’ ‘Sometimes’ ‘Often’ 
‘Always or almost always’). Full listing of all advertisements, information sheets, 
consent forms and questions used in both surveys are available in (Appendices G-L). 
The JLA focus heavily on prioritisation, in particular establishing a final ‘top 10’ 
items at a priority setting workshop. This step was not required or appropriate for 
answering our research question and was therefore omitted.  
Participants 
Parkinson’s UK advertised the surveys on its website and to its online 
Research Support Network, which has over 5000 members interested in Parkinson’s 
research. The advertisement was also distributed to the Parkinson’s UK support 
groups nationwide. Participants were required to be over the age of 18, able to read 
and write in English, have a diagnosis of Parkinson’s and have experienced anxiety 
that impacted on QOL since diagnosis. Those with dementia were excluded.  
Measures 
Both surveys also gathered information on participant demographics and 
clinical status; physical and mental health, level of independence and access to 
psychological or psychiatric treatments. Two standardised psychometric measures 
were used; the Parkinson’s Disease Quality of Life Questionnaire-8 (PDQ-8)17 and 
the Parkinson’s Anxiety Scale (PAS)28. These measures were validated in 
Parkinson’s populations. 19,,20,21 
Procedure  
For each of the surveys, participants accessed a project information sheet, 
consent form and the online survey through hyperlinks in the advertisement. Paper 
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copies of these documents were available on request. The first survey was open 
February-March 2019, and the second survey June-September 2019. 
Ethical Considerations  
Ethical approval was granted by the Faculty of Medicine and Health Sciences 
Research Ethics Committee at the University of East Anglia on 10/01/2019, 
Reference Number: 201819-046 (Appendix M). The British Psychological Society 
(2010)22 guidelines for the conduct of psychological research were adhered to.   
Data Analysis 
The approach taken to NGT analysis was influenced by guidance from the 
JLA Guidebook.16 Each step of the analysis process was first completed by the 
principle author (DC) then reviewed by the steering group before final decisions 
were made. 
Survey One 
The participants’ open-ended responses regarding their anxiety experiences were 
downloaded. Combined, the participant responses totalled 16,503 words. The 
principal author then familiarised themself with the participant responses. Any parts 
of participant responses that clearly did not address the questions were separated, 
reviewed by the rest of the steering group and ultimately removed. The remaining 
data were then systematically analysed by the principal author through coding. An 
inductive approach to coding was adopted, whereby codes were driven by what was 
in the data. This approach can be likened to phase two of the thematic analysis 
process as described by Braun and Clark.23 The codes enabled duplicate or similar 
responses to be grouped together. This process occurred iteratively as the data were 
analysed and resulted in 75 distinct codes being identified (detailed in Appendix N). 
Unsurprisingly given the nature of the survey’s prompting questions, the codes sat 
within broader themes of ‘triggers’, ‘thoughts’, ‘behaviours’, ‘physical’, ‘emotion’ 
and ‘impact’. The coding of the data was reviewed by the steering group. An 
example of a participant response is given below and the coding of this response is 
outlined in Table 1.  
“Because it affects my breathing, I tend to avoid going out to meet people and avoid 
social situations. I start thinking if people are looking at me then it makes my 
symptoms worse ie dyskinesia, when it kicks in increases. The anxiety will last until I 
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take myself out of the situation. It has a big effect; I have to try to not think about it. 
but I have been known to fake feeling ill & not go out. I hate the thought that people 
may look at me”. 
Table 1 
Coding Example 
Participant Response Code Label Code Name 
It affects my breathing P1 Fight or flight 
I tend to avoid going out to meet people & 
avoid social situations 
B7 Avoid social situations 
I start thinking if people are looking at me TH6 Social evaluation 
It makes my symptoms worse i.e. 
dyskinesia, when it kicks in increases 
I6 Increases Parkinson’s symptoms 
The anxiety will last until I take myself out 
of the situation 
B5 Escape 
I have to try to not think about it B14 Attempt to distract from anxiety 
I have been known to fake feeling ill and 
not go out 
B7 Avoid social situations 
I hate the thought that people may look at 
me 
TH6 Social evaluation 
The steering group met again with the aim of converting the 75 codes into 
‘indicative statements’ that could be presented to participants of the second survey. It 
was important that each statement represented the items captured by the code and 
was easy for participants to read. In many cases this meant that more than one 
statement was used per code. For example, code TH13 (toileting) was summarised 
with two indicative statements, ‘I worry about the embarrassment of having a 
toileting accident (being incontinent)’ and ‘I am embarrassed by the frequency and 
urgency with which I need to urinate’. In total 137 ‘indicative’ statements were 
generated and agreed upon. This process included a PPI volunteering piloting the 
statements in survey form. The analysis process is summarised in Figure 1.  
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Figure 1. Flow chart providing overview of phase one of analysis. 
Survey Two 
Compared with the labour-intensive qualitative analysis of the survey one 
responses, the quantitative analysis of survey two was far simpler. Descriptive 
statistics were used, with participant Likert responses totalled for each item, then 
median values calculated for each. The median scores were then ranked in order 
from highest to lowest to establish an overall ranking of the items. The 
demographics of participants from both surveys were also analysed and reported 
using descriptive statistics.  
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Results 
Two-hundred and five participants completed the first brainstorming survey, 
and 341 completed the second rating survey. The demographics and clinical 
characteristics of participants in both surveys is presented in Table 1. The 
respondents were reasonably representative of the membership of Parkinson’s UK 
i.e. slightly younger, less advanced in their Parkinson’s, and with less ethnic 
diversity than the whole UK population of people with Parkinson’s.24 We allowed 
PwP who had historic experience of anxiety to participate in this survey, but in each 
survey, at least 70% of participants exceeded the PAS threshold for anxiety disorder. 
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A total of 137 descriptive statements were generated following the analysis 
of the first survey and then rated by participants of the second survey. At the rating 
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stage, the rate of missing data was between 0.3% and 2.1%. One hundred and six of 
the items are presented in Tables 2-4. These are the items with a median score of at 
least 3 points (where 3 was described as “sometimes” on the Likert scales). For the 
items relating to ‘impact’, those with a median of at least 4 (‘agree’) are included. 
All items that have lower median values can be found in Appendix O.  
The items listed in this paper have been grouped as Triggers (32), Thoughts 
(32), Behaviours (15), Physical sensations (8), Emotions (8), Impact (11). Across the 
groups, 12% of the items were directly related to Parkinson’s (P), e.g. 'When I see 
others at the later stage of Parkinson's’. In contrast, 27.5% of the items seemed to 
represent anxiety experiences common outside of the Parkinson’s population (N), 
e.g. ‘I try to distract myself from the anxiety’. The remaining 60.5% of items, whilst 
common outside of Parkinson’s population, are likely exacerbated by the 
Parkinson’s experience (EP). It is also noteworthy that, among the items with the 
highest median score ‘often’, the percentage of items directly related to Parkinson’s 
increases to 40%. In the ‘often’ category, this equals the percentage of items that are 
likely exacerbated by Parkinson’s (40%) and is double the percentage of those 
common outside of Parkinson’s (20%). 
Table 3 
Rated List of Anxiety Triggers 
Triggers N 
Median 
Likert 
Score 
Theme 
When I feel time pressured (for example making it to an 
appointment in time or at a supermarket till where I have to 
coordinate tasks quickly) 
339 4 EP 
When I am not able to perform a task or role that I previously would 
have been able to 
339 4 EP 
When I see others at the later stage of Parkinson's 336 4 P 
My anxiety was triggered or made worse in the period just after my 
diagnosis of Parkinson’s 
 
 
 
339 3* P 
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Table 3 
Rated list of Anxiety Triggers 
Triggers N Median Theme 
When I am not occupied/busy 331 3 P 
At night 332 3 N 
When I am tired 335 3 EP 
When I have tremor  338 3 P 
When I have difficulty with movement or coordination 339 3 P 
By being outside my home 334 3 EP 
When in confined or enclosed spaces    339 3 N 
When in public settings 336 3 EP 
When I am in crowded and/or noisy places 339 3 EP 
If people are too close and I feel my movement is restricted 339 3 EP 
When I am travelling 337 3 EP 
When I am in social situations (where one may be observed or 
evaluated by others, such as speaking in public or meeting new 
people) 
338 3 EP 
When I am ignored in social situations 338 3 EP 
When I eat in public 337 3 EP 
When I am unsure if I can reach a toilet in time 336 3 EP 
When others do not understand what I am experiencing  334 3 EP 
When loved ones get upset 339 3 EP 
When I have disagreements with others or am criticised by others 336 3 EP 
When I am stressed by life or work (e.g. when a number of tasks fall 
together) 
334 3 EP 
When I do not meet demands or expectations 336 3 EP 
When trying to organise myself and make decisions  337 3 EP 
When I am having a medical consultation/appointment 339 3 EP 
When reading about Parkinson's  333 3 P 
I am not aware what the trigger is or why the anxiety occurs 332 3 N 
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Note. P = directly related to Parkinson’s; N = normal for anxiety outside of Parkinson’s EP = common 
anxiety experience but likely exacerbated by Parkinson’s. Likert Scale: 1 = Not at all, 2 = Rarely, 3 = 
Sometimes, 4= Often, 5 = Always. *= ranked against different labels, 1 = strongly disagree, 2 = 
Disagree, 3 = Neither Agree or Disagree, 4= Agree, 5 = Strongly Agree.  
 
Table 4 
Rated List of Anxious Thoughts 
Thoughts N Median Theme 
I worry about the rate at which my Parkinson’s symptoms progress and how I  
will cope at their worst 
340 4 P 
I worry about the impact of my Parkinson’s on my family and how they will 
cope 
340 4 P 
I compare my current abilities to my past abilities 337 4 EP 
I worry about small things that never used to bother me as much 337 4* N 
I view my anxiety as a proportionate and rational response to the difficulties I 
experience with Parkinson’s 
337 4* P 
There is no fixed focus to my worry; I worry about anything, including 
irrational things, things I have no control over 
338 4* N 
I compare my health status to those who are in better health 337 3 EP 
I worry about falling and/or the consequences of falling 338 3 P 
I worry about my speech (e.g. not speaking clearly or being understood) 338 3 P 
I worry I will get dementia 337 3 EP 
I worry that I am not able to contribute and will let others down or become a 
burden 
337 3 EP 
I worry about my death 
 
335 3 EP 
 
 
Table 3 
Rated list of Anxiety Triggers 
   
Triggers N Median Theme 
When I have difficulties with sexual performance 178 3 EP 
When I am in pain 267 3 EP 
When I am alone 
When the ground looks slippery  
332 
337 
3 
3 
N 
EP 
 
Anxiety in Parkinson’s Disease 
63 
 
Table 4 
Rated List of Anxious Thoughts 
 
 
Thoughts N Median Theme 
I worry I will Lose control and not be able to do my everyday tasks 
I worry I will lose my identity 
340 
333 
3 
3 
EP 
EP 
I worry about my future ability to be an effective parent or carer for those who 
need my support 
335 3 EP 
I view my anxiety as largely irrational and out of proportion  334 3* N 
I feel out of control with my worry and find it hard to stop 334 3* N 
I blow things out of proportion and make mountains out of molehills* 338 3 N 
I worry about having to go into a care home and the quality of the care I 
would receive there 
339 3 EP 
I worry about upsetting those close to me or making things difficult for them 339 3 EP 
I worry how others will perceive my Parkinson’s symptoms and that they will 
judge me negatively 
336 3 P 
I worry about eating in public and that others will judge me negatively 338 3 EP 
I am embarrassed by the frequency and urgency with which I need to urinate 334 3 EP 
I worry about the embarrassment of having a toileting accident (being 
incontinent) 
339 3 EP 
I worry that I will be not be able to function properly in public situations (e.g. 
on escalators, in supermarkets, in pubs) 
339 3 EP 
I worry about feeling anxious; how long it will last for, whether it will impact 
on my health, or how I will cope with it 
337 3 EP 
I worry about what is causing my anxiety   337 3 N 
I worry that others will notice I’m anxious 338 3 N 
I think about past events over and over again 336 3 N 
I worry about the possibility of failing or making a mistake 337 3 N 
I worry about the possibility of being late to appointments 339 3 EP 
I worry about the welfare of others 337 3 N 
Note. P = directly related to Parkinson’s; N = normal for anxiety outside of Parkinson’s EP = common 
anxiety experience but likely exacerbated by Parkinson’s. Likert Scale: 1 = Not at all, 2 = Rarely, 3 = 
Sometimes, 4= Often, 5 = Always. *= ranked against different labels, 1 = strongly disagree, 2 = 
Disagree, 3 = Neither Agree or Disagree, 4= Agree, 5 = Strongly Agree.  
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Table 5 
Rated List of Anxious Behaviours, Physical Sensations, Emotions, and Impact 
Behaviours N Median Theme 
I am more argumentative or short tempered   339 3 N 
I try to disguise my anxiety 339 3 N 
I try to distract myself from the anxiety 336 3 N 
I plan things in great detail, including how to get out of a situation/location 
quickly (e.g. sit near the exit or toilet) 
339 3 EP 
When I enter an anxiety provoking situation I try to get in and out of the 
situation as quickly as possible 
337 3 N 
I prefer to be accompanied by someone familiar when going into new 
places/situations 
340 3 EP 
I withdraw and isolate myself 338 3 N 
I avoid giving an opinion or disagreeing with others 339 3 EP 
I avoid decision making and/or positions of responsibility 336 3 EP 
I avoid social interactions 337 3 EP 
I over-analyse or check over things more than I need to 336 3 EP 
I avoid public situations   340 3 EP 
In public, I select food or drink that is easier to manage or I avoid eating or 
drinking altogether  
338 3 EP 
I avoid busy or crowded places 
I avoid confined spaces or places that are not easy to escape from 
339 
338 
3 
3 
EP 
EP 
Physical Sensations    
Fatigue or tiredness 339 4 EP 
Changes to body temperature  333 3 EP 
Increased sweating 333 3 EP 
Muscle tension 336 3 EP 
Stomach discomfort (churning/butterflies)  335 3 EP 
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Table 5 
Rated List of Anxious Behaviours, Physical Sensations, Emotions, and Impact 
Physical Sensations N Median Theme 
I need to use the toilet 334 3 EP 
Restlessness 
Increased Heart Rate 
336 
332 
3 
3 
N 
N 
Emotions    
Feeling overwhelmed  338 3 EP 
Feeling of dread 338 3 N 
Feeling nervous 339 3 N 
Feeling panicked 335 3 N 
Feeling frightened/scared/terrified 338 3 N 
Feeling upset 336 3 N 
Feeling irritated 333 3 N 
Feeling angry 337 3 N 
Impact    
Has restricted me and impacted my freedom and independence 337 3 EP 
Has made my Parkinson’s symptoms worse 337 3 P 
Has impacted my sleep 337 3 EP 
Has impacted my relationships 337 3 EP 
Has made me more isolated 338 3 EP 
Has made it harder to complete daily tasks  339 3 EP 
Has made it hard to think clearly 
Has impacted my confidence 
336 
338 
3 
3 
EP 
N 
Has made it hard to express myself 339 3 EP 
Has impacted my ability to work 167 3 EP 
Has impacted my ability to be an effective parent or carer for those who need 
my support                                                                                                                                                
183 
 
3 EP 
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Note. P = directly related to Parkinson’s; N = normal for anxiety outside of Parkinson’s EP = common 
anxiety experience but likely exacerbated by Parkinson’s. Likert Scale: 1 = Not at all, 2 = Rarely, 3 = 
Sometimes, 4= Often, 5 = Always.  
Discussion 
The present paper represents the largest study to date examining the nature of 
anxiety in Parkinson’s. Two online surveys, co-created with PPI volunteers, were 
used to identify the anxiety experiences of a total of 394 PwP. It is the first paper to 
capture the broad (137 distinct statements) and the nuanced nature of these 
experiences. It highlights why characterising anxiety in Parkinson’s through 
traditional anxiety frameworks has posed a challenge. Whilst recognising that that 
there is no ‘one size fits all’ characterisation of anxiety for PwP, this research 
methodology enabled the rating of the anxiety experiences to highlight those most 
commonly experienced. It has also facilitated the identification of a number of 
common themes among the items which ultimately have significant implications for 
research and clinical practice. 
A common thread throughout the listed items is that a significant proportion 
of the anxiety mirrors that of a non-Parkinson’s population. The strong presence of 
safety seeking and avoidance behaviours, the presence of meta-worry, negative 
comparison to past abilities, catastrophising of anxiety symptoms, fear of social 
judgement and fear of failure are all examples of this.25 This is encouraging as it may 
indicate that some of the guiding principles of existing evidence-based psychological 
interventions may be applicable to the experience of anxiety in PwP. 
In contrast, many of the most prominent anxiety experiences are those which 
are specific to the experience of Parkinson’s. Similarly, the majority of items are 
likely exacerbated by the Parkinson’s experience. The identification of these items in 
this study aligns with the paradigm that the mainstream conceptualisation and 
treatment of anxiety could benefit from augmentation with Parkinson’s-specific 
considerations in order to maximise effectiveness.10 It also invites reflection on the 
services supporting these patients and the expertise required to deliver the treatment. 
For example, a psychological practitioner considering a trigger such as 'when I feel 
time pressured (for example making it to an appointment in time or at a supermarket 
till where I have to coordinate tasks quickly)', would likely benefit from Parkinson’s-
specific knowledge of the possible impact of motor, cognitive and sensory symptoms 
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of Parkinson’s that may influence the feeling of time pressure. Similarly, they would 
be better placed to consider the possibility that the physical experiences of fatigue, 
restlessness, muscle tension may be Parkinsonian symptoms, as opposed to anxiety.  
Integrated, multidisciplinary care models have already been found to be 
beneficial for the treatment of other Parkinson’s symptoms.26 There is a growing 
argument that a more integrated and multidisciplinary approach to anxiety care is 
this population is required.9 Given the Parkinson’s-specific nature of much of the 
anxiety reported by participants, the findings of the present study support this. They 
also indicate that anxiety symptoms can be triggered by other Parkinson’s symptoms 
and vice versa. This provides further support for a multidisciplinary approach that 
joins up these previously fragmented treatment pathways. This study also highlights 
that “seeing others at the later stage of Parkinson's” is a prominent trigger for many, 
thus a traditional group intervention format involving patients at a range of disease 
stages may impact attendance, attrition and efficacy of the intervention. 
Further, it may be useful to consider whether some of the anxiety experiences 
may have commonality with anxiety in other ‘long-term health conditions’. Moss‐
Morris27 calls for ‘unified theory’ in chronic diseases. For example, the existing 
body of work focusing on adjustment to diagnoses of long term conditions28 may be 
applicable to those identifying with anxiety being ‘worse in the period just after my 
diagnosis of Parkinson’s’. Similarly, worry about ‘becoming a burden’ or ‘how 
family will cope’ may benefit from existing interventions relating to anxieties 
regarding progression of disease.29It is also apparent how many of the anxiety items 
involve those close to the PwP, whether as thoughts (‘I worry about the impact of 
my Parkinson’s on my family and how they will cope’, triggers ('When loved ones 
get upset’) or behaviours (‘I prefer to be accompanied by someone familiar when 
going into new places/situations’). With this in mind, interventions that consider the 
family may be valuable. Early support for this notion was provided by a partner-
assisted CBT intervention, which resulted in reduced anxiety and caregiver burden.30  
Limitations   
The study provides a broad description of common experiences of anxiety in 
PWP, but we recognise that there are sub-populations that may have quite different 
experiences of anxiety when compared to each other. We have plans for further 
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analysis to examine these issues and to determine what characteristics group and 
correlate with each other.   
Online recruitment and participant input was central to achieving large scale 
participation nationwide, as was access to the Parkinson’s UK Research Support 
Network and support groups. However, it is likely this will have biased the 
population to have limited representation of those with more severe disease, lower 
socioeconomic status, or from ethnic minorities.8  
Recommendations for Future Research 
Links to CBT conceptualisations and interventions dominate the discussion 
because they have the greatest evidence base in Parkinson’s at this time. However, 
psychological conceptualisations such as acceptance and commitment and 
compassion focussed approaches may all glean valuable insight from this data. There 
is indeed some support for the utility of these therapeutic modalities in the treatment 
of anxiety in PwP,31,32 but more research is required. 
Conclusions 
This is the largest survey characterising anxiety in Parkinson’s. Anxiety in 
Parkinson’s is complex with generic, Parkinson’s-specific and Parkinson’s-enhanced 
aspects. It is hoped this characterisation can inform the design of future assessment 
and psychological therapies, possibly enhancing efficacy. 
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Chapter Five: Extended Methodology 
Overview of Chapter 
This chapter relates to the methodology of the empirical project, building on 
the information presented in Chapter Four. It includes information about the 
measures used and ethical considerations. 
Measures 
In each survey, two standardised clinical psychometric measures were used 
to characterise the participant sample. The Parkinson’s Disease Quality of Life 
Questionnaire 8 (PDQ-8; Jenkinson, Fitzpatrick, Peto, Greenhall, & Hyman, 1997) 
measured participant health related quality of life through eight self-report items. 
Each item is rated on a five-point scale (‘never’, ‘occasionally’, ‘sometimes’, ‘often’, 
‘always – or cannot do at all’). This is a valid and reliable (Cronbach’s alpha = 0.81) 
measure of health-related quality of life for people with Parkinson’s (Tan, Lau, 
Wing, Au, & Luo, 2007). It has also been used by other researchers as a measure of 
quality of life in PwP (Martinez-Martin et al., 2004). As it is not designed to give 
prescriptive scores it has no prescribed cut off scores for determining ‘caseness’, but 
potential scores range from zero to 32. The Parkinson’s Anxiety Scale (PAS; 
Leentjens et al., 2014) was used to measure anxiety in people with Parkinson’s. The 
PAS measures anxiety on a 12-item patient-rated scale with three subscales for 
persistent anxiety, episodic anxiety, and avoidance behaviour. Each scale item 
consisted of five responses. A total score of above 13-14 is deemed indicative of the 
presence of an anxiety disorder. This is a valid and reliable measure of anxiety in a 
Parkinson’s population with internal consistency (Cronbach’s coefficient of 0.91).  
Ethical Considerations 
The project was granted ethical approval by the Faculty of Medicine and 
Health Sciences Research Ethics Committee at the University of East Anglia on 
10/01/2019, reference number: 201819 - 046 (Appendix M). The research adhered to 
The British Psychological Society (2010) guidelines for the conduct of psychological 
research.   
 Before completing the online survey at either phase of this project, 
participants were required to read the information sheet and complete a consent form 
(Appendices H, I, K, L). The consent forms provided the participant an opportunity 
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to confirm that they understood and agreed to the information provided in the 
information sheet regarding the research process. The ability to access our online 
link and complete the surveys, or indeed to contact the lead author for a paper copy 
to be sent to them was taken as indicative of appropriate mental capacity. 
For the online survey and online ranking form, participants were made aware 
that, because their data were non-identifiable, it would not be possible for data to be 
withdrawn once provided. They were however reminded that until they submitted 
their responses, they could still withdraw their involvement. There was a small 
possibility that some participants might experience distress when completing the 
surveys. In view of this, contact details of supporting agencies were signposted at 
every stage of the process. The signposting was to their local GP, and the free and 
confidential helplines offered by Parkinson’s UK, The Samaritans and SANE. 
All data were stored in line with the General Data Protection Regulation 
(2018). The research methodology was such that the participants were not 
identifiable by their responses. At each phase of data collection, participants were 
given the option to provide their contact details if they wanted to be involved in the 
next phase of data collection, or to receive information about the findings of the 
research when complete. Where provided, these personal details were never linked to 
their responses. The participant responses and participant contact details were always 
stored separately and securely either on password protected online survey databases. 
Contact details will only be kept for 2 years after the participants have completed the 
surveys. This will allow for the results of the study to be distributed to them in a lay 
report. All anonymised data will be kept for 10 years on the secure UEA server.  
Participants were made aware that their participation in any of the phases of 
data collection was voluntary and that they were not obliged to take part. The 
methodology was such that deception was not required in this study. A short debrief 
statement was placed prior to the point at which participants submitted their 
responses. This included researcher contact information and signposting information.  
For the involvement of PPI volunteers, the Health Research Authority (HRA; 
2016) have clarified that because PPI volunteers play an advisory and planning role 
that is distinct from that of the participants, ethical approval is not required for their 
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involvement. Prior to agreeing to take part in the project they were provided with 
information about the project and their role. Travel expenses were refunded.  
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Chapter Six: Additional Results and Discussion 
Overview of Chapter 
This chapter outlines additional findings obtained from the empirical research 
project, which have not been reported in the Empirical Paper. Firstly, anxiety 
experiences that were not included in the empirical paper will be reported and briefly 
discussed. However, most of the chapter is dedicated to the responses to additional 
questions included in the first survey, that were not discussed in the empirical paper. 
These relate to participants’ methods of anxiety management. The results are listed, 
but these are preceded by an introduction to this line of enquiry.  
Additional Anxiety Experiences 
As was outlined in the Empirical Paper, participants rated the anxiety 
experience on a Likert scale from one to five. Following analysis, those experiences 
with a median score of two (‘rarely’) or below were not included in the empirical 
paper so have been listed in Table 1.  
The medians of these 31 items suggest that, taken as a whole population, they 
occur rarely or have limited impact. It is notable that key themes identified in the 
empirical paper also appear to be present in these items. It appears that some of these 
anxiety experiences are generic anxiety experiences common to the general 
population (29%) whilst others are a direct result of Parkinsonian presentation (10%) 
or at least exacerbated by it (61%). The ratio of items falling into each of these 
categories is also comparable to that of the Empirical Project.    
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Table 1 
Rated Anxiety Statements Not Reported in Empirical Paper 
 
 
 
 
 
Triggers N Median Theme 
When I am at home 334 2 N 
When exercising  332 2 EP 
When walking 333 2 EP 
When I am unhappy about the healthcare I am receiving 336 2 EP 
When I wake up 334 2 EP 
By specific seasons or extremes of weather  333 2 EP 
When I have hallucinations 75 2 P 
Around menstruation 6 1.5 N 
When I drink caffeine  337 1 N 
When I smell strong smells or odours 334 1 N 
Thoughts    
When experiencing physical symptoms of anxiety, I worry that they 
mean something more catastrophic  
332 2 N 
I worry that I stand out as different 338 2 EP 
I worry about dribbling and that others will judge me negatively 338 2 P 
I worry that someone will knock me over in busy places 340 2 EP 
I focus too much on my medication (e.g. when its due, side effects, 
whether it’s working) 
334 2 EP 
I am worried that others are embarrassed to be with me 338 2 EP 
I fear being left alone because others are not able to cope with my 
symptoms 
336 2 EP 
I worry about money and my ability to maintain financial security 339 2 EP 
I worry I will freeze (stop moving) in hazardous situations 337 2 P 
I worry about my employability 333 1 EP 
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Table 1 
Rated Anxiety Statements Not Reported in Empirical Paper 
Note. P = anxiety symptom directly related to Parkinson’s presentation; N = anxiety experience 
common outside of Parkinson’s population; EP = anxiety experience common outside of anxiety 
population but likely exacerbated by Parkinson’s presentation. Likert Scale: 1 = Not at all, 2 = Rarely, 
3 = Sometimes, 4= Often, 5 = Always.  
 
Introduction to the Management of Anxiety 
In 2014, Deane and colleagues established that the second greatest of all 
future research priorities identified by participants with direct and personal 
experience of Parkinson’s was ‘effective stress and anxiety management’. The 
importance of this research direction was also echoed by our PPI volunteers in our 
early steering group meetings. As described in previous chapters, the steering group 
believed that an important step towards this research goal was to first of all develop a 
more comprehensive characterisation of anxiety in Parkinson’s. It was hypothesised 
that a greater characterisation would provide a foundation for development of 
appropriate intervention. The methodology used to achieve this improved 
characterisation has been described in the empirical paper. 
Behaviours N Median Theme 
I avoid driving  328 2 EP 
I avoid some methods of travel (e.g. public transport, car travel, 
plane travel, etc.) 
337 2 EP 
I avoid leaving home 333 2 EP 
I drink alcohol to try to reduce my anxiety and/or Parkinson’s 
symptoms  
337 1 EP 
I physically harm myself when anxious 336 1 N 
Physical Symptoms    
Difficulty breathing  336 2 N 
Feeling very alert and focused 226 2 EP 
Headache 332 2 EP 
Feeling disorientated or dizzy 337 2 N 
Nausea 336 2 EP 
Chest discomfort 332 2 N 
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In addition to characterising the anxiety, the steering group believed it was 
important to gain an improved understanding of means by which PwP currently 
attempt to manage their anxiety. There is some published research exploring the role 
of psychosocial interventions (Yang, Sajatovic, & Walter, 2012) for anxiety in PwP 
as well as anecdotal accounts from our PPI volunteers and beyond about the benefits 
of activities such as dancing and boxing. However, to our knowledge, no research 
has yet sought to capture the detailed insights of how PwP currently attempt to 
manage their anxiety.  
The importance of developing a more comprehensive characterisation of 
methods that PwP use to manage anxiety in Parkinson’s is evident. So, a secondary 
aim of the study described in the empirical paper was to enhance the existing 
characterisation by seeking the detailed insights of PwP who have experience of such 
anxiety. The research questions were ‘What methods of anxiety management do PwP 
currently use?’ and ‘How would PwP rank such methods in terms of effectiveness?’. 
The steering group aimed to address these research questions by incorporating 
questions about anxiety management into the online surveys previously described in 
the empirical paper (Appendices I and L). The questions included in the 
brainstorming survey were open ended, exploring anything that participants may 
have found helpful to manage or reduce anxiety. The questions also prompted 
participants to consider lifestyle choices, therapies, communication types and 
anything else they have found helpful (Appendix I). The planned methodology was 
the modified Nominal Group Technique (NGT) approach described in Chapter 4.  
Anxiety Management Analysis 
The participants’ open-ended responses regarding their ‘anxiety 
management’ were downloaded. Combined, the participant responses totalled 8968 
words. The principal author then familiarised themself with the participant 
responses. Any parts of participant responses that clearly did not address the 
questions were separated, reviewed by the rest of the steering group and ultimately 
removed. The remaining data was then systematically analysed by the principal 
author through coding. An inductive approach to coding was taken, whereby codes 
were driven by what was in the data. This approach can be likened to phase two of 
the thematic analysis process as described by Braun and Clark (2006). The codes 
enabled duplicate or similar responses to be grouped together. This process occurred 
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iteratively as the data was analysed and resulted in 27 distinct codes being identified 
(detailed in Appendix P). Unsurprisingly given the nature of the survey’s prompting 
questions, the codes sat within broader themes of ‘communication’, ‘lifestyle’ and 
‘therapies’. The coding of the data was reviewed by the steering group. An example 
of a participant response it written below, whilst the coding of this response is 
outlined in Table 2. 
“Talking to others with Parkinson's is helpful as you realise you're not the 
only one to feel this way. I do a lot of paper crafting and find it very relaxing. 
Exercise and my hobbies help to relax me”. 
 
Table 2 
Coding Example 
Participant Response Code Label Code Name 
Talking to others with Parkinson's is 
helpful as you realise you're not the 
only one to feel this way 
C4 Parkinson’s specific 
I do a lot of paper crafting and find 
it very relaxing. 
L5 and L6 Staying Occupied. 
Hobbies/leisure 
Exercise and my hobbies help to 
relax me 
L7 and L6 Exercise 
Hobbies/Leisure 
 
The steering group met again with the intention of converting the 27 codes 
into ‘indicative statements’ that could be presented to participants of the second 
survey. However, it was clear from our previous experience that generating 
statements that represented the items captured by the codes would significantly 
increase the size of the second survey. Concerns were raised that, if the survey was 
to include these additional items, it would be too time consuming and burdensome 
for participants to complete. Therefore, at this point, the PPI volunteers piloted the 
second survey without the inclusion of any ‘anxiety management’ items. Following 
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the pilot, the decision was taken not to proceed with the process of converting the 
codes to ‘indicative statements’. It was accepted that addressing the second research 
question described above was beyond the scope of the current project. The analysis 
process is summarised in Figure 1. 
 
Figure 1. Flow chart providing overview of phase one of additional analysis. 
Anxiety Management Results 
Although anxiety management codes were not converted to representative 
statements and taken to the second survey, it is important to report a summary of the 
anxiety management strategies that were reported. The steering group has therefore 
deduplicated the anxiety management strategies within each code, and made a 
summary statement for each. These are listed below (Tables 3-5). A total of 192 
unique items were generated. For the purposes of reporting the findings, they have 
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been broadly grouped into three categories: communication (33), lifestyle (85) and 
therapies (74). 
Table 3 
Means of Communication for Anxiety Management 
 
 
 
 
Communication 
General 
Communication in general  
Letting others know if I am having difficulties 
Talking with others who experience anxiety 
Talking to others who share their anxiety experiences 
Being open and honest about what I am experiencing 
Communication with select people 
Explaining my symptoms to people who don't know me very well 
Social Network 
Talking to trusted friends 
Talking to close family members 
Connecting in the community (non-Parkinson's related) 
Online communication (such as emails, chat forums, social media) 
Professionals 
Talking to a Parkinson's specialist professional (such as a Parkinson's nurse or consultant) 
Talking to non-Parkinson's specialist professional (such as a support worker, GP or carers support) 
Parkinson’s Specific 
Attending support groups for Parkinson’s 
Talking to others who have Parkinson's 
Talking to others who DO NOT have Parkinson's 
Communication with Parkinson's UK  
Talking to people at Parkinson's specific events  
Communication with people who understand Parkinson's  
Support groups are not a useful means of communication as those attending have such different 
attitudes to me 
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Table 3 
Means of Communication for Anxiety Management 
 
Table 4 
Lifestyle Choices for Anxiety Management 
Lifestyle 
Managing Demands 
Not overloading myself with commitments, demands or pressures 
Pacing myself and not overdoing things 
Keeping an organised schedule of appointments 
Taking time away from work or retiring 
Sticking to a routine 
Dedicating time to myself  
Speaking to employment professionals 
Being in a quiet or calm environment 
         Breaking down complex tasks into smaller more manageable steps 
   Not thinking too far ahead, instead taking each day as it comes 
 
Communication 
Not Helpful 
Communicating in a support group environment 
Talking to others 
Talking to others makes the anxiety worse 
Communicating with others with Parkinson's makes the anxiety worse 
Communication has no long-term benefit on my anxiety 
Do Not Talk 
I choose not to talk with others about my difficulties 
I do not feel the need to communicate with others 
I would like to communicate more but I am not sure of the required steps to gain such support 
I find that others do not want to talk with me about my difficulties 
I find it hard to find the words to talk to others about my experience 
I do not talk about my experience because I find it do not want to draw attention to myself 
I do not talk to those close to me about how I am feeling as I do not want to upset or burden them 
I do not communicate because the anxiety is too severe to talk through 
 
Anxiety in Parkinson’s Disease 
83 
 
Table 4 
Lifestyle Choices for Anxiety Management 
Lifestyle 
Diet 
Maintaining a healthy and satisfying diet 
Alcohol consumption 
Avoiding alcohol consumption  
Sticking to a specialist diet 
Weight management 
Sleep 
Having a good sleep routine 
Getting good sleep  
Having one or more daytime nap or sleep 
Not sleeping in the day time  
Laying down completely flat on the floor for a short while  
Having a relaxing quiet time to rest 
Sleeping alone  
Taking medication to aid sleep  
Occupying myself when I am struggling to sleep  
Connection 
Being around other people  
Having sex  
Being around friends, family or other familiar people  
Socialising with other people who have Parkinson's  
Helping or supporting others  
Spending time with my pets or with animals 
Staying Occupied 
Taking part in anything that is absorbing and engages my mind  
Keeping my mind active with things such as quizzes, puzzles, playing cards  
Keeping occupied and busy 
Keeping my hands busy as it reduces the tremor 
Driving 
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Table 4 
Lifestyle Choices for Anxiety Management 
 
 
Lifestyle 
Hobbies/Leisure 
   Engaging in one or more hobbies 
Attending a choir or singing group 
Listening to music 
Attending a Parkinson's singing class 
Planning and taking holidays or day trips 
Holidays and daytrips help my anxiety as long as I am accompanied 
Exercise 
Any form of exercise 
Gentle exercise 
Moderate exercise 
Intense exercise 
Specialist exercise classes for those with Parkinson's (for example dancing, PD warrior, PD attack, PD gym 
and fitness, Active with Parkinson's programme) 
Living an active lifestyle 
Cycling (outdoor or on machines) 
Home based exercise 
Swimming 
Boxing 
Running 
Golf 
Badminton 
Horse riding 
Football 
Going to the gym 
Circuit training 
Weight training 
Outdoor bowls 
Exercise classes 
Dancing 
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Table 4 
Lifestyle Choices for Anxiety Management 
Lifestyle 
Mind-Body Exercises 
Pilates  
Yoga 
Tai-chi 
Qigong 
Yoga for Parkinson’s 
Skype yoga 
Being Outdoors 
Spending time outdoors in the fresh air 
Being among nature 
Gardening 
Being by the sea 
Being in the countryside 
Relaxation 
Relaxation techniques 
Taking baths  
Audio relaxation recordings 
Lavender oil 
Aromatherapy oils 
Other 
Faith or prayer   
Not doing any medical reading at night 
Laughter 
Sitting on my hands 
Staying well informed about Parkinson's (through reading, lectures, courses etc) 
Try to keep things as they were before so as to maintain a sense of normality 
Meeting new people and facing anxiety provoking situations  
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Table 5 
Therapies and Anxiety Management 
Therapies 
Psychological Therapies 
Cognitive Behavioural Therapy  
Counselling  
Talking therapy  
Psychological therapy 
Course on resilience 
Psychiatrist appointment 
Psychotherapy  
Therapy   
Compassion Focussed Therapy 
Cognitive Analytic Therapy 
Self-Management Group  
Neuropsychology 
Physical Therapies 
Occupational therapy  
Neurophysiotherapy 
Speech therapy 
Live loud (PUK speech communication support) 
Physiotherapy 
Group physiotherapy 
Physical health specialists 
Parkinson’s UK therapy centre 
Mindfulness 
Meditation 
Mindfulness 
Guided meditation  
Breathing exercises  
Progressive muscle relaxation (body scan) 
Mindful colouring 
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Table 5 
Therapies and Anxiety Management 
Therapies 
Medication 
Medication  
Adjustments to medication 
Alternative Medicine 
Homeopathy  
CBD oil 
Serotone 5htp supplements 
Other 
Maintaining positive mindset 
Using imagery of a ‘safe space' 
Self-talk/rationalising 
Trying to ignore the anxiety 
Concentrating on achievements  
Being kind to myself 
Trying to stay calm  
Getting on with things 
Reminding myself it's not my fault 
Waiting for it to pass 
Not dwelling on it 
Accepting that anxiety is just as much a part of my condition as any other symptoms 
Staying in the moment - avoid dwelling on future 'what if's' 
Not Helpful 
No therapy has been helpful 
Counselling 
Acupuncture 
Meditation 
Mindfulness  
Breathing exercises (exacerbate tremors) 
CBT – wasn’t specific enough, therapist would need to understand PD 
CBT  
CBT – no long-term benefit 
Tai Chi – no long-term benefit 
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Table 5 
Therapies and Anxiety Management 
 
Therapies 
Massage – no long-term benefit 
 
Not Attempted 
I have not tried any therapy 
Therapy is not needed 
I avoid therapies 
Access Challenges 
Can’t access psychological therapy 
No funding for long term counselling 
Waiting list for counselling too long 
Tai chi was too expensive 
Counselling was too expensive 
Mobility impacts ability to access therapy engagement 
No therapy has been offered to me 
Complementary Therapies 
Reiki 
Bowen therapy 
Massage 
Reflexology 
Chiropractic  
Acupuncture 
Hypnotherapy  
Autogenic therapy 
Conductive education  
 
Anxiety Management Discussion 
In the first survey of this thesis portfolio, 205 PwP responded to questions 
regarding their methods of anxiety management. To our knowledge, this is the first 
survey to use open ended questions to characterise anxiety management in PwP. 
Whilst participant responses were analysed and transformed into representative 
statements for rating in a second survey, no further stages of research or analysis 
followed. It is therefore acknowledged that conclusions are limited. However, 
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tentative reflections are made on some of the broad themes that are present and 
consideration given to areas that future research may wish to take forwards. 
The participant responses highlight the perceived value of engaging in 
exercise and physical activity. There is a growing evidence base for the value of 
physical exercise in Parkinson’s disease (for a review see Lauzé, Daneault, & Duval, 
2016). However, the focus of these studies has been on the physical gains, with the 
few that focused on mental health benefits focussing on depression. Future research 
should investigate the potential anxiety benefits of exercise for PwP, especially given 
the growing evidence advocating the benefits of exercise to mental health in the 
general population (Mikkelsen, Stojanovska, Polenakovic, Bosevski, & 
Apostolopoulos, 2017). Similarly, many participants reported benefit from a range of 
established ‘PwP only’ group activities (not exclusive to physical activity). There is 
already some evidence that is indicative of a range of benefits associated with 
attendance of such groups (Sharma, Robbins, Wagner, & Colgrove, 2015). But 
again, their impact on anxiety has not yet been measured and future research is 
needed to clarify this. For many, being outside in natural surroundings was 
considered a way of reducing anxiety. This appears to align with existing research 
outside of Parkinson’s relating to the reduction in anxiety associated with direct 
contact with nature (Kohlleppel, Bradley, & Jacob, 2002). 
Various means of communication were identified as helpful. Many expressed 
the value of communicating with others with knowledge or experience of 
Parkinson’s and/or anxiety. Meanwhile others did not find this helpful, preferring to 
communicate with ‘non-experts’. Additionally, some people did not find any anxiety 
benefits from communicating. There were also a range of examples where 
participants did not feel able to communicate. These reasons included not wanting to 
burden others, not being able to initiate the conversation, or not knowing the 
channels to access support.  
Participants listed a large array of ‘therapies’ as helpful. These included 
pharmacological, physical, psychological and complementary therapies as well as 
alternative medicines. As outlined in the empirical paper, some research studies have 
begun to view the efficacy of Cognitive Behavioural Therapy (CBT) interventions 
for anxiety among PwP, but this is not yet the case with the other psychological 
therapies. Given the range of psychological therapies listed by the survey 
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participants, consideration of the efficacy of these therapies for those with 
Parkinson’s may be useful for future research. A significant number of physical 
therapies were listed. Whilst there is an evidence base for their physical benefit for 
PwP (Keus et al., 2007), studies are yet to explore the potential impact on anxiety. In 
light of our findings, this may be a valuable avenue for further research to explore. 
Finally, complementary therapies and alternative therapies were used by a number of 
participants. Whilst these are not evidence based, it this study provides a useful 
snapshot of the extent of their use among this population.  
A range of access difficulties were cited in relation to psychological 
therapies. These stemmed from mobility issues, waiting lists and cost. In other 
chronic physical health conditions, efforts have been made to address this through 
the creation of specialist pathways within mental health services which prioritise 
timely treatment and flexibility to complete home visits (Clarke et al., 2018; National 
Collaborating Centre for Mental Health, 2018). These survey responses highlight 
that that such access is not present for those with PwP. In our population, many of 
those who did access therapies did not find them helpful. This was the case for a 
number of therapies, but for CBT some participants expanded on the reasons why it 
was not helpful. Firstly, it was critiqued for its lack of long-term benefit. It was said 
to lack specificity to Parkinson’s and it was suggested that the therapist would 
require specific knowledge of Parkinson’s. This appears to be supported by the 
findings of the empirical paper. 
For many participants, methods that help them to manage life demands have 
a positive impact on anxiety. Examples include pacing, routine, self-care, relaxation 
and breaking tasks into smaller steps. Given the impairment in activities of daily 
living found stemming from motor and non-motor Parkinson’s symptoms (Bhatia & 
Gupta, 2003), it is understandable that techniques for managing life demands are 
valued by many participants as a means of managing anxiety. Interestingly, whilst 
managing demands was important, many participants also highlighted the 
importance of keeping ‘occupied’. 
Participants raised the importance of sleep to the management of anxiety. 
Sleep disturbance is known to exacerbate anxiety symptom severity in the general 
population (Cox & Olatunji, 2016). It is also a common non-motor symptom of 
Parkinson’s (Chaudhuri, Healy, & Schapira, 2006) with a known relationship with 
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anxiety (Borek, Kohn, & Friedman, 2006). Our findings indicate that, for many, 
effective sleep management contributed to reduction in anxiety. Similarly, many 
participants referred to dietary adjustments that reduce anxiety. Research into 
Nutrition and Parkinson’s is in its infancy, but preliminary findings suggest that 
adjustments to diet can influence both motor and non-motor symptoms (Seidl, 
Santiago, Bilyk, & Potashkin, 2014). 
Limitations 
As previously stated, the second phase of the NGT was not completed with 
this data set. As a result, the findings of this part of the study are limited to the 
‘brainstorming’ phase. Whilst this provides a broad overview of anxiety 
management techniques of our participants, at such a preliminary stage, the 
conclusions are limited.  
Future Research 
It is planned that this research team will build on these preliminary findings. 
The second phase of NGT should achieve insight into the extent to which 
participants identify with each technique as a useful anxiety management tool. This 
next phase should also aim to better understand the benefits of the approaches, 
considering: the time taken for the benefit to be felt, the longevity of the benefit, 
whether the benefit extended to other symptoms of Parkinson’s, whether the 
approaches have been recommended by medical professionals.  
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Chapter Seven: Discussion and Critical Evaluation 
Overview of Chapter 
The final chapter summarises and integrates the findings from the systematic 
review (Chapter 2) and empirical research project (Chapters 4 and 6). A critical 
evaluation of each will be provided and the strengths and limitations discussed. The 
overall clinical implications are considered and recommendations for future research 
made. Reflections on the process of completing the thesis portfolio are also included. 
Finally, a conclusion from the whole portfolio is provided.    
Main Findings 
Systematic Review 
The systematic review examined the evidence for the relationship between 
anxiety and quality of life in (PwP) by systematically identifying, selecting, 
synthesising and interpreting studies that investigated this relationship. Twenty-two 
research studies were included. From these, 17 correlation coefficients were 
extracted (directly or through conversion from standardised beta) and meta-analysed. 
The weighted pooled estimate effect size of the relationship between anxiety and 
quality of life was large (r = 0.53). The incorporation of a meta-analysis was 
beneficial as it pooled many studies and therefore offers a more precise estimate of 
the relationship. The systematic review also extracted regression data from 20 
studies. The review of regression-based findings provided a useful summary of 
models that examined the extent to which anxiety predicts QOL in PwP. The 
regression models of 18 of these studies found that anxiety accounted for significant 
variance in QOL. Placed among other variables, such as disease stage, activities of 
daily living, disability and depression, it was consistently among the strongest 
predictors of QOL and in many cases accounted for unique variance in QOL. 
Empirical Project 
The aim of the empirical research project was to develop an in-depth 
characterisation of anxiety in Parkinson’s from large surveys of PwP. The steering 
group, including two Patient and Public Involvement volunteers, sought to achieve 
this though two co-designed online surveys using a modified Nominal Group 
Technique. The first survey used open ended questions to collect qualitative accounts 
of the anxiety experiences of 205 PwP. These responses were analysed and 
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converted into representative statements that captured the experiences. These 
statements were then rated in a second online survey by 341 participants according 
to how much they identified with each experience. Quantitative analysis of the 
statement rankings produced a summary list of the anxiety experiences that were 
ranked according to the extent that participants identified with each experience. This 
study is the largest one worldwide to characterise anxiety in PwP. It identified that 
the anxiety experiences of this sample were wide ranging. Among these diverse 
experiences it was noticeable that some experiences were akin to common anxiety 
experiences that are well identified among those without Parkinson’s. In contrast, the 
majority of the anxiety experiences related specifically to, or were aggravated by, 
challenges associated specifically with Parkinson’s.   
An additional component of the first brainstorming survey asked PwP how 
they managed their anxiety. This resulted in the identification of a very wide range 
of methods used by PwP. Given the number of methods identified, advice from PPI 
input was that including the items in the second survey would be too burdensome to 
complete. The decision was therefore taken not to include them in the second survey. 
Whilst conclusions drawn from this brainstorming phase are inevitably limited, it 
does provide a useful insight into the range of methods used among over 200 PwP 
who experience anxiety. Many methods were unconventional, but even the more 
conventional ones have a limited evidence base in this population. In line with 
previous findings (Deane et al., 2014), this data highlights the need for further 
research into anxiety management. 
Synthesis of Main Findings 
Both studies contribute to research evidence on anxiety in Parkinson’s, 
therefore addressing one of the top three Parkinson’s research priorities identified by 
those with direct and personal experience of Parkinson’s (Deane et al., 2014). Taken 
together, these studies highlight the significance of anxiety among PwP, and provide 
much more information on its character.   
Critical Evaluation 
Systematic Review 
The systematic review is the first to review existing evidence on the 
relationship between anxiety and QOL in PwP. A key strength is that the study not 
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only provides a quantitative synthesis of studies through meta-analysis of 
correlations, but extends the review to incorporate findings of multiple regression 
models.  
We acknowledge that, to some extent, the findings of the current review are 
unsurprising. After all, it is well established that increased anxiety is related to 
poorer QOL (Mendlowicz & Stein, 2000). This is a finding that has been replicated 
across a number of physical health domains, with correlation and regression analyses 
investigated the anxiety-QOL relationship (Blakemore et al. 2014; Morris, Van 
Wijck, Joice, & Donaghy, 2013; Mosaku, Kolawole, Mume, & Ikem, 2008; 
Nekouei, Yousefy, Nekouei, & Sadeqhi, 2010). However, this review is the first to 
examine the relationship between anxiety and QOL for PWP.  
It is evident from the review that a key approach to exploring the relationship 
between anxiety and QOL is to perform correlation and/or regression analyses on 
participant scores on anxiety and QOL measures. All 22 studies reviewed in this 
paper took this approach. Whilst this approach is common, we acknowledge that it is 
one that can be conceptually critiqued. The primary concern is that one of the 
domains captured by quality of life measures is ‘psychological wellbeing’. For 
example, the PDQ-39 and PDQ-8 capture psychological wellbeing as one of eight 
domains of wellbeing, including mobility, social support, communication and 
activities of daily living. Of course, one component of ‘psychological wellbeing’ is 
anxiety. Thus, it is likely that even though QOL is a multifaceted construct, the 
extent to which the scores on the QOL and anxiety measures are related is inflated 
by the fact that they both measure anxiety to some extent. In future, this 
methodological issue may be addressed by the study teams exploring the effects of 
removing anxiety items from the QOL measures at point of analysis. 
In consideration of this methodological issue, one approach considered in this 
review was to complete additional analyses where the ‘psychological wellbeing’ 
domain of QOL measures was removed from the analyses in order to review the 
anxiety-QOL relationship without the QOL items that directly explored anxiety. 
However, this was not possible as only three correlation studies and three regression 
studies reported the relationship between the anxiety measure and each of the 
subdomains of the QOL measures. Further, four of these six studies used the PDQ-
39 as a QOL measure. In this measure, the questions that address anxiety are 
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distributed among a number of the sub-domains, rather than being clustered into one. 
Removing these sub-domains would remove other valuable ‘non psychological’ 
components of QOL and therefore undermine the analysis. The remaining two 
studies reported just two subdomains of the SF-36, physical and mental. Further 
analysis whereby the ‘mental’ questions were removed would be not be appropriate 
as only two of those 18 questions were anxiety focused. We therefore accept that the 
correlation and regression statistics may be inflated, but that this is a problem 
inherent with the methodology used by the studies reviewed. 
It is acknowledged that confidence in the review findings would be increased 
if the screening, eligibility and inclusion processes of studies were entirely 
independently duplicated. However, the pragmatic approach whereby the principle 
investigator (DC) took any uncertainties for discussion with the project supervisor 
(KD) was deemed sufficiently thorough. The independent duplication of quality 
assessment by an additional author (CI) for 50% of articles was also adequate. It is 
acknowledged that exclusion of ‘grey literature’, additional literature and articles 
that were not written in English increase the risk of publication bias. However, a 
focus on peer-reviewed research facilitated a systematic and transparent review 
process and was an appropriately pragmatic approach in the context of a thesis 
portfolio. 
It is important to consider that the rate of heterogeneity in the meta-analysis 
was substantial according to Higgins and Green’s (2011) interpretation. This 
heterogeneity was likely influenced by differences in methodologies, assessment 
methods and demographic differences among participants (Huedo-Medina, Sanchez-
Meca, Marin-Martinez, & Botella 2006). This is well exemplified by the variation in 
how the studies assessed both anxiety and QOL, with six measures of anxiety and 
four measures of QOL used. Whilst such heterogeneity is common in meta-analyses 
(Higgins, 2008), this inconsistency must be held in mind when interpreting the 
findings (Higgins, Thompson, Deeks & Altman, 2003). Despite the heterogeneity 
reducing when studies that estimated r from standardised beta were removed in the 
sensitivity analysis, the decision was taken not to remove them from the overall 
meta-analysis. This decision increases heterogeneity, but did not inflate the effect 
size estimate and enabled the inclusion of five additional studies.  
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Overall, the quality of the included studies was good and methodologies 
robust. However, in the majority of studies, this quality was limited by the omission 
of sample size justification. This raised concerns that the studies may be 
underpowered, particularly for the multiple regressions. An effort to address this was 
made in this review by comparing study sample sizes of studies including multiple 
regressions against well-established sample size criteria. Additionally, studies’ 
acknowledgment and management of collinearity was also considered. In doing so it 
was highlighted that five studies met the sample size and collinearity criteria and 
therefore invited more confidence in their findings. The high consistency with which 
anxiety significantly predicted QOL among those studies that met the criteria and 
those that did not was noted. It is also notable that some of the multiple regression 
studies reported unstandardised beta values, rather than the standardised beta values 
reported by the majority. Whilst unstandardised values enable interpretation of 
whether anxiety is a significant predictor of QOL, it does not allow the comparison 
of predictive ability across variables. This therefore restricted conclusions for these 
studies. 
Empirical Project 
The empirical project is the largest existing study examining the nature of 
anxiety in Parkinson’s. It has generated a valuable data set with unique findings and 
significant potential for future analyses.  
The presence of PPI input for the entirety of the project is a significant 
strength. The benefits of this are reviewed in detail in Chapter Three, but PPI 
involvement was particularly valuable for designing accessible surveys and 
analysing participant responses to the first survey. The support during the design 
phase likely increased the accessibility and acceptability of the survey, a notion 
supported by participant feedback. In the analysis of open-ended survey responses, 
researcher coding decisions are known to threaten the reliability and validity of 
findings (Seidel & Kelle, 1995). Having PPI input to the steering group that 
reviewed all such decisions significantly increases confidence in the reliability and 
validity of our findings.  
The use of modified NGT research methodology was a strength. It facilitated 
the recruitment of large participant numbers and brought the benefits of both 
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qualitative and quantitative methodologies, offering relatively detailed and nuanced 
participant description as well as quantitative rating of anxiety experiences. Thus, it 
enabled the research project to achieve its aim to capture the broad range of anxiety 
experiences among PwP and to gain understanding of the extent to which these are 
experienced.  
Whilst NGT was chosen following careful consideration of potential research 
methodologies, the approach is not without weakness. As with thematic analysis, 
relative to some other methodologies it enables rich analysis of participant responses 
but without follow-up and clarification. Yet, approaches such as extended semi-
structured interviews would likely invite richer participant responses and also give 
the research interviewers the opportunity to seek clarification through follow up 
questions. It is also important to acknowledge that the online format of the 
methodology likely biases the population. Low socioeconomic status and older age 
are both associated with lower rates of access to the internet (OFCOM, 2019; Tirado-
Morueta, Aguaded-Gómez, & Hernando-Gómez, 2018). It is therefore probable that 
our approach underrepresented these groups. The online approach also did not 
support accessibility for those with dementia.  
The study provides a broad description of common experiences of anxiety in 
PWP, offering an important overview of participant experiences. In doing so, it 
addresses a significant gap in the literature. However, as outlined in Chapter One, it 
is known that neither Parkinson’s or anxiety are experienced in a uniform way. It 
may therefore be the case that sub-populations among these participants have quite 
different experiences of anxiety when compared to each other. The research team has 
plans for further analyses to examine these issues.  
Participant anxiety responses were ranked according to their median values. 
The decision was taken not to use mean values. This was in accordance with the 
argument that means should not be used to represent ordinal data from Likert scales 
(Jamieson, 2004). Whilst this decision is justified, it must be acknowledged that the 
use of medians restricts the sensitivity with which the items are ranked, with many 
items sharing the same median score.  
Implications of Current Findings 
Theoretical Implications 
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The theoretical implications of the rich characterisation of anxiety in PWP 
provided by the empirical study, were considered with respect to the augmented 
CBT model by Egan and colleagues (2015). In particular, we considered which 
aspects of the augmented CBT model were supported by our findings, which aspects 
could be developed further and which aspects we were unable to comment on. This 
reflection is achieved narratively but is also illustrated in Figure 1. 
There are some elements of the Egan et al. augmented CBT model that fall 
outside the scope of the current study. For example, our study does not incorporate 
depression, the factors that maintain it, or its relationship with anxiety. Further, the 
survey methodology focussed on the maintenance of anxiety in PWP, rather than the 
more deep-rooted longitudinal factors such as core beliefs, cohort beliefs or illness 
beliefs, cited in the Egan et al. model. Their model also uses arrows to represent 
causal links between components. As our findings are predominantly qualitative and 
focus on the experience of anxiety in PWP, it is not possible to comment on 
causality. We make this distinction in our diagrammatic representation by using lines 
to link these components, rather than arrow heads. 
The Egan et al. model was developed in response to the argument that a CBT 
model for PWP would need to be augmented to incorporate Parkinson’s specific 
components. Given that such a high proportion of the anxiety experiences identified 
in our study were influenced by Parkinsonian elements, our findings support this 
fundamental principle of the model. It is also important to reflect that there was a 
distinct proportion of the anxiety experiences that did not seem to be ‘Parkinson’s 
specific’, but which were nevertheless, consistent with CBT for anxiety. The Egan et 
al. model is grounded in second wave CBT. Consistent with this, our findings 
suggest that for a proportion of experiences of anxiety in PWP, formulation within 
second wave CBT approaches for anxiety would be appropriate.   
 ‘Parkinson’s related cognitions’ have a central role in the Egan et al. (2015) 
model. It proposes that anxiety is associated in particular with ‘illness 
overgeneralising and catastrophising.’ Our results support this, but suggest that 
additional Parkinson’s related cognitions are also present. Firstly, while Egan et al. 
(2015) suggest ‘rumination’ and ‘comparison to previous function and comparison to 
others’ contribute to depression, our findings suggest they are also a feature of the 
anxiety experience. Our study also identifies two further types of Parkinson’s related 
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cognitions, namely ‘feared social judgement of symptoms’ (e.g. ‘I worry how others 
will perceive my Parkinson’s symptoms and that they will judge me negatively) and 
‘feared impact on others’ (e.g. ‘I worry about upsetting those close to me and making 
things difficult for them’).    
Behavioural responses to anxiety are a key part of the Egan et al. model and 
in particular, ‘Counter-productive behaviours’ (safety behaviours) and 
‘hypervigilance’ as factors maintaining anxiety in PWP. The presence of these 
behavioural responses is supported by our findings. Further, our findings suggest that 
‘avoidance and social isolation’, a factor which the existing model links to 
depression, can also form part of the anxiety experience.  
The physical sensations associated with the anxiety experience are not 
addressed in the Egan et al. model. Our current findings suggest that these are a 
significant part of the anxiety experience in this population. The physical symptoms 
reported, whilst common across anxiety, are notable in that many could also be 
Parkinsonian in nature. For example, increased fatigue, sweating, muscle tension and 
urinary and faecal urgency are also known symptoms of Parkinson’s (Chaudhuri et 
al., 2005).  
Finally, the Egan et al. model places an emphasis on the way that 
Parkinsonian symptoms and an individual’s cognitive and behavioural responses to 
them contribute to the anxiety experience. The findings of our study highlight that 
for many people in this population, the experience of anxiety can additionally 
contribute to an exacerbation of other Parkinsonian symptoms (e.g. ‘anxiety has 
made my Parkinson symptom’s worse’). This is not currently captured by the Egan 
et al. model.  
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Greyed out = Part of existing model, but unable to comment on these areas as not addressed by this 
study.      
            = Part of the existing model that is supported by the present study.  
            = Added to the model following based on the present study.             
Figure 1. A visual representation of the theoretical implications of the current study 
with respect to the Egan et al. (2015) augmented CBT model of depression and 
anxiety in Parkinson’s. 
Clinical Implications 
The systematic review brings the significance of the relationship between 
anxiety and QOL to the fore. As well as consistently highlighting a strong 
relationship between the two constructs it demonstrates that anxiety was frequently 
among the variables predicting the greatest, and sometimes unique, variance in QOL. 
Crucially, the relationship between anxiety and QOL appears comparable to other 
long-term health conditions (Mosaku, Kolawole, Mume, & Ikem, 2008) where 
patients have greater access to psychological interventions than PwP do (Clarke, 
Furmaniak, & Pilling, 2018). Given that untreated mental health in physical health 
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patients is associated with significant detriment to the patient and the healthcare 
system (Naylor et al., 2012), it is important that this review was conducted. 
The existing evidence base for the use of psychological therapy for anxiety in 
PwP is in its infancy. With an unpublished randomised control trial (RCT) for 
Cognitive Behavioural Therapy (CBT) underway in this population (Mulders et al., 
2018), the evidence is currently limited to case studies, pilots studies and single case 
experimental designs (Calleo et al., 2015; Dissanayaka et al., 2017; Feeney, Egan, & 
Gasson, 2005; Kraepelien, Svenningsson, Lindefors, & Kaldo, 2015; Mohlman et al., 
2010; Troeung, Egan, & Gasson, 2014). This empirical project demonstrates that 
some of the participant population experience some similar anxiety experiences to 
people without Parkinson’s. This may offer some promise that some components of 
existing mainstream CBT formulation and practices may be applicable to PwP.  
The findings also invite reflection on the degree of specialist knowledge of 
Parkinson’s symptoms that may be required by psychological therapists in order to 
effectively treat anxiety co-occurring in this disease. Further, this study highlighted 
that anxiety symptoms can be triggered by other Parkinson’s symptoms. Therefore, 
the indirect role that optimal control of other Parkinson’s symptoms (e.g. by 
optimising medications) might have on anxiety, should be considered. Additionally, 
it may be possible to draw on existing research into managing anxiety in chronic 
disease. For example, managing the anxieties of adjusting to a diagnosis or about the 
feared progression of disease (De Ridder, Geenan, Kuijer, & van Middendorp, 2008; 
Herschbach et al., 2010). 
The empirical project also highlights that, for PwP, people close to them are 
regularly implicated in their anxiety experience. Research exploring psychological 
therapy that incorporates PwP as well as their wider support network has indicated 
that this more systemic approach can bring benefit to PwP and those around them 
(Dissanayaka et al., 2017). It is hoped that the present study further presents the 
potential benefit to be gained from incorporating the system around the individual 
into onward assessment, formation and intervention.  
Areas for Future Development 
The strong association found between anxiety and quality of life for PwP,  
provides some support for the existing notion that researchers and clinicians should 
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place greater emphasis on seeking to improve the assessment, conceptualisation and 
intervention for anxiety in Parkinson’s. The findings in the empirical project have 
provided a useful foundation regarding the unique character of anxiety is 
Parkinson’s. It is hoped that other research will build on these findings. It would be 
interesting to better characterise methods used by PwP to manage their anxiety and 
then rank their efficacy and acceptability. This would inform the design of 
therapeutic packages which might be wider than a singular intervention. 
This research provides the first two surveys of a programme of research 
designed to better conceptualise the anxiety experience of PwP. The next stage, 
which is already underway, is to use exploratory factor analysis of the data collected 
to develop a psychometric scale that captures the anxiety experience of PwP. The 
only existing anxiety measure for PwP, is the Parkinson’s Anxiety Scale (PAS) 
(Leentjens et al., 2014). The PAS is limited to 12 items across the domains of 
persistent anxiety, episodic anxiety and avoidance behaviours. Given the range of 
anxiety experiences identified in this empirical project, and the large number of 
themes that fall outside of the persistent, episodic and avoidance categories,  the 
generation of our new anxiety scale from a rich data set should be a valuable 
additional resource.   
In acknowledgment of the fact that neither Parkinson’s or anxiety are 
experienced uniformly by every individual, the data we have collected will then be 
analysed to establish whether the anxiety experience changes according to variables 
associated with Parkinsonian presentation. Initially, this will be achieved by 
comparing PAS anxiety scores among different subgroups (e.g. time since diagnosis, 
Parkinson’s phenotype) of Parkinsonian presentation. Then, Structural Equation 
Modelling (SEM) will be used to model the associations between the ranked anxiety 
items described in this study – allowing us to test the hypothesis that the model 
changes according to Parkinsonian presentation.  
Having then developed a more comprehensive characterisation and 
assessment of Parkinsonian anxiety, ultimately the research team aim to use this to 
inform the development of a psychological intervention for anxiety in PwP. It is 
important to acknowledge however, that there is currently significant distance 
between the findings of the current study and the actual implementation of any 
tangible changes to future clinical practice. It is well documented that translating 
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research findings to changes to healthcare practice is a challenging process, 
especially if the changes are complex or require re-organisation of care or better 
collaborations between disciplines (Wensing, Grol, & Grimshaw, 2020). If this 
“evidence to practice gap” (Woolf, 2008) is to be bridged, it is important to reflect 
on the challenges. A framework of these challenges (Wensing et al., 2020), will now 
be discussed. 
The first factor identified is the credibility of the proposed changes 
themselves. We recognise therefore, that the current findings are in their infancy. 
There is significant scope for extending the findings further. This may include 
validation of the model, development of a related intervention, a feasibility 
randomised control trial (RCT) and if appropriate, a full RCT. It is likely that this 
more extensive body of research would hold more credibility and likelihood of 
translation into clinical practice.   
The attitudes, opinions and values of the targeted professionals and ‘opinion 
leaders’ is another of the identified factors. With this in mind it would be useful to 
consult these professionals throughout the process of developing changes. In this 
field, it would be particularly useful to liaise with opinion leaders such as the 
recently established Parkinson’s UK Excellence Network Mental Health Hub, a 
group comprised of expert researchers and clinicians with the aim of developing best 
practice. It is important to ensure professionals see the value in identifying the 
“additional” complexity of anxiety identified by this project. If they see it as an 
additional burden of learning without value then it is unlikely to be implemented.  
Another important factor to consider is the needs, attitudes and preferences of 
the patient group. Given that these elements are intrinsically embedded within this 
project, there is hope that this will facilitate the translation process. The economic 
and organisational context in which the translation sits is also a consideration. It is 
well established that the National Health Service can be a challenging environment 
for the adoption of innovation and change (Department of Health and Social Care, 
2016). Looking to examples of where such translations have successfully occurred 
with health psychology in the NHS may provide useful direction.  
Finally, the methods and strategies for dissemination and implementation are 
considered important. It is hoped that widespread dissemination of our findings not 
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only though peer reviewed articles and international movement disorders 
conferences but also in lay reports for members of Parkinson’s UK and in 
distribution to the Parkinson’s UK Excellence Network Mental Health Hub will 
support this. Providing appropriate training in the delivery of the intervention is also 
important. 
Reflections on the Process of Completing the Thesis Portfolio 
My primary reflection is on the extent to which I believe the project 
benefitted from the PPI involvement. From the outset of the involvement of the two 
PPI volunteers (BC and JM), my motivation for the project increased significantly. 
Listening to first-hand accounts of their experiences and their reasons why the 
project had potential to add significant value was powerful. It gave me an increased 
sense of the project’s value and the importance of maximising its potential. In terms 
of their direct contribution, their recommendations for making the participant facing 
content more user friendly was vital. Whilst this took a number of iterations, the 
benefits to accessibility were notable. It was particularly pleasing to receive a letter 
of praise from a participant regarding the clarity of our first survey compared to his 
previous experiences as a research participant. The PPI expertise added to an already 
wide range of expertise of colleagues in the steering group; KD (researcher with over 
20 years expertise in Parkinson’s as well as a disabled person and wheelchair user 
with experience of a functional movement disorder), CF (Clinical Psychologist), CIC 
(CBT Therapist). I valued this range of perspectives hugely.  
The recruitment of large participant numbers from across the UK added 
significant value to the empirical project. Given that participants were required to 
have a diagnosis of Parkinson’s and have experienced anxiety to an extent that 
impacts quality of life, there was the potential for recruitment to be a challenge. 
Fundamental to successful recruitment was the support of Parkinson’s UK. This 
taught me the value of maintaining good relationships with key gatekeepers, in this 
case the Research Participation Lead at Parkinson’s UK.  
Overall Conclusions 
Anxiety occurs at a high rate in people with Parkinson’s. The systematic 
review showed that there is a strong correlation between anxiety and QOL. In fact, 
anxiety consistently predicts significant, and sometimes unique variance in QOL. 
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Despite this high negative impact there is little existing evidence for interventions for 
anxiety in PwP.  
The empirical project better characterised the nature of anxiety in PwP. This 
showed that there were aspects of their anxiety experiences that were akin to anxiety 
in the general population. However, there were a substantial set of characteristics 
that were specific to Parkinson’s or had the potential to be aggravated by 
Parkinsonian symptoms. This suggests that, whilst some mainstream anxiety 
interventions may also be effective for PwP, researchers and therapists are likely to 
need knowledge of Parkinson’s-specific context in order to develop and deliver 
relevant and holistic assessments and therapeutic interventions. 
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Appendices 
Appendix A: Symptoms of Parkinson’s  
Adapted from Jankovic, (2008) and Chaudhuri, Yates and Martinez-Martin, (2005). 
Motor Symptoms Non-Motor Symptoms 
Tremor (shaking) 
Bradykinesia (slowness of movement) 
Rigidity (muscle stiffness) 
Postural instability (difficulty maintaining 
balance) 
Hypomimia (Reduced facial expression)  
Dysarthria (speech difficulty) 
Dysphagia (difficulty swallowing)  
Sialorrhea (excessive salivation or 
drooling) 
Decreased arm swing 
Shuffling gait 
Altered gait 
Difficulty rising from chair or turning in 
bed 
Micrographia (abnormally small 
handwriting)  
Difficulty cutting food 
Difficulty eating  
Difficulty maintaining hygiene 
Slow activities of daily living 
Glabellar reflex (limited inhibition of 
blink reflex)  
Blepharospasm (twitch of the eye lid) 
Dystonia (muscle spasms and 
contractions) 
Striatal deformity (abnormal postures of 
hands/feet)  
Scoliosis (twisting of the spine)  
Camptocormia (forward bending of the 
spine) 
Cognitive 
Cognitive impairment 
Bradyphrenia (slowness of thought, slower 
information processing) 
Word finding difficulties 
Attention deficit 
Neuropsychiatric 
Depression 
Apathy 
Anxiety 
Anhedonia (reduced motivation pleasure) 
Hallucinations  
Delusions  
Dementia 
Repetitive behaviour 
Confusion  
Delirium (could be drug induced)  
Obsessional behaviour (usually drug induced) 
Sensory 
Ageusia (taste disturbance/loss) 
Pain (shoulder, back) 
Paraesthesia (tingling sensation) 
Smell disturbance/loss 
Autonomic Nervous System 
Constipation 
Bladder disturbance 
Urinary and sexual dysfunction 
Abnormal sweating 
Seborrhoea (excessive secretion of sebum) 
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Weight loss 
Dry eyes 
Orthostatic hypotension (falling blood pressure 
when standing or sitting) 
Falls related to orthostatic hypotension 
Coat hanger pain (neck and shoulder) related 
to orthostatic hypotension 
Hypersexuality (likely to be drug induced) 
Sleep Disorders 
Insomnia 
REM behaviour disorder  
Non-REM-sleep related movement disorders  
Vivid dreams 
Daytime drowsiness  
Sleep fragmentation 
Restless legs syndrome 
Sleep disordered breathing 
Gastrointestinal Symptoms (overlap with 
Autonomic Symptoms)  
Dribbling of saliva 
Ageusia (loss of taste)  
Dysphagia (choking)  
Difficulty swallowing  
Reflux 
Vomiting 
Nausea 
Constipation  
Unsatisfactory voiding of bowel  
Faecal incontinence 
Other  
Fatigue 
Diplopia  
Blurred vision  
Weight loss  
Weight gain (possibly drug induced) 
 
Anxiety in Parkinson’s Disease 
127 
 
 
Appendix B: Movement Disorder Journal Author Guidelines 
Author Guidelines 
Editorial Office Information 
A. Jon Stoessl, CM, MD, FRCPC, FCAHS 
Editor-in-Chief 
University of British Columbia 
Vancouver, British Columbia, Canada 
Email: jon.stoessl@ubc.ca 
Julie Nash 
Managing Editor 
Phone: 919-650-1459 
Fax: 919-287-2768 
Email: mdjedoffice@movementdisorders.org 
Manuscript Submission Information 
Submit your manuscripts online at http://mc.manuscriptcentral.com/mds. Please note: 
Manuscripts submitted online are marked as received on the day of submission, evaluated by 
the Editor-in-Chief, and assigned to an associate editor to oversee the review process. Papers 
that are not determined to be of sufficient clinical/scientific interest, focus, or relevance by at 
least two senior editors may be rejected without review. Through your individual Author 
Center on this website, you can view the status of your manuscript as it progresses through 
the review process. Notification of the final disposition of each manuscript will be sent by e-
mail to the corresponding author on the day of decision. 
To submit your manuscript online: 
• Go to the submission website (http://mc.manuscriptcentral.com/mds) 
• Click on the "Check for Existing Account" button at the bottom of the opening page. If you 
do not already have an account, then create one by clicking on the "Create an Account" 
button. You will then be able to submit your manuscript. 
• Click on “Author Center.” Follow the on-screen instructions carefully. Tables and figures 
should be uploaded as individual files and not part of the manuscript text. (You do not need 
to mail hard copies of your manuscript). 
• At the end of a successful submission, you will see a confirmation screen with your 
manuscript number, and you will receive a separate E-mail confirmation of manuscript 
reception by the journal. If these two messages do not appear, then go into your Author 
Center and make sure that you have clicked on the “Submit” button or contact technical 
support at http://mchelp.manuscriptcentral.com/gethelpnow/question.htm 
 
Submission of MDS commissioned articles. 
Prior to writing for a Task Force, Evidence Based Medicine (EBM) Reviews Guidelines, etc, 
the Chief Editor of Movement Disorders(MD) must be advised of the intent by the chair of 
the Task Force, EMB and PG groups. If the topic is agreed to be appropriate for MD, the 
task force may submit the final manuscript for peer review and editor decision regarding 
publication. If the topic is deemed to be better suited for Movement Disorders Clinical 
Practice (MDCP), this will be transmitted to author and chairperson. 
The final manuscript needs to conform to the following criteria: 
1. Quality of manuscript- The manuscript must be clearly written, thinking in the readership 
and scientific community, to be published in the printed version. For figure/table limits, 
please see the "Scope" section, as the limit will depend on the type of manuscript you 
submit. Additional data may be presented as supplemental data available online. 
 
Anxiety in Parkinson’s Disease 
128 
 
2. Length- 7000 words maximum. 
3. Authors- The first 8 will be shown in the top page after the article. All other involved 
authors will be listed as part of the Study Task Force/Group, etc. 
English Language Editing 
 
The editor of Movement Disorders strongly encourages authors from non-English speaking 
countries to have their manuscripts reviewed and corrected by an English language editing 
service before submission. All submitted manuscripts must be written in clear, correct and 
unambiguous English. We may reject papers that do not meet these standards. Wiley English 
Language Editing Services offer expertise in language editing, translation, and manuscript 
preparation services for International researchers seeking publication in international 
journals. 
 
Wiley’s English Editing Services: http://wileyeditingservices.com/en/ 
 
Please note that while this service will greatly improve the readability of your paper, it does 
not guarantee acceptance of your paper by the journal. 
Video Submission 
File size limitations: Files may be no larger than 50 MB. 
General Information: When submitting manuscripts online, authors must indicate whether 
the article has an accompanying video. Video must be submitted with manuscripts online in 
a digital format. If an article includes video, the upper right corner of the of the manuscript 
must be marked “Video is part of ms.” Video clips should be limited to 100 seconds unless 
formal approval is obtained from the editorial office. Authors must also supply, as part of the 
manuscript, a video legend for the video clip. If the author does not have the capacity to 
generate an electronic video, the author may contact the editorial office for assistance. 
Content: Video content should be edited to illustrate the key findings in a concise and 
informative manner. They should be less than 100 seconds in duration, except for special 
instances, which must be cleared in advance with the appropriate chief editor. Legends for 
the video segments should be placed at the end of the article and should concisely and 
sequentially describe what is seen in the video so that it can be understood by the viewer. Do 
not repeat explanatory material that is already in text. The video should be of high quality 
(both in content and visibility). The video should be edited to ensure maximal efficiency and 
make the specific point; particularly, it should demonstrate the features described in the text 
of the manuscript. In addition, the video should be labeled and should directly follow the 
sequence and content of the video legend. The use of text and/or special transition effects 
between the titles, subtitles and video segments is permitted. The video you submit should 
be the final product that will be published with the article. The Editors reserve the right to 
request additional video editing by the authors (which may delay publication). 
Patient Consent: The corresponding author must confirm in the author copyright form 
(Article V) that he or she has received a signed release form from each patient videotaped 
authorizing the offline and/or online distribution of this video material. Manuscripts with 
videos will not be accepted for publication until the signed copyright form (Article V) with 
appropriate documentation is received. For tips on preparing your video for submission, see 
the Technical Note by Jog and Grantier on digital video preparation. This article appears in 
volume 16, issue 6, and is available to all readers. 
Policy Regarding Inappropriate Submissions and Publications 
The editors, members of the editorial board, and publisher's staff at Movement Disorders 
take their responsibility seriously to assure that the highest ethical publishing standards are 
maintained by assisting in safeguarding the medical scientific literature against fraudulent 
publications. Please note manuscript submissions are now submitted for plagiarism detection 
through CrossCheck. Wiley‘s policy is based on the 'Guidelines on Good Publication 
 
Anxiety in Parkinson’s Disease 
129 
 
Practice' published by the Committee on Publication Ethics (COPE) and can be found at 
Author Services. Examples of fraud in scientific research include (but are not limited to): 
 
1) The submission of duplicate publications using similar data (i.e., attesting that work 
submitted is original when, in fact, it was submitted to or accepted by another journal); 
2) Falsification of data, copyright, or information regarding conflict of interest; 
3) Submission of work from other sources that was not done by the author and is presented 
as a new and original (plagiarism); 
4) Authorship (allowing one’s name to appear as an author or adding an author to a 
manuscript) without substantial input or without having agreed to submission of the 
manuscript. 
 
The above examples are not meant to be a comprehensive list of fraudulent publication 
practices. Rather, it should provide adequate basis for careful consideration of avoidable 
conflicts and editorial scrutiny regarding inappropriate preparation and submission of 
manuscripts. 
Manuscripts that have appeared in publications that are not peer-reviewed, are not registered 
in Pub Med, or are available only on the Internet, will be considered for publication in 
Movement Disorders as long as the Editor is informed and grants approval prior to 
submission of the manuscript for review. 
If there are questions as to any issues regarding inappropriate submission, the Editor should 
be consulted prior to the submission. If a submitted or published manuscript is discovered or 
suspected to be inappropriate, the authors will be asked for a written explanation. If the 
rationale provided by the authors remains unsatisfactory in the judgment of the editors, the 
manuscript will be rejected or retracted. Retractions become a matter of public record and 
are registered in Pub Med. The provost (or equivalent) of the authors' academic institutions 
will be informed of inappropriate submissions or publications, and the authors will not be 
allowed to subsequently submit their research to MDS. The leadership of MDS will also 
inform the editors and publishers of other journals that have published such manuscripts. 
Cover Letter, Author Copyright Form, and Legal Information 
Cover Letter. 
The cover letter should briefly describe the scientific or clinical importance of the 
manuscript. It must confirm that all authors have read the manuscript, the paper has not been 
previously published, and it is not under simultaneous consideration by another journal. 
Also, a statement that no ghost writing by anyone not named on the author list must be 
included (see Editorial in Movement Disorders 2005;20:1536). Identify the corresponding 
author and provide a complete mailing address, telephone number, and email address for 
each author where possible. 
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(4) a statement of acknowledgment--each of the first three statements must be read and 
signed by each author. The corresponding author must sign the acknowledgment statement 
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DeAngelis CD. Authorship for research groups. JAMA 2002;288:3166-3168). 
Documentation of Author Roles 
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project and manuscript preparation. These should include but not be restricted to: 1. 
Research project: A. Conception, B. Organization, C. Execution; 2. Statistical Analysis: A. 
Design, B. Execution, C. Review and Critique; 3. Manuscript Preparation: A. Writing of the 
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Data Access and Responsibility 
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(1) they have had full access to the data 
(2) they have the right to publish all the data, and 
(3) they have had the right to obtain independent statistical analyses of the data 
For any report containing original data, at least one author should indicate that he or she 
“takes responsibility for the integrity of the data and the accuracy of the data analysis” 
(DeAngelis CD, Fontanarosa PB, Flanagan A. Reporting financial conflicts of interest and 
relationships between investigators and research sponsors. JAMA 2001;286:89-91). 
Patient Consent 
When submitting a patient video or photograph in which a patient can be identified, the 
corresponding author must provide the Movement Disorders journal with a written 
confirmation (author copyright form, Article V) that stipulates that authorization signed by 
the patient has been obtained in compliance with any laws regarding patient authorizations 
relating to the use or disclosure of protected health information of the jurisdiction(s) to 
which the patient and the physician are subject including, if applicable, the United States 
Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). Manuscripts 
including, without limitation, a patient video or photograph will not be reviewed until a 
signed author's accompanying statement (see Item V) has been received. 
Copyright 
The International Parkinson and Movement Disorder Society will hold copyright to all 
published articles and videos. If you are a government employee, please check the 
“Government-Owned Work” checkbox. 
Financial Disclosures 
All submissions require two entries that cover financial disclosure of all authors: 
§ Financial disclosure related to research covered in this article: A statement that documents 
all funding sources and potential conflicts of interest from each author that relate to the 
research covered in the article submitted must be included on the title page, regardless of 
date. This material will be printed with the published article. 
§ Full financial disclosure for the previous 12 months: A statement that documents all 
funding sources, regardless of relationship to the current research in the article, from each 
author must be attached to the article at the end of the manuscript on the last page. 
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discretion. The copyright form that is signed by each author confirms that both of these 
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Movement Disorders will attempt to accommodate authors of manuscripts dealing with 
extremely topical issues or with findings of great scientific or clinical importance by offering 
Expedited Review and Publication. Expedited papers will be reviewed and published within 
8 to 10 weeks. 
Scope 
Movement Disorders publishes Editorials (by invitation only), Reviews, Viewpoints 
(Opinion and Hypotheses driven) Research Articles, Brief Reports and Letters. All articles 
in Movement Disorders, including letters, can be accompanied by a video when appropriate. 
The following are the requirements for each submission type: 
• Editorials: Invited Editorials are typically 1500-2000 words with 10-15 references and can 
include one figure or table. Editorial are solicited by the Editor-in-Chief. 
• Research Articles: Full-length articles should present new clinical or scientific data in a 
field related to movement disorders. The format should include: Structured Abstract: 
(Background, Objectives, Methods, Results, Conclusions) Up to 250 words with no 
abbreviations. Text: Up to 3700 words excluding of abstract, legends and references. 
Minimal abbreviations. Tables and/or figures: Up to 5. Legends: Should be concise and 
describe results without repeating data in text. The word count must appear on the title page. 
Videos: See Video section above for the video guidelines. 
• Reviews: Clinical and basic science Reviews are generally published upon request or after 
agreement with the Editor-in-Chief. Unsolicited Reviews will also be considered for 
publication; however, authors are strongly encouraged to contact the Editor-in-Chief in 
advance of submission. Reviews can be up to 5000 words, excluding the unstructured 
abstract, legends, and references, and should include no more than 6 authors. The word 
count must appear on the title page. 
• Scientific Perspectives: The purpose of these articles is to discuss recent important 
scientific results and methodologies and to place them into a clinical and translational 
context. Length should be no more than 5000 words, and figures and tables can be included. 
These will have priority in review and production, with a goal of publication within 6 weeks 
of submiss 
Form of Manuscripts 
Pages should be numbered in succession, the title page being number one. 
The text of the manuscript should be in the following sequence: 
(1) Title page: 
The opening page of each manuscript should include: 
(a) article title (no abbreviations/acronyms).Titles should be short, specific and clear. They 
should not exceed 100 characters. Do not use abbreviations/acronyms in the title; 
(b) authors' names, degrees, and affiliations (indicate the specific affiliation of each author 
by superscript, Arabic numerals); 
(c) name, address, telephone and email address of the corresponding author; 
(d) word count; 
(e) a running title not exceeding 45 letters and spaces; 
(f) Key words – up to 5; 
(g) Financial Disclosure/Conflict of Interest concerning the research related to the 
manuscript: All information on support and financial issues from all authors relative to the 
research covered in the submitted manuscript must be disclosed regardless of date. Other 
financial information unrelated to the current research covering the past year will be 
documented at the end of the manuscript (see below). 
(h) Funding sources for study. 
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(2) Abstract 
Structured Abstract: We require that authors submit structured abstracts. The page following 
the title page of Full-Length Articles should include an abstract of up to 250 words. The 
abstract should be structured. The page following the title page of a Brief Report should 
include a structured abstract of up to 150 words. Reviews should include an unstructured 
abstract. Viewpoints do not need any abstract. 
(3) Introduction 
Give a brief description of the background and relevance of the scientific contribution. 
(4) Methods 
Describe the methodology of the study. For experimental investigation of human or animal 
subjects, please state in this section that an appropriate institutional review board approved 
the project. For those investigators who do not have formal ethics review committees, the 
principles outlined in the “Declaration of Helsinki” should be followed. For investigations in 
human subjects, state in this section the manner in which informed consent was obtained 
from the subjects. A letter of consent must accompany all photographs, patient descriptions, 
and pedigrees in which a possibility of identification exists. The authors are responsible for 
ensuring anonymity. 
 (5) Results 
No specific regulations. 
 (6) Discussion 
No specific regulations. 
 (7) Acknowledgment 
No specific regulations. These may be published on line at the discretion of the editor. 
(8) Authors' Roles 
List all authors along with their specific roles in the project and preparation of the 
manuscript. 
These may include but are not restricted to: 
1) Research project: A. Conception, B. Organization, C. Execution; 
2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 
3) Manuscript: A. Writing of the first draft, B. Review and Critique. 
 (9) Financial Disclosures of all authors (for the preceding 12 months) 
Full Financial Disclosures of all Authors for the Past Year: Information concerning all 
sources of financial support and funding for the preceding twelve months, regardless of 
relationship to current manuscript, must be submitted with the following categories 
suggested. 
List sources or “none”. 
Stock Ownership in medically-related fields 
Intellectual Property Rights 
Consultancies 
Expert Testimony 
Advisory Boards 
Employment 
Partnerships 
Contracts 
Honoraria 
Royalties 
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Other 
 (10) References 
See “Details of Style” below for the proper formatting of citations and References. 
(11) Video Legend 
No specific regulations but should be concise and reflect the sequence of observations on the 
video 
(12) Figures 
Figures and Illustrations: Adapt any figures to an appropriate size of art and letters to make 
them readable in the printed version. Illustrations in full color are accepted at additional 
charge from the publisher. In the case of review articles or in special circumstances, color 
articles may be included at no charge with the permission of the Chief Editor. Any 
illustration or figure from another publication must be acknowledged in the figure legend, 
and the copyright holder’s written permission to reprint in print and online edition of 
Movement Disorders must be submitted to the editors. 
In addition, figures to illustrate concepts are welcome particularly in review articles, and 
may be enhanced by a professional artist at no cost to author at the discretion of the Editors. 
(13) Tables 
Tables should be typed neatly, each on a separate page, with a title above and any notes 
below. Explain all abbreviations. Do not repeat the same information in tables and figures 
that is present in text. Tables and figures should be uploaded as individual files and not part 
of the manuscript text. (You do not need to mail hard copies of your manuscript). 
*Tables and Figure Legends 
Double-space legends of fewer than 40 words for tables and figures. For photomicrographs, 
include the type of specimen, original magnification, and stain type. Include internal scale-
markers on photomicrographs when appropriate. Where applicable, indicate the method used 
to digitally enhance images. 
 Copyright and Disclosure Forms 
The corresponding author should upload one PDF file that includes copyright and disclosure 
forms for all authors to the Movement Disorders submission site with the revised version of 
the paper. These forms also can be emailed to mdjedoffice@movementdisorders.org. 
Digital Artwork Preparation 
For best reproduction, electronic artwork files must be in TIFF or EPS format, at a resolution 
of 600 dpi or higher, sized to print. Movement Disorders offers Rapid Inspector™ to help 
ensure that your electronic graphics files are suitable for print purposes. This free, stand-
alone software application will help you to inspect and verify illustrations right on your 
computer. Go to http://rapidinspector.cadmus.com/wi/index.jsp and create a new account. 
JPG files are of low resolution and will not be acceptable for publication. 
Details of Style 
No patient identifiers (e.g., patient initials) are to be included in the manuscript or video 
(e.g., case reports, tables, figures, etc.). 
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Units of measure: Conventional units of measure according to the Systeme International (SI) 
are preferred. The metric system is preferred for length, area, mass, and volume. Express 
temperature in degrees Celsius. 
Drug Names: Use generic names only in referring to drugs, followed in parentheses after 
first mention by any commonly used generic variant. 
Abbreviations: Follow the list of abbreviations given in "Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals" (see section on References). For additional 
abbreviations, consult the CBE Style Manual (available from the Council of Biology 
Editors, 9650 Rockville Pike, Bethesda, Maryland 20814, USA) or other standard sources. 
We encourage authors to minimize the use of abbreviations except where they are routinely 
employed and the full term would be cumbersome (eg MPTP). 
Spelling: American spelling is used throughout the Journal. 
References Movement Disorders complies with the reference style given in "Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals". (See Annals of Internal 
Medicine 1982;96:766-771, or British Medical Journal 1982:284:1766-1770.) References 
are to be cited in the text by number, and in the list of References they are to be numbered in 
the order in which they are cited. 
The reference section should be double-spaced at the end of the text, following the sample 
formats given below. 
Provide all authors' names when fewer than seven; when seven or more, list the first three 
and add et al. 
Provide article titles and inclusive pages. 
Accuracy of reference data is the responsibility of the author. 
For abbreviations of journal names, refer to List of Journals Indexed in Index Medicus 
(available from the Superintendent of Documents, U.S. Government Printing Office, 
Washington DC 20402, USA, DHEW Publication No. (NIH) 83-267; ISSN 0093-3821). 
Sample References 
• Journal article: 1. Krack P, Benzzzouz A, Pollak P, et al. Treatment of tremor in 
Parkinson’s disease by Subthalamic nucleus stiumulation. Mov Disord 1998; 13: 907-914. 
• Book: 2.Fahn S, Jankovic J, editors. Principles and Practice of Movement Disorders, 
Philadelphia, Churchill Livingstone, 2010, pp 96. 
• Chapter in a book: 3. Olanow CW. Hpyerkinetic Movement Disorders. In: Fauci A, 
Braunwald E, Kasper D, Hauser S, Longo D, Jameson JL, Loscalzo J. Eds. Harrison’s 
Textbook of Medicine 17th edition. 2008; p2560-2565. 
Accepted Articles: 
Materials Required for Publication 
After acceptance, please check to be sure that you have submitted your signed copyright 
transfer and author consent form as well as permissions forms (if applicable). 
Authors using images of their patients, whether in artwork or video format, must submit a 
copy (signed by the corresponding author) of the copyright transfer and author consent form. 
A sample form is available to authors on Manuscript Central. 
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Proofs 
Proofs must be returned within two days of receipt; late return may cause a delay in 
publication of an article. 
Please check text, tables, legends, and references carefully. To expedite publication, page 
proofs rather than galleys will be sent electronically to the author, and it may be necessary to 
charge for alterations other than correction of printing errors. 
E-mail proof pages to: MDS Production Editor, Movement Disorders. E-mail: 
mdsprod@wiley.com. 
For Video Clips or Pictures of Patients (U.S. Contributors Only) 
The United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) 
According to HIPAA, the following core elements must be included in the consent form: 
1. A specific and meaningful description of the information to be used 
2. The name of the Physician and/or Hospital allowed to disclose the information 
3. That the video clip and/or photograph will be submitted for publication in a peer-reviewed 
medical journal 
4. That the video clip and/or photograph will eventually be used by the readers of a peer-
reviewed medical journal for educational purposes 
5. An expiration date that relates to the individual or the purpose of the use or disclosure 
6. The individual’s signature and the date the authorization is signed. 
 In addition, the patient’s consent form should include the following: 
1. A statement that the Patient has the right to revoke his or her consent in writing 
2. A statement regarding whether the Physician has the ability to condition medical 
treatment on the Patient’s giving such consent 
3. A statement that information, once disclosed, may be subject to further disclosure by the 
recipient journal, in which case confidentiality would no longer be assured. The consenting 
party must understand, additionally, that in some cases the video might be re-presented 
elsewhere because the journal has policies that allow permissions and/or use copyrighted 
materials with other educational organizations. The consenting party must understand that in 
such a case the signed author’s consent form may be shared with this third party and the 
consenting party consents to this sharing of information for educational purposes. 
Reporting Guidelines 
Data reporting should follow appropriate checklists and guidelines (e.g., STROBE for 
observational trials; CONSORT for clinical trials), and other checklists should be consulted 
for other reports including diagnostic accuracy (STARD) or meta-analyses (PRISMA). 
Additional guidance on checklists and guidelines can be found here: http://www.equator-
network.org/ 
Checklists can be downloaded from the following: 
STROBE: http://strobe-statement.org 
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CONSORT: http://www.consort-statement.org/consortstatement/ 
STARD: http://www.stard-statement.org/ 
PRISMA: http://www.prisma-statement.org/ 
OnlineOpen 
OnlineOpen is available to authors of primary research articles who wish to make their 
article available to non-subscribers on publication, or whose funding agency requires 
grantees to archive the final version of their article. 
With OnlineOpen, the author, the author's funding agency, or the author's institution pays a 
fee to ensure that the article is made available to non-subscribers upon publication via Wiley 
Online Library, as well as deposited in the funding agency's preferred archive. For the full 
list of terms and conditions, see 
http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms. 
Any authors wishing to send their paper OnlineOpen will be required to complete the 
payment form available from our website at: 
https://onlinelibrary.wiley.com/onlineOpenOrder. Prior to acceptance there is no 
requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen 
if you do not wish to. 
All OnlineOpen articles are treated in the same way as any other article. They go through the 
journal's standard peer-review process and will be accepted or rejected based on their own 
merit. 
Color and Page Charges 
All figures accepted in color will be reproduced in full color in the online edition of the 
journal at no cost to authors. Authors are required to pay the cost of reproducing color 
figures in print unless color charges are waived by the editors. The charge for printing 
figures in color is $700 per figure. Color agreement forms will be sent in conjunction with 
the PDF proofs. 
 
Authors are not required to pay for printed pages, except in the cases of errata. For errata due 
to publisher error, there is no page charge. For errata due to author error, the charge to the 
author is $150 per printed page. 
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Appendix C: Details of Systematic Review Searches 
 
Database Search term 1 And/or Search term 
2 
And/or Search 
term 3 
And/or Search 
term 4 
CINAHL MJ Parkinson 
Disease 
And MJ Quality of 
life 
And TX stress Or TX 
anxiety 
MEDLINE MeSH Parkinson's 
Disease  
And MeSH 
Quality of life 
And TX stress Or TX 
anxiety 
PsycINFO MA Parkinson's 
Disease 
And MA Quality 
of life 
And TX stress Or TX 
anxiety 
Note. MJ = Word in Major Subject Heading, MESH = Medical Subject Headings (MeSH), MA = 
MeSH Subject Headings, TX = All text. 
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Appendix D: National Heart, Lung and Blood Institute Quality Assessment 
Tool for Observational, Cohort and Cross-Sectional Studies. 
NIH NATIONAL HEART, LUNG, AND BLOOD INSTITUTE 
Study Quality Assessment Tools  
Criteria Yes No 
Other 
(CD, 
NR, 
NA)* 
1. Was the research question or objective in this 
paper clearly stated? 
      
2. Was the study population clearly specified and 
defined? 
      
3. Was the participation rate of eligible persons at 
least 50%? 
      
4. Were all the subjects selected or recruited from 
the same or similar populations (including the 
same time period)? Were inclusion and exclusion 
criteria for being in the study prespecified and 
applied uniformly to all participants? 
      
5. Was a sample size justification, power 
description, or variance and effect estimates 
provided? 
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Criteria Yes No 
Other 
(CD, 
NR, 
NA)* 
6. For the analyses in this paper, were the 
exposure(s) of interest measured prior to the 
outcome(s) being measured? 
      
7. Was the timeframe sufficient so that one could 
reasonably expect to see an association between 
exposure and outcome if it existed? 
      
8. For exposures that can vary in amount or level, 
did the study examine different levels of the 
exposure as related to the outcome (e.g., 
categories of exposure, or exposure measured as 
continuous variable)? 
      
9. Were the exposure measures (independent 
variables) clearly defined, valid, reliable, and 
implemented consistently across all study 
participants? 
      
10. Was the exposure(s) assessed more than once 
over time? 
      
11. Were the outcome measures (dependent 
variables) clearly defined, valid, reliable, and 
implemented consistently across all study 
participants? 
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Criteria Yes No 
Other 
(CD, 
NR, 
NA)* 
12. Were the outcome assessors blinded to the 
exposure status of participants? 
      
13. Was loss to follow-up after baseline 20% or 
less? 
      
14. Were key potential confounding variables 
measured and adjusted statistically for their 
impact on the relationship between exposure(s) 
and outcome(s)? 
      
 
The guidance document below is organized by question number from the tool for 
quality assessment of observational cohort and cross-sectional studies. 
Question 1. Research question 
Did the authors describe their goal in conducting this research? Is it easy to 
understand what they were looking to find? This issue is important for any scientific 
paper of any type. Higher quality scientific research explicitly defines a research 
question. 
Questions 2 and 3. Study population 
Did the authors describe the group of people from which the study participants were 
selected or recruited, using demographics, location, and time period? If you were to 
conduct this study again, would you know who to recruit, from where, and from 
what time period? Is the cohort population free of the outcomes of interest at the 
time they were recruited? 
An example would be men over 40 years old with type 2 diabetes who began seeking 
medical care at Phoenix Good Samaritan Hospital between January 1, 1990 and 
December 31, 1994. In this example, the population is clearly described as: (1) who 
(men over 40 years old with type 2 diabetes); (2) where (Phoenix Good Samaritan 
Hospital); and (3) when (between January 1, 1990 and December 31, 1994). Another 
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example is women ages 34 to 59 years of age in 1980 who were in the nursing 
profession and had no known coronary disease, stroke, cancer, hypercholesterolemia, 
or diabetes, and were recruited from the 11 most populous States, with contact 
information obtained from State nursing boards. 
In cohort studies, it is crucial that the population at baseline is free of the outcome of 
interest. For example, the nurses' population above would be an appropriate group in 
which to study incident coronary disease. This information is usually found either in 
descriptions of population recruitment, definitions of variables, or 
inclusion/exclusion criteria. 
You may need to look at prior papers on methods in order to make the assessment 
for this question. Those papers are usually in the reference list. 
If fewer than 50% of eligible persons participated in the study, then there is concern 
that the study population does not adequately represent the target population. This 
increases the risk of bias. 
Question 4. Groups recruited from the same population and uniform eligibility 
criteria 
Were the inclusion and exclusion criteria developed prior to recruitment or selection 
of the study population? Were the same underlying criteria used for all of the 
subjects involved? This issue is related to the description of the study population, 
above, and you may find the information for both of these questions in the same 
section of the paper. 
Most cohort studies begin with the selection of the cohort; participants in this cohort 
are then measured or evaluated to determine their exposure status. However, some 
cohort studies may recruit or select exposed participants in a different time or place 
than unexposed participants, especially retrospective cohort studies–which is when 
data are obtained from the past (retrospectively), but the analysis examines 
exposures prior to outcomes. For example, one research question could be whether 
diabetic men with clinical depression are at higher risk for cardiovascular disease 
than those without clinical depression. So, diabetic men with depression might be 
selected from a mental health clinic, while diabetic men without depression might be 
selected from an internal medicine or endocrinology clinic. This study recruits 
groups from different clinic populations, so this example would get a "no." 
However, the women nurses described in the question above were selected based on 
the same inclusion/exclusion criteria, so that example would get a "yes." 
Question 5. Sample size justification 
Did the authors present their reasons for selecting or recruiting the number of people 
included or analyzed? Do they note or discuss the statistical power of the study? This 
question is about whether or not the study had enough participants to detect an 
association if one truly existed. 
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A paragraph in the methods section of the article may explain the sample size needed 
to detect a hypothesized difference in outcomes. You may also find a discussion of 
power in the discussion section (such as the study had 85 percent power to detect a 
20 percent increase in the rate of an outcome of interest, with a 2-sided alpha of 
0.05). Sometimes estimates of variance and/or estimates of effect size are given, 
instead of sample size calculations. In any of these cases, the answer would be "yes." 
However, observational cohort studies often do not report anything about power or 
sample sizes because the analyses are exploratory in nature. In this case, the answer 
would be "no." This is not a "fatal flaw." It just may indicate that attention was not 
paid to whether the study was sufficiently sized to answer a prespecified question–
i.e., it may have been an exploratory, hypothesis-generating study. 
Question 6. Exposure assessed prior to outcome measurement 
This question is important because, in order to determine whether an exposure 
causes an outcome, the exposure must come before the outcome. 
For some prospective cohort studies, the investigator enrolls the cohort and then 
determines the exposure status of various members of the cohort (large 
epidemiological studies like Framingham used this approach). However, for other 
cohort studies, the cohort is selected based on its exposure status, as in the example 
above of depressed diabetic men (the exposure being depression). Other examples 
include a cohort identified by its exposure to fluoridated drinking water and then 
compared to a cohort living in an area without fluoridated water, or a cohort of 
military personnel exposed to combat in the Gulf War compared to a cohort of 
military personnel not deployed in a combat zone. 
With either of these types of cohort studies, the cohort is followed forward in time 
(i.e., prospectively) to assess the outcomes that occurred in the exposed members 
compared to nonexposed members of the cohort. Therefore, you begin the study in 
the present by looking at groups that were exposed (or not) to some biological or 
behavioral factor, intervention, etc., and then you follow them forward in time to 
examine outcomes. If a cohort study is conducted properly, the answer to this 
question should be "yes," since the exposure status of members of the cohort was 
determined at the beginning of the study before the outcomes occurred. 
For retrospective cohort studies, the same principal applies. The difference is that, 
rather than identifying a cohort in the present and following them forward in time, 
the investigators go back in time (i.e., retrospectively) and select a cohort based on 
their exposure status in the past and then follow them forward to assess the outcomes 
that occurred in the exposed and nonexposed cohort members. Because in 
retrospective cohort studies the exposure and outcomes may have already occurred 
(it depends on how long they follow the cohort), it is important to make sure that the 
exposure preceded the outcome. 
Sometimes cross-sectional studies are conducted (or cross-sectional analyses of 
cohort-study data), where the exposures and outcomes are measured during the same 
timeframe. As a result, cross-sectional analyses provide weaker evidence than 
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regular cohort studies regarding a potential causal relationship between exposures 
and outcomes. For cross-sectional analyses, the answer to Question 6 should be "no." 
Question 7. Sufficient timeframe to see an effect 
Did the study allow enough time for a sufficient number of outcomes to occur or be 
observed, or enough time for an exposure to have a biological effect on an outcome? 
In the examples given above, if clinical depression has a biological effect on 
increasing risk for CVD, such an effect may take years. In the other example, if 
higher dietary sodium increases BP, a short timeframe may be sufficient to assess its 
association with BP, but a longer timeframe would be needed to examine its 
association with heart attacks. 
The issue of timeframe is important to enable meaningful analysis of the 
relationships between exposures and outcomes to be conducted. This often requires 
at least several years, especially when looking at health outcomes, but it depends on 
the research question and outcomes being examined. 
Cross-sectional analyses allow no time to see an effect, since the exposures and 
outcomes are assessed at the same time, so those would get a "no" response. 
Question 8. Different levels of the exposure of interest 
If the exposure can be defined as a range (examples: drug dosage, amount of 
physical activity, amount of sodium consumed), were multiple categories of that 
exposure assessed? (for example, for drugs: not on the medication, on a low dose, 
medium dose, high dose; for dietary sodium, higher than average U.S. consumption, 
lower than recommended consumption, between the two). Sometimes discrete 
categories of exposure are not used, but instead exposures are measured as 
continuous variables (for example, mg/day of dietary sodium or BP values). 
In any case, studying different levels of exposure (where possible) enables 
investigators to assess trends or dose-response relationships between exposures and 
outcomes–e.g., the higher the exposure, the greater the rate of the health outcome. 
The presence of trends or dose-response relationships lends credibility to the 
hypothesis of causality between exposure and outcome. 
For some exposures, however, this question may not be applicable (e.g., the 
exposure may be a dichotomous variable like living in a rural setting versus an urban 
setting, or vaccinated/not vaccinated with a one-time vaccine). If there are only two 
possible exposures (yes/no), then this question should be given an "NA," and it 
should not count negatively towards the quality rating. 
Question 9. Exposure measures and assessment 
Were the exposure measures defined in detail? Were the tools or methods used to 
measure exposure accurate and reliable–for example, have they been validated or are 
they objective? This issue is important as it influences confidence in the reported 
exposures. When exposures are measured with less accuracy or validity, it is harder 
to see an association between exposure and outcome even if one exists. Also as 
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important is whether the exposures were assessed in the same manner within groups 
and between groups; if not, bias may result. 
For example, retrospective self-report of dietary salt intake is not as valid and 
reliable as prospectively using a standardized dietary log plus testing participants' 
urine for sodium content. Another example is measurement of BP, where there may 
be quite a difference between usual care, where clinicians measure BP however it is 
done in their practice setting (which can vary considerably), and use of trained BP 
assessors using standardized equipment (e.g., the same BP device which has been 
tested and calibrated) and a standardized protocol (e.g., patient is seated for 5 
minutes with feet flat on the floor, BP is taken twice in each arm, and all four 
measurements are averaged). In each of these cases, the former would get a "no" and 
the latter a "yes." 
Here is a final example that illustrates the point about why it is important to assess 
exposures consistently across all groups: If people with higher BP (exposed cohort) 
are seen by their providers more frequently than those without elevated BP 
(nonexposed group), it also increases the chances of detecting and documenting 
changes in health outcomes, including CVD-related events. Therefore, it may lead to 
the conclusion that higher BP leads to more CVD events. This may be true, but it 
could also be due to the fact that the subjects with higher BP were seen more often; 
thus, more CVD-related events were detected and documented simply because they 
had more encounters with the health care system. Thus, it could bias the results and 
lead to an erroneous conclusion. 
Question 10. Repeated exposure assessment 
Was the exposure for each person measured more than once during the course of the 
study period? Multiple measurements with the same result increase our confidence 
that the exposure status was correctly classified. Also, multiple measurements enable 
investigators to look at changes in exposure over time, for example, people who ate 
high dietary sodium throughout the followup period, compared to those who started 
out high then reduced their intake, compared to those who ate low sodium 
throughout. Once again, this may not be applicable in all cases. In many older 
studies, exposure was measured only at baseline. However, multiple exposure 
measurements do result in a stronger study design. 
Question 11. Outcome measures 
Were the outcomes defined in detail? Were the tools or methods for measuring 
outcomes accurate and reliable–for example, have they been validated or are they 
objective? This issue is important because it influences confidence in the validity of 
study results. Also important is whether the outcomes were assessed in the same 
manner within groups and between groups. 
An example of an outcome measure that is objective, accurate, and reliable is death–
the outcome measured with more accuracy than any other. But even with a measure 
as objective as death, there can be differences in the accuracy and reliability of how 
death was assessed by the investigators. Did they base it on an autopsy report, death 
certificate, death registry, or report from a family member? Another example is a 
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study of whether dietary fat intake is related to blood cholesterol level (cholesterol 
level being the outcome), and the cholesterol level is measured from fasting blood 
samples that are all sent to the same laboratory. These examples would get a "yes." 
An example of a "no" would be self-report by subjects that they had a heart attack, or 
self-report of how much they weigh (if body weight is the outcome of interest). 
Similar to the example in Question 9, results may be biased if one group (e.g., people 
with high BP) is seen more frequently than another group (people with normal BP) 
because more frequent encounters with the health care system increases the chances 
of outcomes being detected and documented. 
Question 12. Blinding of outcome assessors 
Blinding means that outcome assessors did not know whether the participant was 
exposed or unexposed. It is also sometimes called "masking." The objective is to 
look for evidence in the article that the person(s) assessing the outcome(s) for the 
study (for example, examining medical records to determine the outcomes that 
occurred in the exposed and comparison groups) is masked to the exposure status of 
the participant. Sometimes the person measuring the exposure is the same person 
conducting the outcome assessment. In this case, the outcome assessor would most 
likely not be blinded to exposure status because they also took measurements of 
exposures. If so, make a note of that in the comments section. 
As you assess this criterion, think about whether it is likely that the person(s) doing 
the outcome assessment would know (or be able to figure out) the exposure status of 
the study participants. If the answer is no, then blinding is adequate. An example of 
adequate blinding of the outcome assessors is to create a separate committee, whose 
members were not involved in the care of the patient and had no information about 
the study participants' exposure status. The committee would then be provided with 
copies of participants' medical records, which had been stripped of any potential 
exposure information or personally identifiable information. The committee would 
then review the records for prespecified outcomes according to the study protocol. If 
blinding was not possible, which is sometimes the case, mark "NA" and explain the 
potential for bias. 
Question 13. Followup rate 
Higher overall followup rates are always better than lower followup rates, even 
though higher rates are expected in shorter studies, whereas lower overall followup 
rates are often seen in studies of longer duration. Usually, an acceptable overall 
followup rate is considered 80 percent or more of participants whose exposures were 
measured at baseline. However, this is just a general guideline. For example, a 6-
month cohort study examining the relationship between dietary sodium intake and 
BP level may have over 90 percent followup, but a 20-year cohort study examining 
effects of sodium intake on stroke may have only a 65 percent followup rate. 
Question 14. Statistical analyses 
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Were key potential confounding variables measured and adjusted for, such as by 
statistical adjustment for baseline differences? Logistic regression or other regression 
methods are often used to account for the influence of variables not of interest. 
This is a key issue in cohort studies, because statistical analyses need to control for 
potential confounders, in contrast to an RCT, where the randomization process 
controls for potential confounders. All key factors that may be associated both with 
the exposure of interest and the outcome–that are not of interest to the research 
question–should be controlled for in the analyses. 
For example, in a study of the relationship between cardiorespiratory fitness and 
CVD events (heart attacks and strokes), the study should control for age, BP, blood 
cholesterol, and body weight, because all of these factors are associated both with 
low fitness and with CVD events. Well-done cohort studies control for multiple 
potential confounders. 
Some general guidance for determining the overall quality rating of 
observational cohort and cross-sectional studies 
The questions on the form are designed to help you focus on the key concepts for 
evaluating the internal validity of a study. They are not intended to create a list that 
you simply tally up to arrive at a summary judgment of quality. 
Internal validity for cohort studies is the extent to which the results reported in the 
study can truly be attributed to the exposure being evaluated and not to flaws in the 
design or conduct of the study–in other words, the ability of the study to draw 
associative conclusions about the effects of the exposures being studied on 
outcomes. Any such flaws can increase the risk of bias. 
Critical appraisal involves considering the risk of potential for selection bias, 
information bias, measurement bias, or confounding (the mixture of exposures that 
one cannot tease out from each other). Examples of confounding include co-
interventions, differences at baseline in patient characteristics, and other issues 
throughout the questions above. High risk of bias translates to a rating of poor 
quality. Low risk of bias translates to a rating of good quality. (Thus, the greater the 
risk of bias, the lower the quality rating of the study.) 
In addition, the more attention in the study design to issues that can help determine 
whether there is a causal relationship between the exposure and outcome, the higher 
quality the study. These include exposures occurring prior to outcomes, evaluation of 
a dose-response gradient, accuracy of measurement of both exposure and outcome, 
sufficient timeframe to see an effect, and appropriate control for confounding–all 
concepts reflected in the tool. 
Generally, when you evaluate a study, you will not see a "fatal flaw," but you will 
find some risk of bias. By focusing on the concepts underlying the questions in the 
quality assessment tool, you should ask yourself about the potential for bias in the 
study you are critically appraising. For any box where you check "no" you should 
ask, "What is the potential risk of bias resulting from this flaw in study design or 
execution?" That is, does this factor cause you to doubt the results that are reported 
 
Anxiety in Parkinson’s Disease 
147 
 
in the study or doubt the ability of the study to accurately assess an association 
between exposure and outcome? 
The best approach is to think about the questions in the tool and how each one tells 
you something about the potential for bias in a study. The more you familiarize 
yourself with the key concepts, the more comfortable you will be with critical 
appraisal. Examples of studies rated good, fair, and poor are useful, but each study 
must be assessed on its own based on the details that are reported and consideration 
of the concepts for minimizing bias. 
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Appendix E: Quality Ratings 
Principle Author (DC) Quality Ratings: 
Article Population 
clearly 
defined 
Participation 
rate at least 
50% 
Subject 
recruited from 
same or 
similar 
populations. 
Were 
inclusion and 
exclusion 
criteria pre 
specified and 
applied 
uniformly to 
all 
participants? 
Was sample 
size 
justification, 
power 
description, or 
variance and 
effect 
estimates 
provided.  
Were 
measures 
clearly 
defined, valid, 
reliable and 
implemented 
consistently 
across all 
study 
participants? 
Notes 
Chrischilles et 
al., 2002 
*     *Limited detail 
on recruitment 
 
Carod Artal et 
al., 2007 
               *    *Does not 
report 
participation 
rate 
Carod-Artal et 
al., 2008 
               *    *Does not 
report 
participation 
rate 
McKinlay et 
al., 2008 
* ** ***           **** *Limited detail 
on recruitment 
**115 invited, 
49 took part 
*** did not 
report where 
recruited from 
****only 42 of 
49 participants 
completed 
anxiety 
measure 
Rahman et al., 
2008 
*  **   *No diagnostic 
criteria 
** inclusion 
criteria lacked 
clarity 
Quelhas & 
Costa, 2009 
 *    * Does not 
report 
participation 
rate 
 
Gallagher et al., 
2010 
* **    *insufficient 
detail on 
recruitment 
selection 
** Does not 
report 
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participation 
rate 
Haviklova et 
al., 2011 
      
Hinnell et al., 
2012 
 *    *Does not 
report 
participation 
rate 
Dubayova et 
al., 2012 
 *    *participation 
rate below 
50% 
Hanna & 
Cronin 
Golomb, 2012 
* **    *Limited detail 
on recruitment 
**Does not 
report 
participation 
rate 
Skorvanek et 
al., 2013  
* **    *Excludes 
age<65 
**Does not 
report 
participation 
rate 
 
Fereshtehnejad 
et al., 2014 
 *    *Does not 
report 
participation 
rate 
 
Baig et al. 2015 *     *Includes only 
those < 3.5 
years since 
diagnosis  
Fereshtehnejad 
et al., 2015 
 *    *Does not 
report 
participation 
rate 
Jones et al., 
2015 
 *    *Does not 
report 
participation 
rate 
Walton et al., 
2015 
 
 *    *Does not 
report 
participation 
rate 
 
Wu et al., 2015 
 
 **    * Includes 
only those < 5 
years since 
diagnosis 
**Does not 
report 
 
Anxiety in Parkinson’s Disease 
150 
 
participation 
rate 
 
Fan et al., 2016 
 
* ** 
                                     *Limited detail 
on recruitment 
**Does not 
report 
participation 
rate 
D’Iorio et al., 
2017 
 *    *Does not 
report 
participation 
rate 
Yoon et al., 
2017 
* **    * Includes 
only those < 2 
years since 
diagnosis 
**Does not 
report 
participation 
rate 
Prisnie et al., 
2018 
                       
Note. Green = criterion met; Red = criterion not met, Amber = unclear whether criterion was met.  
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Additional Author (CI) Quality Ratings: 
Article Population 
clearly defined 
Participation 
rate at least 50% 
Subject 
recruited from 
same or similar 
populations. 
Were inclusion 
and exclusion 
criteria pre 
specified and 
applied 
uniformly to all 
participants? 
Was sample size 
justification, 
power 
description, or 
variance and 
effect estimates 
provided.  
Were measures 
clearly defined, 
valid, reliable 
and 
implemented 
consistently 
across all study 
participants? 
Notes 
Chrischilles et 
al., 2002 
*     *did not 
adequately 
detail how the 
participants 
were recruited 
Carod Artal et 
al., 2007 
 *    * not reported 
Carod-Artal et 
al., 2008 
 *    * not reported 
McKinlay et al., 
2008 
* ** ***  **** * did not 
adequately 
detail how the 
participants 
were recruited 
** 49 
participants 
from total of 
115 
*** did not 
report from 
where 
participants 
were recruited 
**** not all 
participants 
completed the 
anxiety measure 
Rahman et al., 
2008 
*  **   * did not 
adequately 
detail how the 
participants 
were recruited 
** inclusion and 
exclusion 
criteria were not 
outlined 
Quelhas & 
Costa, 2009 
 *    * not reported 
Gallagher et al., 
2010 
* **    * did not 
adequately 
detail how the 
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participants 
were recruited 
** not reported 
Haviklova et al., 
2011 
      
Hinnell et al., 
2012 
 *    *not reported 
Dubayova et al., 
2012 
 *    *only 31.3% 
Hanna & Cronin 
Golomb, 2012 
* **    * did not 
adequately 
detail how the 
participants 
were recruited 
**not reported 
 Note. Green = criterion met; Red = criterion not met, Amber = unclear whether criterion was met.  
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Appendix F: Articles Reviewed at Full-Text Screening 
Paper Reason for Exclusion Exclusion 
Code 
"<Ru Lai et al. - 2018 - Clinical Factors 
Associated with the Quality Of Life in 
Patients with Parkinson’s disease.pdf>." 
No reference to anxiety. No 
validated measure of 
anxiety used. 
2 
Aarsland, D., Marsh, L., & Schrag, A. (2009). 
Neuropsychiatric symptoms in Parkinson's 
disease. Movement disorders: official journal 
of the Movement Disorder Society, 24(15), 
2175-2186. 
Just a general review of 
psychology in Parkinson’s. 
No measures. 
3 
Aarsland, D., Taylor, J. P., & Weintraub, D. 
(2014). Psychiatric issues in cognitive 
impairment. Movement Disorders, 29(5), 651-
662. 
Just a review of psych in 
Parkinson’s. no measures or 
actually study. 
3 
Akanova, A. A., Kamenova, S. U., 
Yeshmanova, A. K., Beltenova, A. G., & 
Kondybayeva, A. M. (2015). The evaluation 
of cognitive skills and the quality of life 
between Parkinson Disease patients and 
healthy aged people above 60 years 
old. Advances in Gerontology, 28(4), 741-
748. 
In Russian – unable to 
access. 
1 
Anderson, K. E., Gruber‐Baldini, A. L., 
Vaughan, C. G., Reich, S. G., Fishman, P. S., 
Weiner, W. J., & Shulman, L. M. (2007). 
Impact of psychogenic movement disorders 
versus Parkinson's on disability, quality of 
life, and psychopathology. Movement 
disorders: official journal of the Movement 
Disorder Society, 22(15), 2204-2209. 
Compares Parkinson’s to 
another illness across a 
number of domains, (QOL 
and anxiety included). But 
does not look at link 
between anxiety and QOL 
in Parkinson’s. 
4 
Backer, J. H. (2006). "The symptom 
experience of patients with Parkinson's 
disease." Journal of Neuroscience Nursing 
38(1): 51-57.  
No measures 2 
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Balestrino, R., & Martinez-Martin, P. (2017). 
Reprint of “Neuropsychiatric symptoms, 
behavioural disorders, and quality of life in 
Parkinson's disease”. Journal of the 
Neurological Sciences, 374, 3-8. 
A narrative review of 
studies that look at 
psychiatric symptoms and 
QOL. 
3 
Barone, P., Antonini, A., Colosimo, C., 
Marconi, R., Morgante, L., Avarello, T. P., ... 
& Cicarelli, G. (2009). The PRIAMO study: a 
multicenter assessment of nonmotor 
symptoms and their impact on quality of life 
in Parkinson's disease. Movement disorders: 
official journal of the Movement Disorder 
Society, 24(11), 1641-1649. 
impact of anxiety alone was 
not able to be determined as 
A & D combined for 
correlation 
  
 
2 
Bucks, R. S., Cruise, K. E., Skinner, T. C., 
Loftus, A. M., Barker, R. A., & Thomas, M. 
G. (2011). Coping processes and health‐
related quality of life in Parkinson's 
disease. International Journal of Geriatric 
Psychiatry, 26(3), 247-255. 
No validated measure of 
anxiety used. 
2 
Bugalho, P., Lampreia, T., Miguel, R., 
Mendonça, M. D., Caetano, A., & Barbosa, R. 
(2016). Non-Motor symptoms in Portuguese 
Parkinson’s Disease patients: correlation and 
impact on Quality of Life and Activities of 
Daily Living. Scientific reports, 6, 32267. 
combining anxiety with 
insomnia before correlating 
it with QOL etc. 
2 
Cubí-Mollá, P., De Vries, J., & Devlin, N. 
(2014). A study of the relationship between 
health and subjective well-being in 
Parkinson’s disease patients. Value in 
Health, 17(4), 372-379. 
No validated measure of 
anxiety used. 
2 
Chaudhuri, K. R., Sauerbier, A., Rojo, J. M., 
Sethi, K., Schapira, A. H. V., Brown, R. G., ... 
& Tsuboi, Y. (2015). The burden of non-
motor symptoms in Parkinson's disease using 
a self-completed non-motor questionnaire: a 
simple grading system. Parkinsonism & 
related disorders, 21(3), 287-291. 
they don’t directly correlate 
anxiety with QOL 
4 
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Diaz, A. P., Freitas, F. C., de Oliveira Thais, 
M. E., da Silva Areas, F. Z., Schwarzbold, M. 
L., Debona, R., ... & Shukla, A. W. (2016). 
Variables associated with physical health-
related quality of life in Parkinson’s disease 
patients presenting for deep brain 
stimulation. Neurological Sciences, 37(11), 
1831-1837. 
Reports HADS overall score 
in the regression (ie 
grouping anxiety and 
depression together). 
Therefore does not isolate 
the anxiety.  
 
2 
Dissanayaka, N. N., White, E., O'Sullivan, J. 
D., Marsh, R., Pachana, N. A., & Byrne, G. J. 
(2014). The clinical spectrum of anxiety in 
Parkinson's disease. Movement 
Disorders, 29(8), 967-975. 
This is a descriptive 
overview of anxiety in 
Parkinson’s. No measures. 
3 
Dissanayaka, N. N., Sellbach, A., Silburn, P. 
A., O'Sullivan, J. D., Marsh, R., & Mellick, 
G. D. (2011). Factors associated with 
depression in Parkinson's disease. Journal of 
affective disorders, 132(1-2), 82-88. 
Explores factors associated 
with depression. (anxiety 
being one of them) – it does 
not explore anxiety and 
QOL. 
4 
Dowding, C. H., Shenton, C. L., & Salek, S. 
S. (2006). A review of the health-related 
quality of life and economic impact of 
Parkinson’s disease. Drugs & aging, 23(9), 
693-721. 
A comprehensive review of: 
QOL in Parkinson’s 
disease specific QOL costs, 
burden  
components (not inc 
anxiety). 
3 
Fereshtehnejad, S. M., Ghazi, L., 
Shafieesabet, M., Shahidi, G. A., Delbari, A., 
& Lökk, J. (2014). Motor, psychiatric and 
fatigue features associated with nutritional 
status and its effects on quality of life in 
Parkinson’s disease patients. PLoS One, 9(3), 
e91153. 
This is about nutrition status 
and factors that impact it 
(anxiety being one) - with a 
view that nutrition status 
impacts QOL – speculative 
link. 
4 
Forjaz, M. J., Frades-Payo, B., & Martinez-
Martin, P. (2009). The current state of the art 
concerning quality of life in Parkinson's 
disease: II. Determining and associated 
factors. Revista de neurologia, 49(12), 655-
660. 
In Spanish – not able to 
access. 
1 
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Frazier, L. D. (2000). Coping with disease-
related stressors in Parkinson's disease. The 
Gerontologist. 
rejected because it looks at 
the factors that predict stress 
and factors that predict QOL 
- but doesn’t look at stress 
predicting QOL. 
4 
Gison, A., Dall’Armi, V., Donati, V., Rizza, 
F., & Giaquinto, S. (2014). Dispositional 
optimism, depression, disability and quality 
of life in Parkinson’s disease. Functional 
neurology, 29(2), 113. 
About optimism - not about 
anxiety and QOL. 
4 
Gison, A., Rizza, F., Bonassi, S., Dall’Armi, 
V., Lisi, S., & Giaquinto, S. (2014). The 
sense-of-coherence predicts health-related 
quality of life and emotional distress but not 
disability in Parkinson’s disease. BMC 
neurology, 14(1), 193. 
About sense of coherence - 
not about anxiety and QOL. 
4 
Gison, A., Rizza, F., Bonassi, S., Donati, V., 
& Giaquinto, S. (2015). Effects of 
dispositional optimism on quality of life, 
emotional distress and disability in 
Parkinson’s disease outpatients under 
rehabilitation. Functional neurology, 30(2), 
105. 
About dispositional 
optimism - not about 
anxiety and QOL. 
4 
Gökçal, E., Veysel Eren, G. Ü. R., Selvitop, 
R., YILDIZ, G. B., & Talip, A. S. İ. L. 
(2017). Motor and non-motor symptoms in 
Parkinson’s disease: effects on quality of 
life. Archives of Neuropsychiatry, 54(2), 143. 
No reference to anxiety. 2 
Goldsworthy, B., & Knowles, S. (2008). 
Caregiving for Parkinson's disease patients: 
an exploration of a stress-appraisal model for 
quality of life and burden. The Journals of 
Gerontology Series B: Psychological Sciences 
and Social Sciences, 63(6), P372-P376. 
About the burden and 
quality of life of Parkinson's 
disease caregivers based on 
a stress-appraisal model. 
Not about anxiety and QOL. 
6 
Ghorbani Saeedian, R., Nagyova, I., 
Krokavcova, M., Skorvanek, M., 
Rosenberger, J., Gdovinova, Z., ... & van 
Dijk, J. P. (2014). The role of social support 
Looks at role of social 
support in anxiety and 
4 
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in anxiety and depression among Parkinson’s 
disease patients. Disability and 
rehabilitation, 36(24), 2044-2049. 
depression in Parkinson’s. 
Not on topic. 
Greene, T., & Camicioli, R. (2007). 
Depressive symptoms and cognitive status 
affect health‐related quality of life in older 
patients with Parkinson's disease. Journal of 
the American Geriatrics Society, 55(11), 
1888-1890. 
No validated measure of 
anxiety used. 
2 
Grün, D., Pieri, V., Vaillant, M., & Diederich, 
N. J. (2016). Contributory factors to caregiver 
burden in Parkinson disease. Journal of the 
American Medical Directors 
Association, 17(7), 626-632. 
No validated measure of 
anxiety used. 
2 
Handley, J. (1999). "Psychological aspects of 
Parkinson's diseases." Elderly Care 11(4): 34-
36.  
No measures validated 2 
Havlikova, E., Rosenberger, J., Nagyova, I., 
Middel, B., Dubayova, T., Gdovinova, Z., ... 
& van Dijk, J. P. (2008). Clinical and 
psychosocial factors associated with fatigue 
in patients with Parkinson's 
disease. Parkinsonism & related 
disorders, 14(3), 187-192. 
No direct correlation of 
anxiety with QOL 
4 
Hill, M. S. (2016). "Physical Activity 
Behavior and Health-Related Quality of Life 
in Parkinson's Disease Patients: Role of 
Social Cognitive Variables." Physical 
Activity Behavior & Health-related Quality of 
Life in Parkinson's Disease Patients: Role of 
Social Cognitive Variables: 1-1.  
Anxiety not explored 
/measured 
7 
Hurt, C. S., Burn, D. J., Hindle, J., Samuel, 
M., Wilson, K., & Brown, R. G. (2014). 
Thinking positively about chronic illness: An 
exploration of optimism, illness perceptions 
and well‐being in patients with P arkinson's 
disease. British Journal of Health 
Psychology, 19(2), 363-379. 
No validated measure of 
anxiety used (merges 
anxiety and depression with 
overall HADS score). 
2 
 
Anxiety in Parkinson’s Disease 
158 
 
Hurt, C. S., Landau, S., Burn, D. J., Hindle, J. 
V., Samuel, M., Wilson, K., & Brown, R. G. 
(2012). Cognition, coping, and outcome in 
Parkinson's disease. International 
Psychogeriatrics, 24(10), 1656-1663. 
Does not refer to anxiety or 
QOL.  
 
4 
Isais-Millán, S., Piña-Fuentes, D., Guzmán-
Astorga, C., Cervantes-Arriaga, A., & 
Rodríguez-Violante, M. (2016). Prevalence of 
neuropsychiatric disorders in drug-naive 
subjects with Parkinson’s disease (PD). Gac 
Med Mex, 152(3), 357-363. 
In Spanish – not able to 
access. From abstract, 
doesn't look at QOL - just 
reports prevalence of 
neuropsychiatric disorders 
in PD. 
1 
Kadastik-Eerme, L., Muldmaa, M., Lilles, S., 
Rosenthal, M., Taba, N., & Taba, P. (2016). 
Nonmotor features in Parkinson’s disease: 
what are the most important associated 
factors?. Parkinson’s Disease, 2016. 
No validated measure of 
anxiety used. - only mental 
state - not broken down as 
sub-item in regression either 
2 
Karlsen, K. H., Tandberg, E., Årsland, D., & 
Larsen, J. P. (2000). Health related quality of 
life in Parkinson's disease: a prospective 
longitudinal study. Journal of Neurology, 
Neurosurgery & Psychiatry, 69(5), 584-589. 
No reference to anxiety. 7 
Kasten, M., Hagenah, J., Graf, J., Lorwin, A., 
Vollstedt, E. J., Peters, E., ... & Klein, C. 
(2012). Cohort Profile: a population-based 
cohort to study non-motor symptoms in 
parkinsonism (EPIPARK). International 
journal of epidemiology, 42(1), 128-128k. 
Descriptive study. Not 
looking at QOL and anxiety 
3 
Kasten, M., Kertelge, L., Brüggemann, N., 
van der Vegt, J., Schmidt, A., Tadic, V., ... & 
Binkofski, F. (2010). Nonmotor symptoms in 
genetic Parkinson disease. Archives of 
neurology, 67(6), 670-676. 
Descriptive. Not related to 
anxiety and QOL. 
3 
Lee, S. M., Kim, M., Lee, H. M., Kwon, K. 
Y., & Koh, S. B. (2015). Nonmotor 
symptoms in essential tremor: Comparison 
with Parkinson's disease and normal 
Compares prevalence of 
non-motor symptoms 
between essential tremor 
and Parkinson’s patients. 
8 
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control. Journal of the neurological 
sciences, 349(1-2), 168-173. 
Leroi, I., Ahearn, D. J., Andrews, M., 
McDonald, K. R., Byrne, E. J., & Burns, A. 
(2011). Behavioural disorders, disability and 
quality of life in Parkinson's disease. Age and 
ageing, 40(5), 614-621. 
Recruits those with apathy 
and impulse control 
difficulties – too selective 
8 
Lutz, S. G., Holmes, J. D., Ready, E. A., 
Jenkins, M. E., & Johnson, A. M. (2016). 
Clinical presentation of anxiety in parkinson’s 
disease: a scoping review. OTJR: occupation, 
participation and health, 36(3), 134-147. 
Descriptive review of 
anxiety in Parkinson’s. 
3 
Lyons, K. E., & Pahwa, R. (2011). The 
impact and management of nonmotor 
symptoms of Parkinson's disease. The 
American journal of managed care, 17, S308-
14. 
Descriptive article on non-
motor symptoms in 
Parkinson’s. No validated 
measures of anxiety. 
3 
Martínez‐Martin, P., Carod‐Artal, F. J., da 
Silveira Ribeiro, L., Ziomkowski, S., Vargas, 
A. P., Kummer, W., & Mesquita, H. M. 
(2008). Longitudinal psychometric attributes, 
responsiveness, and importance of change: 
An approach using the SCOPA‐Psychosocial 
questionnaire. Movement disorders: official 
journal of the Movement Disorder 
Society, 23(11), 1516-1523. 
This is about how well a 
measure can track change.  
4 
Martinez-Martin, P., Rodriguez-Blazquez, C., 
Forjaz, M. J., Frades-Payo, B., Agüera-Ortiz, 
L., Weintraub, D., ... & Chaudhuri, K. R. 
(2015). Neuropsychiatric symptoms and 
caregiver's burden in Parkinson's 
disease. Parkinsonism & related 
disorders, 21(6), 629-634. 
a. It’s about caregiver 
burden 
b. No validated measure of 
anxiety used (depression 
and anxiety merged) 
6 
Martinez-Martin, P. (2011). The importance of non-motor 
disturbances to quality of life in Parkinson's disease. Journal of the 
neurological sciences, 310(1-2), 12-16. 
Review of non-motor 
symptoms and QOL. No 
measures used. 
3 
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Chicago 
 
 
Matsui, K., Tachibana, H., Yamanishi, T., 
Oguru, M., Toda, K., Okuda, B., & Oka, N. 
(2013). Clinical correlates of anhedonia in 
patients with Parkinson's disease. Clinical 
neurology and neurosurgery, 115(12), 2524-
2527. 
 
 
Used measures of anxiety 
and qol. 
However, the conclusion is: 
Anxiety is correlated to 
ability to feel pleasure. 
Ability to feel pleasure is 
correlated to qol. 
4 
McAuliffe, M. J., Baylor, C. R., & Yorkston, 
K. M. (2017). Variables associated with 
communicative participation in Parkinson’s 
disease and its relationship to measures of 
health-related quality-of-life. International 
Journal of Speech-Language 
Pathology, 19(4), 407-417. 
Not anxiety focussed.  7 
McCabe, M. P., Firth, L., & O’Connor, E. 
(2009). A comparison of mood and quality of 
life among people with progressive 
neurological illnesses and their 
caregivers. Journal of clinical psychology in 
medical settings, 16(4), 355-362. 
No validated measure of 
anxiety used. Compares 
neurological disease for 
their rate of mood 
disturbance and QOl.  
2 
Muslimović, D., Post, B., Speelman, J. D., 
Schmand, B., & de Haan, R. J. (2008). 
Determinants of disability and quality of life 
in mild to moderate Parkinson 
disease. Neurology, 70(23), 2241-2247. 
Report overall HADS, not 
HADS-A separately.  
2 
Obeso, I., Casabona, E., Rodríguez-Rojas, R., 
Bringas, M. L., Macías, R., Pavón, N., ... & 
Jahanshahi, M. (2017). Unilateral 
subthalamotomy in Parkinson's disease: 
Cognitive, psychiatric and neuroimaging 
changes. Cortex, 94, 39-48. 
Exploration of whether 
surgical intervention can 
bring about changes in 
movement, psychiatric and 
QOL status. 
 
4 
O’Connor, E. J., & McCabe, M. P. (2011). 
Predictors of quality of life in carers for 
people with a progressive neurological 
About carers in different 
neuro diseases 
6 
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illness: a longitudinal study. Quality of Life 
Research, 20(5), 703-711. 
 
Ozdilek, B., & Gunal, D. I. (2012). Motor and 
non-motor symptoms in Turkish patients with 
Parkinson’s disease affecting family caregiver 
burden and quality of life. The Journal of 
neuropsychiatry and clinical 
neurosciences, 24(4), 478-483. 
Only correlates patient’s 
anxiety with its impact on 
the carer’s QOL 
6 
Non-motor symptoms and quality of life in 
subjects with mild parkinsonian signs 
Compares Parksinon’s to 
other diseases in prevalence 
of anxiety etc 
4 
Perez-Lloret, S., Negre-Pages, L., Damier, P., 
Delval, A., Derkinderen, P., Destée, A., ... & 
Rascol, O. (2014). Prevalence, determinants, 
and effect on quality of life of freezing of gait 
in Parkinson disease. JAMA neurology, 
71(7), 884-890. 
Explores freezing of gait 
and QOL. Not anxiety 
focused. 
7 
Rieu, I., et al. (2016). "Impact of Mood and 
Behavioral Disorders on Quality of Life in 
Parkinson's disease." Journal of Parkinsons 
Disease Print 6(1): 267-277.  
No Anxiety scale 2 
Rizos, A., Martinez-Martin, P., Odin, P., 
Antonini, A., Kessel, B., Kozul, T. K., ... & 
Dietrichs, E. (2014). Characterizing motor 
and non-motor aspects of early-morning off 
periods in Parkinson's disease: an 
international multicenter study. Parkinsonism 
& related disorders, 20(11), 1231-1235. 
Characterising symptoms – 
no impact/QOL measure. 
 
4 
Rizza, F., Gison, A., Bonassi, S., Dall’Armi, 
V., Tonto, F., & Giaquinto, S. (2017). ‘Locus 
of control’, health-related quality of life, 
emotional distress and disability in 
Parkinson’s disease. Journal of health 
psychology, 22(7), 844-852. 
Does not separate out 
anxiety in QOL regression 
2 
Rodríguez-Violante, M., Cervantes-Arriaga, 
A., Corona, T., Martínez-Ramírez, D., 
Morales-Briceño, H., & Martínez-Martín, P. 
No validated measure of 
anxiety used. 
2 
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(2013). Clinical determinants of health-
related quality of life in Mexican patients 
with Parkinson’s disease. Archives of medical 
research, 44(2), 110-114. 
Robottom, B. J., Gruber-Baldini, A. L., 
Anderson, K. E., Reich, S. G., Fishman, P. S., 
Weiner, W. J., & Shulman, L. M. (2012). 
What determines resilience in patients with 
Parkinson's disease?. Parkinsonism & related 
disorders, 18(2), 174-177. 
Focus on resilience and 
factors it correlates, with. 
One of which being anxiety. 
Does not fit remit of anxiety 
and impact. 
4 
Santos-García, D., & de la Fuente-Fernández, 
R. (2013). Impact of non-motor symptoms on 
health-related and perceived quality of life in 
Parkinson's disease. Journal of the 
neurological sciences, 332(1-2), 136-140. 
No validated measure of 
anxiety used. 
 
2 
Santos‐García, D., & De la Fuente‐Fernández, 
R. (2015). Factors contributing to caregivers' 
stress and burden in Parkinson's disease. Acta 
Neurologica Scandinavica, 131(4), 203-210. 
About caregiver. 
Patient anxiety not explored 
 
6 
Sauerbier, A., & Chaudhuri, K. R. (2014). 
Non-motor symptoms: the core of multi-
morbid Parkinson's disease. British Journal of 
Hospital Medicine, 75(1), 18-24. 
Review of non-motor 
symptoms in QOL. 
3 
Schiavolin, S., Raggi, A., Quintas, R., 
Cerniauskaite, M., Giovannetti, A. M., 
Covelli, V., ... & Leonardi, M. (2017). 
Psychosocial difficulties in patients with 
Parkinson’s disease. International Journal of 
Rehabilitation Research, 40(2), 112-118. 
No validated measure of 
anxiety used. Regression 
just groups anxiety into 
Psychosocial difficulties’. 
2 
Schiehser, D. M., Han, S. D., Lessig, S., 
Song, D. D., Zizak, V., & Filoteo, J. V. 
(2009). Predictors of health status in 
nondepressed and nondemented individuals 
with Parkinson's disease. Archives of Clinical 
Neuropsychology, 24(7), 699-709. 
No validated measure of 
anxiety used. Used a 
subsection of the geriatric 
depression scale to measure 
anxiety. 
2 
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Schreurs, K. M., De Ridder, D. T., & 
Bensing, J. M. (2000). A one year study of 
coping, social support and quality of life in 
parkinson's disease. Psychology and 
Health, 15(1), 109-121. 
Explores social support and 
coping - impact on QOL. 
Not anxiety focused. 
7 
Soh, S. E., McGinley, J. L., Watts, J. J., 
Iansek, R., & Morris, M. E. (2012). Health-
related quality of life of Australians with 
Parkinson disease: A comparison with 
international studies. Physiotherapy 
Canada, 64(4), 338-346. 
No reference to anxiety, 7 
Soh, S. E., McGinley, J. L., Watts, J. J., 
Iansek, R., Murphy, A. T., Menz, H. B., ... & 
Morris, M. E. (2013). Determinants of health-
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Therapeutic intervention 
with QOL and anxiety used 
as outcome measures. 
5 
Takahashi, K., Kamide, N., Suzuki, M., & 
Fukuda, M. (2016). Quality of life in people 
with Parkinson’s disease: the relevance of 
About social relationship 
and being heard and how it 
7 
 
Anxiety in Parkinson’s Disease 
164 
 
social relationships and 
communication. Journal of physical therapy 
science, 28(2), 541-546. 
impacts QOL. Not related to 
anxiety. 
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Appendix G: Survey One Advertisement 
Advertisement 
Page 1: Page 1 
 
Volunteers needed to help us to better understand anxiety in Parkinson’s 
 
We are a research team at the University of East Anglia. We need volunteers 
to take part in the first phase of a research project looking at anxiety in 
Parkinson’s. If you choose to take part, you will be asked to complete a 
survey. This will help us to learn from you   about what your anxiety is/was 
like and also about anything that you have found useful to manage or reduce 
the anxiety. 
 
To take part, you must meet the following criteria: 
 
- Have a diagnosis of Parkinson’s 
 
- Be 18+ years old 
 
- Can read and write in English 
 
- Since your Parkinson’s diagnosis, have experienced stress, worry or anxiety to 
an extent that has reduced your quality of life or sense of wellbeing. 
 
- Must not have a diagnosis of dementia or difficulties that would make it 
challenging to complete the survey independently 
 
Interested? 
 
If so, please click 'finish' to find a link to further information about the project 
and the option to take part. 
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Page 2: Final page 
 
 
 
Please click the link below for further information about the project and the 
option to take part: 
 
https://uea.onlinesurveys.ac.uk/information-sheet 
 
If you are unable to complete an online version, we can send you a postal copy. 
Please contact Daniel.curran@uea.ac.uk to request this. 
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Appendix H: Survey One Information sheet 
Information sheet 
Page 1: Page 1 
 
The experience of anxiety in 
Parkinson’s Can you help? 
We wish to invite you to take part in our research project. Before you decide 
whether to take part or not, it is important for you to understand what the 
project is about and what it would involve. Please take time to read through 
this information carefully and discuss it with family or friends if you wish. Ask 
us if there is anything that is not clear. Our contact details are given at the 
end of these pages. 
 
This information sheet is also available as a paper copy from the project lead 
Daniel Curran (contact details listed below). 
 
The research project: 
 
This research team at the University of East Anglia would like to better 
understand the anxiety that people with Parkinson’s can experience. 
 
Why we are carrying out this piece of research 
 
We know that many people with Parkinson’s experience worry, stress and 
anxiety, but we do not know very much about the details of this experience. 
We think that it is important that we find out more about it so that we can 
then find better ways of helping people who experience it. We think that 
asking people who have experienced it is the best way to improve our 
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understanding. 
 
Who do we need to take part? 
 
To take part in the study you must meet the following criteria: 
 
- Have a diagnosis of Parkinson’s 
 
- Have experienced stress, worry or anxiety since your Parkinson’s diagnosis, to 
an extent that has reduced your quality of life and sense of wellbeing 
 
- Be 18+ years old 
 
- Be able to read and write in English 
 
- Must not have a diagnosis of dementia or difficulties that would make it 
challenging to complete the survey independently. 
 
If you do not meet all of these criteria then please do not continue. 
 
What do you need to do? 
 
We would like you to complete an online survey. It should take approximately 
30-40 minutes to complete in total. However, it does not have to be 
completed all at once as you can save it at any time and return to finish it at a 
later time. 
 
If you are unable to complete it online, we encourage you to get in touch with us 
at Daniel.curran@uea.ac.uk so that we can send a paper copy to you. 
 
Who is organising and funding this consultation? 
 
This consultation is funded by the University of East Anglia. It is led by Daniel 
Curran, who is a Trainee Clinical Psychologist in the Medical School at the 
University of East Anglia. From his time working for the NHS he has 
developed a particular interest in anxiety and the ways that it may be 
experienced by people with long term physical health conditions. The project 
is supervised by Dr Katherine Deane and Dr Catherine Ford of   the 
University of East Anglia. Bob Chalmers and Jackie Malyon, who have 
experienced anxiety since being diagnosed with Parkinson’s, have also 
helped us to design  this piece of research. 
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How will I benefit from taking part in the study? 
 
Taking part in the study will not bring any direct benefit to you. However, by 
taking part you will be making a significant contribution to our understanding 
of anxiety in Parkinson’s. Better understanding may enable future studies to 
develop better treatments for anxiety in Parkinson’s. 
 
If you choose to provide us with your contact details then we will keep you up to 
date with the findings of our research. 
 
Has the research been approved on ethical grounds? 
 
This piece of research has been assessed by an independent group of people, 
called the University of East Anglia’s University Research Ethics Committee, 
which protects your safety, rights, wellbeing and dignity. This research has been 
reviewed and approved by them. 
 
What will happen to the information recorded in the consultation? 
 
The answers that you provide to our survey questions will be anonymised and 
analysed. These answers will tell us what triggers the anxiety and how people 
manage it for themselves. The next phase of the research will put those 
answers into priority order. 
 
Eventually this information will be presented in a number of written reports, 
including; a thesis project, a peer reviewed journal article, a report for 
Parkinson’s UK and possibly presentations at Parkinson’s conferences. 
Your anonymised responses may also be used to support future research 
within the university. 
 
Data Security 
 
All results and documents associated with this research are strictly 
confidential. Your responses will not be identifiable by name and will be 
stored securely and privately on a secure University of East Anglia computer 
server which is password protected in line with General Data Protection 
Regulation (2018). 
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If you choose to provide us with your contact details, this information will be 
separate from your survey responses but still stored securely and privately on 
a secure University of East Anglia computer server which is password 
protected. These details will only be used to send you information about the 
next phase of our research or for a report on the project. We will keep your 
details for one year and then destroy them securely. 
 
If you have any questions about how your data is used in this research, in the 
first instance please contact the project lead Daniel Curran 
Daniel.curran@uea.ac.uk. 
 
If you have any further questions or complaints about how your data was 
used you can contact Professor William Fraser who is the Dean of the School 
of Medicine at the University of East Anglia (tel: +44 (0)1603 59 3971, email: 
W.Fraser@uea.ac.uk) or the 
University’s data protection team (tel: +44 (0)1603 59 2431, email: 
dataprotection@uea.ac.uk). If you are dissatisfied in how this team handle your 
data complaint you can complain to the Information Commissioner’s Office. 
Information on how to do this can be found at https://ico.org.uk/make-a-
complaint/your-personal- information-concerns/personal-information-concerns/ 
or via their live chat service ico.org.uk/livechat, or call their helpline on 0303 123 
1113. 
 
What would happen if I said I wanted to take part but then changed my mind? 
 
Up until the point that you submit your responses to the survey, you are free 
to withdraw from the study without consequence. However, once you have 
submitted the survey it is no longer possible to withdraw. This is because 
your name is not attached to your response, so we are not able to identify 
individual responses to remove them. 
 
What if I have a complaint? 
 
In the unlikely event that you have a complaint about this research project, 
you may complain directly to Professor William Fraser who is the Dean of the 
School of Medicine at the University of East Anglia (tel: +44 (0)1603 59 3971, 
email: W.Fraser@uea.ac.uk). 
 
The University of East Anglia have appropriate Public Liability and 
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Negligence Insurance cover for this research project. 
Page 2: Final page 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Yes, I would like to take part in the research – what do I need to do now? 
To take part in the research simply click the following link to access the survey: 
https://uea.onlinesurveys.ac.uk/anxiety 
I am not sure about taking part – where can I get further information? 
We would be very happy to answer any questions you may have. Please contact 
Daniel Curran, Daniel.curran@uea.ac.uk. 
No, I do not wish to take part in the consultation – what do I need to do now? 
Nothing more. We will not contact you again directly, however we will 
be advertising this consultation via a number of routes so you may hear 
about it from another route. 
How to contact us 
You can contact Daniel Curran (chief investigator) daniel.curran@uea.ac.uk 
or Dr Katherine Deane (project supervisor) k.deane@uea.ac.uk 
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Appendix I: Survey One 
 
Survey - Anxiety in Parkinson's 
Page 1: Page 1 
 
 
 
CONSENT FORM 
 
Name of Lead Researcher: Daniel Curran 
 
Title of Project: The experience of anxiety in Parkinson’s 
 
 
1. Please read each of the statements below and click in each box if you agree 
with the statement. 
 
  
Required 
I agree 
I confirm that I have read the information sheet provided for the 
anxiety study. I have had the opportunity to consider the 
information, ask questions and have had these answered 
satisfactorily. 
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I understand that my participation is voluntary, and that at any point 
up until  I submit my survey responses I am free to withdraw from 
the study without any impact on my care. However, I also 
understand once I have submitted my response I am not able to 
withdraw from the study as there is no way for the researchers to 
know which response was mine. 
 
 
 
 
 
I understand that if I decide to share my contact details, they will be 
kept by the research team for a year. 
 
 
I understand that the information collected about me will be used to 
support other research in the future, and may be shared 
anonymously with other researchers. 
 
 
 
I understand that my data will be stored confidentially and securely 
by the research team at the University of East Anglia 
 
 
I understand that the findings from this research will be published 
 
 
I agree to take part in this study. 
 
 
 
 
If you have selected each of the above boxes and wish to proceed to the online 
survey please click 'next' below. 
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Page 2: survey 
 
Gender Are you:  Required 
 
 
Age How old are you?  Required 
 
 
Sexual Orientation How would you describe your sexual orientation?  
Required 
 
male   
female 
transgender 
other 
prefer not to say 
18-30 
31-50 
51-64 
65-80 
81+ 
Prefer not to say 
Heterosexual / Straight 
Bisexual 
Homosexual Other 
Prefer not to say 
2. 
3. 
4. 
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Ethnicity How would you describe your ethnic origin? (Please select one box only) 
 Required 
 
 
Living Arrangements What are your living arrangements?  Required 
 
 
If you ticked to say that you live in your own home, which of the following applies: 
 
 
Health How long is it since you were diagnosed with Parkinson’s?  Required 
 
 
 
White 
Black or Black British Asian 
or Asian British 
Mixed/multiple ethnic groups Other 
Prefer not to say 
I live in my own home 
I live in supported accommodation / care home Other 
I live with my partner and/or family but I do not receive care from them or from external 
carers 
I live with my partner and/or family and I do receive care from them or from external carers 
I live alone and do not receive care from anybody 
I live alone with some support from paid carers or partner or family etc Other 
Prefer not to say 
5. 
6. 
6.a. 
7. 
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9. 
11. 
 
 
 
Have you fallen in the last 12 months?  Required 
 
 
 
Have you experienced freezing of gait (when walking, do you suddenly stop or 
freeze as if your feet are stuck to the floor) in the past month?  Required 
 
 
Over the past week, have you usually had shaking or tremor?  Required 
 
 
Over the past week have you had difficulty with repetitious movements eg. difficulty 
with typing or buttoning a shirt or does your handwriting progressively get smaller?  
Required 
 
Yes No 
Yes  
No 
Not at all OR I do have some but it does not cause problems with any activities Yes 
tremor causes problems with some or all activities 
Yes  
No 
8. 
10. 
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Do you have any other physical health conditions in addition to Parkinson’s?  
Required 
 
 
If so, please list them below: 
 
 
Have you received an anxiety diagnosis from a medical professional?  Required 
 
 
Have you received any psychological support for your anxiety?  Required 
 
 
If so, did you find it helpful? 
 
 
 
Have you received any other mental health diagnoses?  Required 
 
 
 
 
 
 
If so, please list them below: 
No 
Yes  
No 
Yes  
No 
Yes  
No 
Yes 
12. 
12.a. 
13. 
14. 
14.a. 
15. 
15.a. 
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Are you prescribed any medication to support you with anxiety  Required 
 
 
If so, please list your anxiety medications below: 
 
Yes  
No 
16. 
16.a. 
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Page 3: Parkinson’s Disease Quality of Life 
Questionnaire (PDQ-8) 
 
Due to having Parkinson’s disease, how often during the last month have you: 
 
  
 
Never 
 
 
Occasionally 
 
 
Sometimes 
 
 
Often 
Always 
- or 
cannot 
do at 
all 
Had difficulty getting around in 
public? 
 
 
 
 
 
 
 
 
 
 
Had difficulty dressing 
yourself? 
 
 
 
 
 
 
 
 
 
 
Felt depressed? 
 
 
 
 
 
 
 
 
 
 
Had problems with your close 
personal relationships? 
 
 
 
 
 
 
 
 
 
 
Had problems with your 
concentration, e.g. when 
reading or watching TV? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Felt unable to communicate 
with people properly? 
 
 
 
 
 
 
 
 
 
 
Had painful muscle cramps or 
spasms? 
 
 
 
 
 
 
 
 
 
 
Felt embarrassed in public due 
to  having  Parkinson’s 
disease? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please check that you have selected one response option per question 
 
PDQ-8 © Copyright, Oxford University Innovation Limited 1998. All Rights Reserved. The 
authors, being Professor Crispin Jenkinson, Professor Ray Fitzpatrick and Ms Viv Peto, 
17. 
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have asserted their moral rights. 
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Page 4: Anxiety 
 
Anxiety 
 
In the past four weeks, to what extent did you experience the following symptoms? 
 Required 
 
Please don't select more than 1 answer(s) per row. Please 
select at least 5 answer(s). 
 
Not at all, 
or never 
Very mild, 
or rarely 
Mild, or 
sometimes 
Moderate, 
or often 
Severe, or 
(nearly) 
always 
Feeling anxious or 
nervous 
 
 
 
 
 
 
 
 
 
 
Feeling tense or 
stressed 
 
 
 
 
 
 
 
 
 
 
Being unable to 
relax 
 
 
 
 
 
 
 
 
 
 
Excessive worrying 
about everyday 
matters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fear of something 
bad, or even the 
worst, happening 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the past four weeks, did you experience episodes of the following symptoms?  
Required 
 
Please don't select more than 1 answer(s) per row. Please 
select at least 4 answer(s). 
18. 
19. 
 
Never Rarely Sometimes Often 
Nearly 
always 
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Panic or intense 
fear 
 
 
 
 
 
 
 
 
 
 
Shortness of breath 
 
 
 
 
 
 
 
 
 
 
Heart palpitations 
and heart beating 
fast (not related to 
physical effort or 
activity) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fear of losing 
control 
 
 
 
 
 
 
 
 
 
 
 
 
In the past four weeks, to what extent did you fear or avoid the following situations? 
 Required 
 
Please don't select more than 1 answer(s) per row. Please 
select at least 3 answer(s). 
 
Never Rarely Sometimes Often 
Nearly 
always 
Social situations 
(where one may be 
observed, or 
evaluated by 
others, such as 
speaking in public, 
or talking to 
unknown people) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20. 
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Public settings 
(situations from 
which it may be 
difficult or 
embarrassing to 
escape, such as 
queues or lines, 
crowds, bridges, or 
public 
transportation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specific objects or 
situations (such as 
flying, heights, 
spiders or other 
animals, needles 
or blood) 
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22. 
23. 
Page 5: More detail on your anxiety 
 
We understand that people experience anxiety in all sorts of different ways and that the 
questions that you have just answered about anxiety may not have covered everything. 
So we would really like for you to share with us your individual experience of anxiety 
since your Parkinson’s diagnosis. There is no right or wrong answer – anything you think 
of is valuable to us. 
 
We have left several text boxes below for you to tell us more about your anxiety. There  
are some questions at the top of each box that might help you to think about your anxiety, 
but please do not feel that you have to stick only to the questions. Please be as detailed 
as you can. 
 
How would you describe your anxiety? 
 
 
 
What runs through your mind when you are anxious? Are there things or that you 
particularly worry or think about? Do you notice the anxiety in your body (physical 
symptoms), if so in what way? 
 
 
 
Is the anxiety constant? If not, how long does it last for (e.g. minutes, hours, days, 
weeks, months, years)? Do you find that there are particular things or environments that 
set the anxiety off or make it worse? 
 
 
21. 
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24. 
25. 
26. 
 
 
 
 
How does the anxiety impact on your life? Does the anxiety change your behaviour at 
all, if so, how? Are there things that you avoid because they make you anxious, what is it 
about those situations? 
 
 
If you take medication for Parkinson’s, do you think this has any effect on your 
anxiety? 
 
 
Is there anything else that you would like to tell us about your anxiety that you have 
not already mentioned? 
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27. 
28. 
Page 6: What are the things that you find 
helpful? 
We also recognise that people are likely have all different sorts of ways to try to manage 
their anxiety. However, we don’t know very much about what these methods are. We are 
really curious to know about things you have tried and found helpful to manage or   
reduce the anxiety. Again, there is no right or wrong answer, please be as specific as 
possible. 
 
We have left space below for you to tell us more. We have also left some examples but 
please do not feel that you have to stick to them – they are only suggestions. Only you 
know what has worked for you. Please be as detailed as you can. 
Communication. Have you found talking about your experiences helpful  to 
manage or reduce your anxiety? For example: support groups, speaking to friends/family, 
speaking with others who have anxiety, speaking with others who have Parkinson’s, or 
any other form of communicating? 
 
 
Types of therapies. Have you found any ‘therapies’ helpful to reduced or manage 
your anxiety? For example: any psychological talking therapy (such as counselling or 
cognitive behaviour therapy), relaxation techniques, medication,  complementary 
therapies (such as yoga, tai chi, massage, acupuncture), meditation, or any other forms of 
therapy. 
 
 
Lifestyle. Are there parts of your lifestyle that you have found helpful to reduce or 
manage your anxiety? For example: exercise, travel, hobbies, dietary changes, sleep 
routines, or any other parts of your lifestyle. 
29. 
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30. 
 
 
 
 
Anything else you find helpful. Are there any other things that you find helpful to reduce or 
manage your anxiety? 
 
Page 7: submission of survey 
 
The survey is nearly complete. 
 
Remember for queries related to the survey, you can contact Daniel Curran (chief 
investigator) daniel.curran@uea.ac.uk or Dr Katherine Deane (project supervisor) 
k.deane@uea.ac.uk 
 
We would like you to know that more information about anxiety in Parkinson’s can be 
found on the Parkinson’s UK website https://www.parkinsons.org.uk/information-and- 
support/anxiety 
 
We would also like to make you aware that there are free and confidential helplines that 
you can contact for advice and support, see below: 
 
Call Samaritans for free any time on 116 123. They offer a confidential listening 
service. See also https://www.samaritans.org/ 
Call Parkinson’s UK on Free* confidential helpline 0808 800 0303 Monday to Friday 
9am–8pm 
Call SANEline on 0300 304 7000 between 4.30pm and 10.30pm each evening. 
You may also wish to speak to your GP if you feel you need further support with 
coping with your anxiety. 
 
To submit your responses please click ‘finish’ below. Please remember that clicking 
‘finish’ will confirm that your consent to participate in this survey. 
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Page 8: Final page 
 
 
 
 
Thank you very much for taking the time to complete this survey. We really value your 
contribution. 
 
Remember, you can contact Daniel Curran (chief investigator) daniel.curran@uea.ac.uk 
or Dr Katherine Deane (project supervisor) k.deane@uea.ac.uk 
 
We would like to remind you that more information about anxiety in Parkinson’s can be 
found on the Parkinson’s UK website https://www.parkinsons.org.uk/information-and- 
support/anxiety 
 
There are also free and confidential helplines that you can contact for advice and 
support, see below: 
 
Call Samaritans for free any time on 116 123. They offer a confidential listening 
service. See also https://www.samaritans.org/ 
Call Parkinson’s UK on Free* confidential helpline 0808 800 0303 Monday to Friday 
9am–8pm 
Call SANEline on 0300 304 7000 between 4.30pm and 10.30pm each evening. 
It may also be advisable to contact your GP 
 
What’s next? 
 
You now have the option to provide us with your contact email. Please do this if you 
would like either or both of the following: 
 
For us to contact you to tell you more about the second phase of our research. Once 
again, your involvement would be greatly appreciated. 
For us to provide you with a brief report of our research findings when the project is 
complete. 
If either option interests you, please click on the following link. 
https://uea.onlinesurveys.ac.uk/contact-details 
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Appendix J: Survey Two Advertisement 
 
Advertisement 
Page 1: Page 1 
 
 
 
Volunteers needed to help us to better understand anxiety in Parkinson’s 
 
We are a research team at the University of East Anglia. We need volunteers to take part 
in the second phase of a study looking at anxiety in Parkinson’s. 
 
If you choose to take part, you will be asked to answer some survey questions about 
things our previous participants (who have experienced anxiety since being diagnosed 
with Parkinson’s) have said about their anxiety. Specifically, we would like to know how 
much you relate to their experiences about what the anxiety is like. 
 
Please note, you can take part in this survey regardless of whether or not you took part in 
our previous research. 
 
To take part, you must meet the following criteria: 
 
- Have a diagnosis of Parkinson’s 
 
- Be 18+ years old 
 
- Can read and write in English 
 
- Since your Parkinson’s diagnosis, have experienced stress, worry or anxiety to an extent 
that has reduced your quality of life or sense of wellbeing. 
 
- Must not have a diagnosis of dementia or difficulties that would make it challenging to 
complete the survey independently 
 
Interested? 
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If so, please click 'finish' to find a link to further information about the project and the 
option to take part. 
Page 2: Final page 
 
 
 
Please click the link below for further information about the project and the option to take 
part: 
 
https://uea.onlinesurveys.ac.uk/information-sheets 
 
If you are unable to complete an online version, we can send you a postal copy. Please 
contact Daniel.curran@uea.ac.uk to request this. 
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Appendix K: Survey Two Information Sheet 
Information sheet 
Page 1: Page 1 
 
 
 
The experience of anxiety in Parkinson’s Can you 
help? 
We wish to invite you to take part in our research project. Before you decide whether to 
take part or not, it is important for you to understand what the project is about and what it 
would involve. Please take time to read through this information carefully and discuss it 
with family or friends if you wish. Ask us if there is anything that is not clear. Our contact 
details are given at the end of these pages. 
 
This information sheet is also available as a paper copy from the project lead Daniel 
Curran (contact details listed below). 
 
The research project 
 
This research team at the University of East Anglia would like to better understand the 
anxiety that people with Parkinson’s can experience. 
 
Why we are carrying out this piece of research 
 
Earlier in the year we asked many people with Parkinson's to tell us more about their 
experiences of anxiety. We have collected their responses and made a list of the main 
themes that this group raised. We now want to move into a second phase of research 
where we encourage people with Parkinson's to rate how much they can relate to each of 
these experiences that were identified. We feel that by doing this we will gain an even 
greater insight into the anxiety experience of people with Parkinson's. 
 
Please note, you can take part in this survey regardless of whether or not you took part in 
our previous research. 
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Who do we need to take part? 
 
To take part in the study you must meet the following criteria: 
 
- Have a diagnosis of Parkinson’s 
 
- Have experienced stress, worry or anxiety since your Parkinson’s diagnosis, to an extent 
that has reduced your quality of life and sense of wellbeing 
 
- Be 18+ years old 
 
- Be able to read and write in English 
 
- Must not have a diagnosis of dementia or difficulties that would make it challenging to 
complete the survey independently. 
 
If you do not meet all of these criteria then please do not continue. 
 
What do you need to do? 
 
We would like you to complete an online survey. It should take approximately 30-45 
minutes to complete in total. However, it does not have to be completed all at once as 
you can save it at any time and return to finish it at a later time. 
 
If you are unable to complete it online, we encourage you to get in touch with us at 
Daniel.curran@uea.ac.uk so that we can send a paper copy to you. 
 
Who is organising and funding this consultation? 
 
This consultation is funded by the University of East Anglia. It is led by Daniel Curran,  
who is a Trainee Clinical Psychologist in the Medical School at the University of East 
Anglia. From his time working for the NHS he has developed a particular interest in 
anxiety and the ways that it may be experienced by people with long term physical health 
conditions. The project is supervised by Dr Katherine Deane and Dr Catherine Ford of   
the University of East Anglia. Bob Chalmers and Jackie Malyon, who have experienced 
anxiety since being diagnosed with Parkinson’s, have also helped  us  to  design  this 
piece of research. 
 
How will I benefit from taking part in the study? 
Taking part in the study will not bring any direct benefit to you. However, by taking part 
you will be making a significant contribution to our understanding of anxiety in  
Parkinson’s. Better understanding may enable future studies to develop better treatments 
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for anxiety in Parkinson’s. 
 
If you choose to provide us with your contact details then we will keep you up to date with 
the findings of our research. 
 
Has the research been approved on ethical grounds? 
 
This piece of research has been assessed by an independent group of people, called the 
University of East Anglia’s University Research Ethics Committee, which protects your 
safety, rights, wellbeing and dignity. This research has been reviewed and approved by 
them. 
 
What will happen to the information recorded in the consultation? 
 
The answers that you provide to our survey questions will be anonymised and analysed. 
The findings will be presented in a number of written reports, including; a thesis project, a 
peer reviewed journal article, a report for Parkinson's UK and possibly presentations at 
Parkinson's conferences. Your anonymised responses may also be used to support  
further research within the university. 
 
Data Security 
 
All results and documents associated with this research are strictly confidential. Your 
responses will not be identifiable by name and will be stored securely and privately on a 
secure University of East Anglia computer server which is password protected in line 
with General Data Protection Regulation (2018). 
 
If you choose to provide us with your contact details, this information will be separate 
from your survey responses but still stored securely and privately on a secure University 
of East Anglia computer server which is password protected. These details will only be 
used to send you a report on the project. We will keep your details for one year and then 
destroy them securely. 
 
If you have any questions about how your data is used in this research, in the first 
instance please contact the project lead Daniel Curran Daniel.curran@uea.ac.uk. 
 
If you have any further questions or complaints about how your data was used you can 
contact Professor William Fraser who is the Dean of the School of Medicine at the 
University of East Anglia (tel: +44 (0)1603 59 3971, email: W.Fraser@uea.ac.uk) or the 
University’s data protection team (tel: +44 (0)1603 59 2431, email: 
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dataprotection@uea.ac.uk). If you are dissatisfied in how this team handle your data 
complaint you can complain to the Information Commissioner’s Office. Information on 
how to do this can be found at https://ico.org.uk/make-a-complaint/your-personal- 
information-concerns/personal-information-concerns/ or via their live chat service 
ico.org.uk/livechat, or call their helpline on 0303 123 1113. 
 
What would happen if I said I wanted to take part but then changed my mind? 
 
Up until the point that you submit your responses to the survey, you are free to withdraw 
from the study without consequence. However, once you have submitted the survey it is 
no longer possible to withdraw. This is because your name is not attached to your 
response, so we are not able to identify individual responses to remove them. 
 
What if I have a complaint? 
 
In the unlikely event that you have a complaint about this research project, you may 
complain directly to Professor William Fraser who is the Dean of the School of Medicine 
at the University of East Anglia (tel: +44 (0)1603 59 3971, email: W.Fraser@uea.ac.uk) . 
 
The University of East Anglia have appropriate Public Liability and Negligence 
Insurance cover for this research project. 
 
Page 2: Information sheet 
 
Yes, I would like to take part in the research – what do I need to do now? To take part 
in the research simply click the following link to access the survey: 
https://uea.onlinesurveys.ac.uk/survey-anxiety--parkinsons 
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I am not sure about taking part – where can I get further information? 
 
We would be very happy to answer any questions you may have. Please contact Daniel 
Curran, Daniel.curran@uea.ac.uk. 
 
No, I do not wish to take part in the consultation – what do I need to do now? 
 
Nothing more. We will not contact you again directly, however we will be advertising this 
consultation via a number of routes so you may hear about it from another route. 
 
How to contact us 
 
You can contact Daniel Curran (chief investigator) daniel.curran@uea.ac.uk or Dr 
Katherine Deane (project supervisor) k.deane@uea.ac.uk 
 
THANK YOU FOR READING THIS INFORMATION SHEET 
 
To take part in the research, please click 'finish' to access a link to our survey. 
Page 3: Final page 
 
To begin the survey, simply click on the following link: 
https://uea.onlinesurveys.ac.uk/survey-anxiety--parkinsons 
  
 
Anxiety in Parkinson’s Disease 
197 
 
1. 
Appendix L: Survey Two 
 
New survey - Anxiety in Parkinson's 
 
Page 1: Page 1 
 
 
 
CONSENT FORM 
 
Name of lead researcher: Daniel Curran 
 
Title of Project: The experience of anxiety in Parkinson’s 
 
 
Please read each of the statements below and click in each box if you agree with the 
statement. 
 
  
Required 
I agree 
I confirm that I have read the information sheet provided for the anxiety 
study. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily. 
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I understand that my participation is voluntary, and that at any point up until  
I submit my survey responses I am free to withdraw from the study without 
any impact on my care. However, I also understand once I have submitted 
my response I am not able to withdraw from the study as there is no way for 
the researchers to know which response was mine. 
 
 
 
 
 
I understand that if I decide to share my contact details, they will be kept by 
the research team for a year. 
 
 
I understand that the information collected about me will be used to support 
other research in the future, and may be shared anonymously with other 
researchers. 
 
 
 
I understand that my data will be stored confidentially and securely by the 
research team at the University of East Anglia 
 
 
I understand that the findings from this research will be published 
 
 
I agree to take part in this study. 
 
 
 
 
If you have selected each of the above boxes and wish to proceed to the online survey 
please click 'next' below. 
Page 2: survey 
How would you describe your gender?  Required 
 
 
How old are you? Optional 
 
 
Male  Female 
Transgender 
Other 
Prefer not to say 
2. 
3. 
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6. 
 
 
How would you describe your sexual orientation?  Required 
 
 
How would you describe your ethnic origin? (Please select one box only)  
Required 
 
 
 
 
Earlier this year (March-April) we produced another survey about anxiety and 
Parkinson's. Did you take part in that survey too? 
 
 
 
What are your living arrangements?  Required 
Asian or Asian British Mixed/multiple 
ethnic groups Other 
Prefer not to say 
Heterosexual / Straight 
Bisexual 
Homosexual / Gay Other 
Prefer not to say 
White 
Black or Black British 
Yes No 
4. 
5. 
7. 
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If you ticked to say that you live in your own home, which of the following applies: 
 
I live in my own home 
I live in supported accommodation / care home Other 
I live with my partner and/or family but I do not receive care from them or from external 
carers 
I live with my partner and/or family and I do receive care from them or from external carers 
I live alone and do not receive care from anybody 
I live alone with some support from paid carers or partner or family etc Other 
Prefer not to say 
7.a. 
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10. 
12. 
How long is it since you were diagnosed with Parkinson’s? (in years)  Required 
 
 
 
Have you fallen in the last 12 months?  Required 
 
 
Have you experienced freezing of gait (when walking, do you suddenly stop or 
freeze as if your feet are stuck to the floor) in the past month?  Required 
 
 
Over the past week, have you usually had shaking or tremor?  Required 
 
 
Over the past week have you had difficulty with repetitious movements eg. difficulty 
with typing or buttoning a shirt or does your handwriting progressively get smaller?  
Required 
 
 
 
 
 
 
Do you have any other physical health conditions in addition to Parkinson’s?  
Required 
No 
Yes No 
Yes No 
Yes shaking or tremor causes problems with some or all activities 
Not at all OR I do have some shaking or tremor but it does not cause problems with any 
activities 
Yes 
8. 
9. 
11. 
13. 
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14.a. 
16. 
 
 
If so, please list them below: 
 
 
 
When did you first experience anxiety that impacted your quality of life? 
 
 
If you experienced the anxiety before your Parkinson's diagnosis, what has been 
your experience of the anxiety since the diagnosis? 
 
 
Overall, to what extent does the anxiety impact on your life?  
 
 
Please select from the following options the one that best describes how often you 
experience anxiety 
Not at all 
Mildly 
Moderately 
Severely 
Yes No 
Before I was diagnosed with Parkinson's After I 
was diagnosed with Parkinson's 
Not applicable Anxiety 
is worse Anxiety is 
unchanged Anxiety is 
better 
13.a. 
14. 
15. 
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To what extent does your anxiety increase when your Parkinson's symptoms are 
bad? 
 
 
Have you received an anxiety diagnosis from a medical professional?  Required 
 
Everyday 
A few days per week A 
few days per month 
Less often 
Never or almost never 
Rarely 
Sometimes 
Often 
Always or almost always 
Yes  
No 
17. 
18. 
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19. Have you received any psychological therapy for your anxiety (for 
example counselling or cognitive behavioural therapy)?  Required 
 
 
If so, did you find it helpful? 
 
 
 
Have you received any other mental health diagnoses?  Required 
 
 
If so, please list them below: 
 
 
Are you prescribed any medication to support you with anxiety?  Required 
 
 
If so, please list your anxiety medications below: 
 
Yes No 
Yes No 
Yes No 
19.a. 
20. 
20.a. 
21. 
21.a. 
 
Anxiety in Parkinson’s Disease 
205 
 
22. How would you describe the impact of your Parkinson's medication on the 
anxiety? 
 
Not applicable 
Makes my anxiety worse Has 
no effect of my anxiety Makes 
my anxiety better 
Makes my anxiety vary, i.e. as I go on/the medication works I get less anxiety, whereas when 
I go off/the medication stops working I get more anxiety 
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Page 3: Parkinson’s Disease Quality of Life 
Questionnaire (PDQ-8) 
 
Due to having Parkinson’s disease, how often during the last month have you: 
 
  
 
Never 
 
 
Occasionally 
 
 
Sometimes 
 
 
Often 
Always 
- or 
cannot 
do at 
all 
Had difficulty getting around in 
public? 
 
 
 
 
 
 
 
 
 
 
Had difficulty dressing 
yourself? 
 
 
 
 
 
 
 
 
 
 
Felt depressed? 
 
 
 
 
 
 
 
 
 
 
Had problems with your close 
personal relationships? 
 
 
 
 
 
 
 
 
 
 
Had problems with your 
concentration, e.g. when 
reading or watching TV? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Felt unable to communicate 
with people properly? 
 
 
 
 
 
 
 
 
 
 
Had painful muscle cramps or 
spasms? 
 
 
 
 
 
 
 
 
 
 
Felt embarrassed in public due 
to  having  Parkinson’s 
disease? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please check that you have selected one response option per question 
 
PDQ-8 © Copyright, Oxford University Innovation Limited 1998. All Rights Reserved. The 
authors, being Professor Crispin Jenkinson, Professor Ray Fitzpatrick and Ms Viv Peto, 
have asserted their moral rights. 
23. 
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Page 4: Anxiety 
 
Anxiety 
In the past four weeks, to what extent did you experience the following symptoms? 
 Required 
Please don't select more than 1 answer(s) per row. Please 
select at least 5 answer(s). 
 
Not at all, 
or never 
Very mild, 
or rarely 
Mild, or 
sometimes 
Moderate, 
or often 
Severe, or 
(nearly) 
always 
Feeling anxious or 
nervous 
 
 
 
 
 
 
 
 
 
 
Feeling tense or 
stressed 
 
 
 
 
 
 
 
 
 
 
Being unable to 
relax 
 
 
 
 
 
 
 
 
 
 
Excessive worrying 
about everyday 
matters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fear of something 
bad, or even the 
worst, happening 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the past four weeks, did you experience episodes of the following symptoms?  
Required 
Please don't select more than 1 answer(s) per row. Please 
select at least 4 answer(s). 
24. 
25. 
 
Never Rarely Sometimes Often 
Nearly 
always 
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Panic or intense 
fear 
 
 
 
 
 
 
 
 
 
 
Shortness of breath 
 
 
 
 
 
 
 
 
 
 
Heart palpitations 
and heart beating 
fast (not related to 
physical effort or 
activity) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fear of losing 
control 
 
 
 
 
 
 
 
 
 
 
 
 
In the past four weeks, to what extent did you fear or avoid the following situations? 
 Required 
Please don't select more than 1 answer(s) per row. Please 
select at least 3 answer(s). 
 
Never Rarely Sometimes Often 
Nearly 
always 
Social situations 
(where one may be 
observed, or 
evaluated by 
others, such as 
speaking in public, 
or talking to 
unknown people) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26. 
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Public settings 
(situations from 
which it may be 
difficult or 
embarrassing to 
escape, such as 
queues or lines, 
crowds, bridges, or 
public 
transportation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specific objects or 
situations (such as 
flying, heights, 
spiders or other 
animals, needles 
or blood) 
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Page 5: More detail on your anxiety 
 
The following pages of questions are based our earlier research where a large number of 
people with Parkinson’s told us about their anxiety. We received a very wide range of 
descriptions of what anxiety felt like and was affected by. It is unlikely that any one   
person would experience all of the things described below. We now want to ask how 
typical each description is of the anxiety that you experience. 
 
On each page the questions are grouped into small tables to make them easier to view. 
But if you would rather view each question individually you can do so by clicking 'view as 
separate questions instead?' (in blue). 
Triggers 
 
How typical is it that your anxiety is triggered or made worse by the items below? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
When I am alone 
 
 
 
 
 
 
 
 
 
 
When I am not 
occupied/busy 
 
 
 
 
 
 
 
 
 
 
When I wake up 
 
 
 
 
 
 
 
 
 
 
At night 
 
 
 
 
 
 
 
 
 
 
When I am tired 
 
 
 
 
 
 
 
 
 
 
By specific 
seasons or 
extremes of 
weather 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that your anxiety is triggered or made worse by the items below? 
27. 
28. 
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Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
When I drink 
caffeine 
 
 
 
 
 
 
 
 
 
 
When I smell 
strong smells or 
odours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When I have tremor 
 
 
 
 
 
 
 
 
 
 
When I have 
difficulty with 
movement or 
coordination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that your anxiety is triggered or made worse by the items below? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
When I am at home 
 
 
 
 
 
 
 
 
 
 
By being outside 
my home 
 
 
 
 
 
 
 
 
 
 
When exercising 
 
 
 
 
 
 
 
 
 
 
When walking 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that your anxiety is triggered or made worse by the items below? 
 
Please don't select more than 1 answer(s) per row. 
29. 
30. 
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 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
When the ground 
looks slippery 
 
 
 
 
 
 
 
 
 
 
When in confined 
or enclosed spaces 
 
 
 
 
 
 
 
 
 
 
When in public 
settings 
 
 
 
 
 
 
 
 
 
 
When I am in 
crowded and/or 
noisy places 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If people are too 
close and I feel my 
movement is 
restricted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When I am 
travelling 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that your anxiety is triggered or made worse by the items below? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
When I am in 
social situations 
(where one may be 
observed or 
evaluated by 
others, such as 
speaking in public 
or meeting new 
people) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31. 
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When I am ignored 
in social situations 
 
 
 
 
 
 
 
 
 
 
When I eat in 
public 
 
 
 
 
 
 
 
 
 
 
When I am unsure 
if I can reach a 
toilet in time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When I feel time 
pressured (for 
example making it 
to an appointment 
in time or at a 
supermarket till 
where I have to 
coordinate tasks 
quickly) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When others do not 
understand what I 
am experiencing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that your anxiety is triggered or made worse by the items below? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
When loved ones 
get upset 
 
 
 
 
 
 
 
 
 
 
When I have 
disagreements with 
others or am 
criticised by others 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32. 
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When I am 
stressed by life or 
work (e.g. when a 
number of tasks fall 
together) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When I do not meet 
demands or 
expectations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When I am not able 
to perform a task or 
role that I 
previously would 
have been able to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When trying to 
organise myself 
and make 
decisions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that your anxiety is triggered or made worse by the items below? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always 
or almost 
always 
When I am having a 
medical 
consultation/appointment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When I am unhappy 
about the healthcare I 
am receiving 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When I see others at the 
later stage of Parkinson's 
 
 
 
 
 
 
 
 
 
 
When reading about 
Parkinson's 
 
 
 
 
 
 
 
 
 
 
 
 
33. 
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I am not aware what the 
trigger is or why the 
anxiety occurs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that your anxiety is triggered or made worse by the items below? 
 
Please don't select more than 1 answer(s) per row. 
 
  
Not 
applicable 
Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always 
or  
almost 
always 
When I have 
hallucinations 
 
 
 
 
 
 
 
 
 
 
 
 
When I have 
difficulties 
with sexual 
performance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When I am in 
pain 
 
 
 
 
 
 
 
 
 
 
 
 
Around 
menstruation 
 
 
 
 
 
 
 
 
 
 
 
 
34. 
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Page 6: More detail on your anxiety 
 
Thoughts 
 
How typical is it that you have thoughts on the following issues when anxious? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
I compare my 
health status to 
those who are in 
better health 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about the 
rate at which my 
Parkinson’s 
symptoms progress 
and how I will cope 
at their worst 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about falling 
and/or the 
consequences of 
falling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about my 
speech (e.g. not 
speaking clearly or 
being understood) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry I will freeze 
(stop moving) in 
hazardous 
situations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry I will get 
dementia 
 
 
 
 
 
 
 
 
 
 
35. 
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How typical is it that you have thoughts on the following issues when anxious? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
I worry about my 
employability 
 
 
 
 
 
 
 
 
 
 
I worry about 
money and my 
ability to maintain 
financial security 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry that I am not 
able to contribute 
and will let others 
down or become a 
burden 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I fear being left 
alone because 
others are not able 
to cope with my 
symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about the 
impact of my 
Parkinson’s on my 
family and how 
they will cope 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I am worried that 
others are 
embarrassed to be 
with me 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that you have thoughts on the following issues when anxious? 
 
Please don't select more than 1 answer(s) per row. 
36. 
37. 
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 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
I worry about my 
death 
 
 
 
 
 
 
 
 
 
 
I focus too much on 
my medication (e.g. 
when its due, side 
effects, whether it’s 
working) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry I will lose 
control and won’t 
be able to do my 
everyday tasks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry I will lose 
my identity 
 
 
 
 
 
 
 
 
 
 
I worry about my 
future ability to be 
an effective parent 
or carer for those 
who need my 
support 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about 
having to go into a 
care home and the 
quality of the care I 
would receive 
there 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that you have thoughts on the following issues when anxious? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
38. 
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I worry about 
upsetting those 
close to me or 
making things 
difficult for them 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry how others 
will perceive my 
Parkinson’s 
symptoms and that 
they will judge me 
negatively 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry that 
someone will 
knock me over in 
busy places 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about 
eating in public 
and that others will 
judge me 
negatively 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about 
dribbling and that 
others will judge 
me negatively 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I am embarrassed 
by the frequency 
and urgency with 
which I need to 
urinate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that you have thoughts on the following issues when anxious? 
 
Please don't select more than 1 answer(s) per row. 
39. 
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 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
I worry about the 
embarrassment of 
having a toileting 
accident (being 
incontinent) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry that I will be 
not be able to 
function properly in 
public situations 
(e.g. on escalators, 
in supermarkets, in 
pubs) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry that I stand 
out as different 
 
 
 
 
 
 
 
 
 
 
I compare my 
current abilities to 
my past abilities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about 
feeling anxious; 
how long it will last 
for, whether it will 
impact on my 
health, or how I will 
cope with it 
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When experiencing 
physical symptoms 
of anxiety, I worry 
that they mean 
something more 
catastrophic (for 
example that I will 
stop breathing, 
pass out, have a 
stroke or a heart 
attack) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that you have thoughts on the following issues when anxious? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
I worry about what 
is causing my 
anxiety 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry that others 
will notice I’m 
anxious 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I think about past 
events over and 
over again 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about the 
possibility of failing 
or making a 
mistake 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about the 
possibility of being 
late to 
appointments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about the 
welfare of others 
 
 
 
 
 
 
 
 
 
 
40. 
 
Anxiety in Parkinson’s Disease 
222 
 
41. 
42. 
Page 7: More detail on your anxiety 
 
Physical symptoms 
 
How typical is it that you experience the following physical symptoms when 
anxious? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
Changes to body 
temperature 
 
 
 
 
 
 
 
 
 
 
Increased sweating 
 
 
 
 
 
 
 
 
 
 
Increased heart 
rate 
 
 
 
 
 
 
 
 
 
 
Headache 
 
 
 
 
 
 
 
 
 
 
Muscle tension 
 
 
 
 
 
 
 
 
 
 
Chest discomfort 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that you experience the following physical symptoms when 
anxious? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
Fatigue or tiredness 
 
 
 
 
 
 
 
 
 
 
Stomach discomfort 
(churning/butterflies) 
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I need to use the 
toilet 
 
 
 
 
 
 
 
 
 
 
Nausea 
 
 
 
 
 
 
 
 
 
 
Feeling 
disorientated or 
dizzy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Restlessness 
 
 
 
 
 
 
 
 
 
 
Difficulty breathing 
 
 
 
 
 
 
 
 
 
 
Feeling very alert 
and focused 
 
 
 
 
 
 
 
 
 
 
 
Page 8: More detail on your anxiety 
 
Emotions 
How typical is it that you experience each of the following emotions when anxious? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always 
or almost 
always 
Feeling overwhelmed 
 
 
 
 
 
 
 
 
 
 
Feeling of dread 
 
 
 
 
 
 
 
 
 
 
Feeling nervous 
 
 
 
 
 
 
 
 
 
 
Feeling panicked 
 
 
 
 
 
 
 
 
 
 
Feeling 
frightened/scared/terrified 
 
 
 
 
 
 
 
 
 
 
Feeling upset 
 
 
 
 
 
 
 
 
 
 
Feeling irritated 
 
 
 
 
 
 
 
 
 
 
Feeling angry 
 
 
 
 
 
 
 
 
 
 
43. 
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44. 
Page 9: More detail on your anxiety 
 
Behavioural changes 
 
How typical is it that you behave in each of the following ways when anxious or to 
avoid becoming anxious? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
I am more 
argumentative or 
short tempered 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I try to disguise my 
anxiety 
 
 
 
 
 
 
 
 
 
 
I try to distract 
myself from the 
anxiety 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I drink alcohol to try 
to reduce my 
anxiety and/or 
Parkinson’s 
symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I physically harm 
myself when 
anxious 
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I plan things in 
great detail, 
including how to 
get out of a 
situation/location 
quickly (e.g. sit 
near the exit or 
toilet) 
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45. 
When I enter an 
anxiety provoking 
situation I try to get 
in and out of the 
situation as quickly 
as possible 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that you behave in each of the following ways when anxious or to 
avoid becoming anxious? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
I prefer to be 
accompanied by 
someone familiar 
when going into 
new 
places/situations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I withdraw and 
isolate myself 
 
 
 
 
 
 
 
 
 
 
I avoid giving an 
opinion or 
disagreeing with 
others 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I avoid decision 
making and/or 
positions of 
responsibility 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I avoid social 
interactions 
 
 
 
 
 
 
 
 
 
 
I avoid leaving 
home 
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46. 
I over-analyse or 
check over things 
more than I need to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How typical is it that you behave in each of the following ways when anxious or to 
avoid becoming anxious? 
 
Please don't select more than 1 answer(s) per row. 
 
 Never or 
almost 
never 
 
Rarely 
 
Sometimes 
 
Often 
Always or 
almost 
always 
I avoid public 
situations 
 
 
 
 
 
 
 
 
 
 
In public, I select 
food or drink that is 
easier to manage 
or I avoid eating or 
drinking altogether 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I avoid busy or 
crowded places 
 
 
 
 
 
 
 
 
 
 
I avoid confined 
spaces or places 
that are not easy to 
escape from 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I avoid driving 
 
 
 
 
 
 
 
 
 
 
I avoid some 
methods of travel 
(e.g. public 
transport, car 
travel, plane travel, 
etc.) 
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Page 10: More detail on your anxiety 
 
Impact 
 
In each of the areas below, to what extent does your anxiety impact you? 
 
Please don't select more than 1 answer(s) per row. 
 
 Not at all Rarely Sometimes Often Always 
Has impacted my 
confidence 
 
 
 
 
 
 
 
 
 
 
Has restricted me 
and impacted my 
freedom and 
independence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Has made my 
Parkinson’s 
symptoms worse 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Has impacted my 
sleep 
 
 
 
 
 
 
 
 
 
 
 
 
In each of the areas below, to what extent does your anxiety impact you? 
 
Please don't select more than 1 answer(s) per row. 
 
 Not at all Rarely Sometimes Often Always 
Has impacted my 
relationships 
 
 
 
 
 
 
 
 
 
 
Has made me 
more isolated 
 
 
 
 
 
 
 
 
 
 
Has made it harder 
to complete daily 
tasks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47. 
48. 
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Has made it hard to 
think clearly 
 
 
 
 
 
 
 
 
 
 
Has made it hard to 
express myself 
 
 
 
 
 
 
 
 
 
 
 
In each of the areas below, to what extent does your anxiety impact you? 
 
Please don't select more than 1 answer(s) per row. 
 
 Not 
applicable 
Not at all Rarely Sometimes Often Always 
Has impacted 
my ability to 
work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Has impacted 
my ability to 
be an 
effective 
parent or 
carer for 
those who 
need my 
support 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 11: More detail on your anxiety 
 
How much do you agree with the following statements about your anxiety? 
 
Please don't select more than 1 answer(s) per row. 
 
 
Strongly 
disagree 
 
Disagree 
Neither 
agree or 
disagree 
 
Agree 
Strongly 
agree 
49. 
50. 
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I view my anxiety 
as a proportionate 
and rational 
response to the 
difficulties I 
experience with 
Parkinson’s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I view my anxiety 
as largely irrational 
and out of 
proportion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
My anxiety was 
triggered or made 
worse in the period 
just after my 
diagnosis of 
Parkinson’s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is no fixed 
focus to my worry; I 
worry about 
anything, including 
irrational things, 
things I have no 
control over 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I feel out of control 
with my worry and 
find it hard to stop 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I worry about small 
things that never 
used to bother me 
as much 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I blow things out of 
proportion and 
make mountains 
out of molehills 
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Page 12: submission of survey 
The survey is nearly complete. 
 
Remember for queries related to the survey, you can contact 
Daniel Curran (chief investigator) daniel.curran@uea.ac.uk or Dr 
Katherine Deane (project supervisor) k.deane@uea.ac.uk 
 
We would like you to know that more information about anxiety in 
Parkinson’s can be found on the Parkinson’s UK website 
https://www.parkinsons.org.uk/information-and- support/anxiety 
 
We would also like to make you aware that there are free and 
confidential helplines that you can contact for advice and support, 
see below: 
 
Call Samaritans for free any time on 116 123. They offer a 
confidential listening service. See also 
https://www.samaritans.org/ 
Call Parkinson’s UK on Free* confidential helpline 0808 800 0303 
Monday to Friday 9am–8pm 
Call SANEline on 0300 304 7000 between 4.30pm and 
10.30pm each evening. You may also wish to speak to your 
GP if you feel you need further support with coping with your 
anxiety. 
 
To submit your responses please click ‘finish’ below. Please 
remember that clicking ‘finish’ will confirm that your consent to 
participate in this survey. 
Page 13: Final page 
 
 
 
 
Thank you very much for taking the time to complete this survey. We 
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really value your contribution. 
 
Remember, you can contact Daniel Curran (chief investigator) 
daniel.curran@uea.ac.uk or Dr Katherine Deane (project supervisor) 
k.deane@uea.ac.uk 
 
We would like to remind you that more information about anxiety in 
Parkinson’s can be found on the Parkinson’s UK website 
https://www.parkinsons.org.uk/information-and- support/anxiety 
 
There are also free and confidential helplines that you can contact 
for advice and support, see below: 
 
Call Samaritans for free any time on 116 123. They offer a 
confidential listening service. See also 
https://www.samaritans.org/ 
Call Parkinson’s UK on Free* confidential helpline 0808 800 0303 
Monday to Friday 9am–8pm 
Call SANEline on 0300 304 7000 between 4.30pm and 
10.30pm each evening. It may also be advisable to contact 
your GP 
 
What’s next? 
 
You now have the option to provide us with your contact email. 
Please do this if you would like us to provide you with a brief report 
of our research findings when the project is complete. 
 
If this interests you, please click on the following link: 
 
https://uea.onlinesurveys.ac.uk/contact-details 
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Appendix M: Ethical Approval from Faculty of Medicine and Health Sciences 
Ethics Committee  
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Appendix N: List of Codes Identified for the Nominal Group Technique 
Analysis in the Empirical Paper 
 
Trigger Thought Behaviour Emotion Physical Impact 
TR1 = 
Unknown 
TH1 = Various 
focal points 
B1 = Safety 
seeking 
behaviours 
E1 = 
Upset 
P1 = Fight 
or flight 
I1 = Verbal 
expression 
TR2 = Social 
situations  
TH2 = Future PD 
progression 
/impact 
B2 = Alcohol E2 = 
Scared 
P2 = 
Fatigue 
I2 = 
Cognition  
TR3 = Out of 
home / in public 
TH3 = Family B3 = 
Checking 
E3 = 
Dread 
P3 = 
Headache 
I3 = Work 
TR4 = Busy / 
crowded / 
environments 
TH4 = Finances 
/employment 
B4 = 
Isolative 
E4 = 
Angry 
 I4 = 
Confidence 
TR5 = Night / 
Sleep/Tired 
TH5 = 
Catastrophic 
misinterpretation 
of physical 
anxiety symptom 
B5 = Escape E5 = 
Irritated 
 I5 = 
Independence 
TR6 =  
Parkinson’s 
Symptoms 
TH6 = Social 
evaluation 
B6 = 
Behavioural 
expression of 
difficult 
emotion 
E6 = 
Nervous 
 I6 = Increase 
Parkinson’s 
symptoms 
TR7 = Time 
pressure / 
Demand / 
Organisation 
TH7 = Process of 
worry 
B7 = Avoid 
social 
situations 
E7 = 
Overwhe
lmed 
 I7 = Sleep 
TR8 = 
Interpersonal/ 
relationship 
TH8 = Meta-
worry 
B8 = Avoid 
busy places 
E8 = 
Stressed 
 I8 = 
Relationships  
TR9 = Confined 
Spaces 
TH9 = Irrational B9 = Avoid 
leaving home 
  I9 = Daily 
tasks 
TR10 = Travel TH10 = 
Something 
catastrophic 
B10 = Avoid 
travel 
   
TR11 = Meeting 
life demands / 
expectations 
TH11 = Going 
out alone 
B11 = Avoid 
new places / 
activities 
   
TR12 = Toilet 
related 
TH12 = Crowds B12 = Avoid 
decision 
making / 
responsibility  
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Trigger Thought Behaviour Emotion Physical Impact 
TR13 = New 
scenarios / out 
of comfort zone 
TH13 = Toilet B13 = 
Attempt to 
disguise 
anxiety  
   
TR14 = Being 
unoccupied 
TH14 = Falling B14 = 
Attempt to 
Distract from 
anxiety  
   
TR15 = 
Chemicals 
TH15 = Being 
alone 
B15 = Self-
harm 
   
TR16 = 
Exercise 
TH16 = Past     
TR17 = Season / 
time of day 
TH17 = Compare 
to others / past 
    
TR18 = 
Menstruation 
TH18 = Speech     
TR19 = 
Isolation 
TH19 = Fear of 
failure 
    
TR20 = 
Medical/PD 
contact 
TH20 = Future 
Dementia 
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Appendix O: Items for Online Appendix for Movement Disorders (Empirical 
Project)  
 
Table 1: Items with medians below the cut off for inclusion in main paper 
Triggers N Median Theme 
When I am at home 334 2 N 
When exercising  332 2 EP 
When walking 333 2 EP 
When I am unhappy about the healthcare I am receiving 336 2 EP 
When I wake up 334 2 EP 
By specific seasons or extremes of weather  333 2 EP 
When I have hallucinations 75 2 P 
Around menstruation 6 1.5 N 
When I drink caffeine  337 1 N 
When I smell strong smells or odours 334 1 N 
Thoughts    
When experiencing physical symptoms of anxiety, I 
worry that they mean something more catastrophic (for 
example that I will stop breathing, pass out, have a 
stroke or a heart attack) 
332 2 N 
I worry that I stand out as different 338 2 EP 
I worry about dribbling and that others will judge me 
negatively 
338 2 P 
I worry that someone will knock me over in busy places 340 2 EP 
I focus too much on my medication (e.g. when its due, 
side effects, whether it’s working) 
334 2 EP 
I am worried that others are embarrassed to be with me 338 2 EP 
I fear being left alone because others are not able to 
cope with my symptoms 
336 2 EP 
I worry about money and my ability to maintain 
financial security 
339 2 EP 
I worry I will freeze (stop moving) in hazardous 337 2 P 
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Note. P = directly related to Parkinson’s; N = normal for anxiety outside of Parkinson’s EP = common 
anxiety experience but likely exacerbated by Parkinson’s. Likert Scale: 1 = Not at all, 2 = Rarely, 3 = 
Sometimes, 4= Often, 5 = Always. 
 
 
Table 2. Full list of participant demographic and clinical information 
situations 
I worry about my employability 333 1 EP 
Behaviours    
I avoid driving 328 2 EP 
I avoid some methods of travel (e.g. public transport, 
car travel, plane travel, etc.) 
337 2 EP 
I avoid leaving home 333 2 EP 
I drink alcohol to try to reduce my anxiety and/or 
Parkinson’s symptoms  
337 1 EP 
I physically harm myself when anxious 336 1 N 
Physical Symptoms    
Difficulty breathing  336 2 N 
Feeling very alert and focused 226 2 EP 
Headache 332 2 EP 
Feeling disorientated or dizzy 337 2 N 
Nausea 336 2 EP 
Chest discomfort 332 2 N 
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Variable Survey one 
percentage (%) of 
participant sample (n 
= 205) 
Survey two 
percentage (%) of 
participant sample 
(n = 341) 
Sexual Orientation 
Heterosexual 
Homosexual  
Bisexual 
Prefer not to say  
Other 
 
95.60 
1.50 
2.00 
1.00 
0 
 
96.50 
0.30 
2.00 
0.30 
0.90 
Living Arrangements 
Live in own home 
Live in supported accommodation 
Other 
 
94.60 
1.50 
3.90 
 
95.60 
0.30 
4.10 
Care arrangements 
Live with family, but do not require 
support from them or others 
Live with family and require support 
from them or others 
Live alone and require no additional care 
Live alone and require support from 
family or others 
Other 
Prefer not to say 
 
57.70 
 
27.80 
 
11.30 
1.50 
1.00 
0.50 
 
58.30 
 
26.10 
 
11.00 
3.40 
0.30 
0.90 
Additional physical health condition 56.60 57.50 
Anxiety diagnosis from medical professional  40.50 33.70 
Overall impact of anxiety on your life 
Not at all  
Mildly  
Moderate  
Severe  
Not asked  
2.10 
35.90 
49.10 
12.60 
Frequency of anxiety Not asked  
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Everyday 
A few days per week  
A few days per month  
Less often  
31.90 
41.30 
21.50 
5.30 
Extent to which anxiety increases when 
Parkinson’s symptoms are bad 
Never or almost never  
Rarely  
Sometimes 
Often 
Always 
Not asked  
5.30 
10.90 
31.80 
35.90 
16.20 
Years since diagnosis  5.08 (4.56) 5.69 (4.64) 
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Appendix P: List of codes identified for the Nominal Group Technique Analysis 
in the Additional Results and Discussion Chapter 
 
Communication Lifestyle Therapies 
C1 = General L1 = Managing Demands T1 = Psychological Therapies 
C2 = Social Network L2 = Diet T2 = Physical Therapies 
C3 = Professionals L3 = Sleep T3 = Mindfulness 
C4 = Parkinson’s specific L4 = Connection T4 = Medication 
C5 = Not helpful L5 = Staying Occupied T5 = Alternative Medicine 
C6 = Do not talk L6 = Hobbies/Leisure T6 = Other 
 L7 = Exercise T7 = Not helpful 
 L8 = Mind body-exercise T8 = Not attempted 
 L9 = Being Outdoors T9 = Access Challenges 
 L10 = Relaxation T10 = Complementary therapies 
 L11 = Other  
 
 
 
 
